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Abstract 
 
Background: 
Neurofibrillary tangles (NFTs) is one of the two ‘hallmarks’ of Alzheimer’s disease (AD). The main 
constitute of these tangles are known as the paired helical filaments (PHFs), which are essentially 
abnormal aggregate of microtubule associated protein Tau. It has been known for many years that the 
hyper-phosphorylation of protein Tau is a persistent feature in NFTs. However, whether hyper-
phosphorylation of Tau is a cause or an effect to aggregation remains elusive. Mass spectrometry can 
now serve as an alternative to immunoblotting analysis for post translational modifications (PTM) 
study.  
Results: 
We developed a mass spectrometry method targeting on Tau protein for phosphorylation study. For 
a decent MS characterisation run, HEK 293 cells confluent in 5-10 plates (50 cm2) are required to be 
fed to the sample processing procedure. Typically, it takes 4-6 days to prepare the cells into MS 
samples. The targeting approach was able to discover peptides less intense by two orders of 
magnitude than that spotted using the general discovery method. The application of the targeted 
method on the soluble Tau recovered from HEK 293 cells allowed the solid discovery of three 
additional Tau phosphopeptide (only one phosphopeptide was discovered previously). Furthermore, 
for the development of the MS targeted method and high purity MS sample preparation, an efficient 
recombinant Tau protein production (in E.coli) protocol and a purification workflow for 
phosphorylated and untagged soluble/functional Tau protein (from HEK 293 cell line) was developed 
respectively. 
 
Conclusion: 
The Tau protein targeted MS method allows solid identification of additional phosphopeptides at two 
orders of magnitude lower peak intensity. The compatible purification protocol for soluble Tau could 
be applied to mammalian cells and tissue that expresses wild type and untagged Tau protein.  
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Abbreviations 
NFTs                                      Neurofibrillary tangles  
AD                                          Alzheimer’s disease  
PHFs                                       Paired helical filaments  
SF                                            Straight filaments 
PTM                                        Post translational modifications  
JNK                                          Jun N-terminal kinase  
ERK                                         Extracellular signal-regulated kinase   
GSK3                                       Glycogen synthase kinases 3  
CDK5                                       Cell division protein kinase 5  
HEK cells                                Human embryotic kidney cells  
WGA                                        Wheat germ agglutinin 
MS                                           Mass spectrometry 
LC                                             Liquid chromatography  
ESI                                            Electrospray ionisation  
MALDI                                     Matrix-assisted laser desorption/ionisation  
LTQ                                         Linear ion trap quadrupole  
CID                                           Collision induced dissociation  
HCD                                         Higher-energy collisional dissociation  
ECD                                           Electron capture dissociation  
ETD                                           Electron transfer dissociation  
DDA                                          Data dependent acquisition 
SIM                                          Selected ion monitoring  
DIA                                           Data independent acquisition 
SRM                                          Selected reaction monitoring 
CRM                                         Consecutive reaction monitoring 
MRM                                       Multiple reaction monitoring 
PRM                                         Parallel reaction monitoring 
HPLC                                         High pressure liquid chromatography 
Ori                                             Origin of replication 
IPTG                                          Isopropyl β-D-1-thiogalactopyranoside  
6 
 
SDS-PAGE                                Sodium dodecyl sulfate- Polyacrylamide gel electrophoresis 
OD                                              Optical density 
DI                                                Deionised 
EM                                              Electron microscopy  
TEM                                            Transmission electron microscopy  
SILAC                                          Stable isotope labelling by amino acid in cell culture  
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1.1. Background  
 
 
a) The significance of Alzheimer’s disease (AD) 
 
Alzheimer’s disease has been recognised as one of the most common neurodegenerative diseases. In 
fact, it accounts for over 80% of dementia cases world-wide among the elderlies. The disease not only 
causes the ultimate death of the Patient, it also paralyses the mental functionality of them for years. 
Hence, it is also a major social and economic issue as significant level of care is required to the patients. 
In 2015, it was estimated that around 200,000 and 5 million AD population were below and above 65 
years of age respectively. By 2050, the total prevalence is expected to be 13.8 million (Kumar A et al., 
2015). According to Alzheimer’s Society, the average cost of care per patient per year in the UK mounts 
up to £32,250.  
 
b) The Tauopathy in AD 
AD is essentially a neurodegenerative disease that ultimately leads to death and is characterised by 
progressive cognitive decline. Neurofibrillary tangles (NFTs) and amyloid plaques have been identified 
as the two ‘hallmarks’ of AD, both of which are characterised by protein aggregation events. The 
fundamental building blocks of NFTs are known as the paired helical filaments (PHFs), which result 
from the abnormal aggregation of a microtubule associated protein (MAP), known as protein Tau. It 
has been known for many years from the study of post-mortem tissues that hyper-phosphorylation of 
protein Tau is a persistent feature in NFTs (Mandelkow EM and Mandelkow E., 2012). However, the 
exact role of hyper-phosphorylation of Tau aggregation in the progression of AD remains mysterious 
(i.e. whether the phosphorylation of protein tau is a cause or result) (Goedert M et al., 2006). Recent 
studies have proposed that the spreading of the Tau filaments follows a nucleation mechanism: It was 
observed that the presence of Tau filament could induce the aggregation of healthy Tau proteins in 
17 
 
vitro (Fridhoff P et al., 1998). Further, cellular pathological models were built on this theory (Nonaka 
T et al., 2010; Guo JL and Lee VM, 2011). 
 
c) PTM study using mass spectrometry  
Immunoblotting analysis has been the standard tool to study post translational modifications (PTMs) 
by default in biochemistry. The method has indeed identified numerous phosphorylation sites on AD 
protein Tau, while being not so demanding with respect to both the quantity and the purity of the 
sample. However, mass spectrometry may serve as a characterisation method to cross check the PTMs 
being reported. In addition, MS allows the development of a general method which can be directly 
used to analyse any sample, whereas, antibodies need to be raised first to enable immunoblotting 
analysis (Mann M 2006). In Chapter 2, the relevant work to date is reviewed in more details.  
 
1.2. Work packages 
 
 
The overall objective was to develop a mass spectrometry method, tailored to study the 
phosphorylation profile of protein Tau. The MS based methods may be used to cross examine the 
findings of the typically employed immunoblotting analysis for PTM studies. In contrast to the previous 
mass spectrometry works, this targeted method was designed to capture only the peptide of interest 
by targeting on their corresponding m/z, hence, not as demanding with regard to sample purity and 
quantity.  
18 
 
 
Figure 1-1: The overall work flow 
 
The building of the targeted method involved work packages across three platform: E.coli, HEK 293 
and mass spectrometer, the overall work flow is illustrated in Figure 1-1.  
 
a) Supporting material production: plasmid amplification and recombinant Tau protein 
production 
 
An E.coli recombinant protein production and Tau plasmid amplification system was built. The 
pcDNA3.1 plasmid containing Tau protein sequence was later used in transient transfection of HEK 
293 cells (building cellular pathology model). Whereas, recombinant Tau protein was used in both MS 
method development and cellular model building. The related work was described in Chapter 3, a 
simple but efficient protocol for the purification of untagged Tau protein from E.coli was developed, 
taking advantage of its hydrophobicity and thermal stability.  
 
b) Producing physiological Tau protein sample: Tauopathy cellular model 
Soluble and insoluble Tau fractions were prepared from mammalian cells for MS studies. An attempt 
to develop Tauopathy cellular model was made, based on the nucleation mechanism proposed for the 
spreading of Tau filament. The HEK 293 cells were transiently transfected with the pcDNA3.1 vector 
to express Tau protein. The transfected cells were then seeded for intracellular Tau aggregation with 
19 
 
the in vitro synthesised filaments assembled from the E.coli produced Tau protein. Chapter 4 describes 
the cellular model and the purification of functional/soluble Tau protein via microtubule pull down 
and TiO2 phospho-species enrichment.  
 
c) MS method targeting on Tau protein: building and testing 
A MS method targeting Tau protein was built based on the data generated from pilot runs. In vitro 
phosphorylation on E.coli recombinant Tau protein was conducted through incubation with various 
kinases. Multiple MS pilot trials were then performed on the tryptic digested recombinant Tau protein. 
An encyclopaedia of Tau peptide and phosphopeptide was archived and used to build a MS method 
targeting on Tau protein. Chapter 5 describes the building and testing the MS Tau protein targeting 
method: it enabled better discovery of phosphopeptide that were otherwise drowned in the 
background noise.  
 
In this study, a comprehensive MS fragmentation spectra package for the tryptic digested Tau protein 
general peptide was reported for the first time. In addition, through in vitro phosphorylation using 
various kinases, a spectra data bank for Tau phosphopeptide is taking shape (currently, the study has 
covered three kinases: ERK, GSK3β and CDK5). In addition, a purification protocol for preparing soluble 
Tau fraction that is pure enough for MS study from mammalian cells (HEK 293) has been developed. 
Finally, a Tau protein targeting MS method was programmed based on the spectra databank. It was 
demonstrated that the targeted method is capable of identifying phosphopeptides in mammalian cell 
sample at much lower abundance. The fragmentation spectra of the Tau protein phosphopeptides 
from mammalian cell samples were also reported for the first time. A solid foundation for confident 
PTM identification is laid here by the Tau protein targeted MS method. Hopefully, this alternative to 
immunoblotting analysis for PTM study would end the controversy regarding the phosphorylation 
profiling of Tau protein.  
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2.1. Introduction  
 
 
Alzheimer’s disease is the most common form of dementia, characterised by progressive cognitive 
decline. According to Alzheimer’s Society, one in a hundred of us would develop AD at certain stage 
of life. One of the two hallmarks of the illness is neurofibrillary tangles found in neuron cells. The main 
constitute of the tangles are known as the paired helical filaments, by its appearance under electron 
microscope. Later, it was understood that the filament is basically abnormal aggregation of a 
microtubule associated protein, named Tau protein.  
 
It was discovered, that Tau aggregate itself could seed for further filament formation of healthy Tau 
in vitro. Hence, a nucleation mechanism was proposed for the spreading of Tau filaments in AD.  
Cellular models have been developed to investigate such hypothesis (Friedhoff P et al., 1998; Nonaka 
T et al., 2010; Guo JL et al., 2011).  
 
Though the pathology of AD still remains elusive, it has been determined that hyper-phosphorylation 
is a distinctive feature of the filament Tau protein. In addition to the conventional PTM study tool, 
immunoblotting analysis, mass spectrometry has made significant progress and is now in good shape 
to serve as an alternative characterisation method. 
 
2.2. Alzheimer’s disease  
 
2.2.1. Discovery  
 
On the 4th of November, 1906, Alois Alzheimer described the first case of a particular type of dementia 
at the 37th conference of South-West German Psychiatrists in Tubingen. In the 8th edition (1910) of 
22 
 
Hand book of Psychiatry, Emil Kraeplelin mentioned the term, Alzheimer’s disease (AD), for the first 
time (Kraepelin E, 1910). The patient who drew Alzheimer’s attention was known as Auguste D, by her 
first name and the first letter of her initial. She was admitted to the Frankfurt hospital at the age of 51 
on the 25th of November, 1901. Four and half years later, she passed away on the 8th of April, 1906 
(Alzheimer A, 1906; Maurer K et al., 1997). 
 
2.2.2. Symptoms  
 
Auguste D showed a striking cluster of symptoms within her four and half years stay in the hospital: 
reduced comprehension and memory, aphasia, disorientation, unpredictable behaviour, paranoia, 
auditory hallucinations and pronounced psychosocial impairment. It was described by Alzheimer that 
one of her first disease symptoms was a strong feeling of jealousy towards her husband (Alzheimer A, 
1906; Alzheimer A, 1907).  
 
 
This was soon followed by rapid progressive memory impairments. She was disoriented carrying 
objects around and screamed loudly sometimes. In her last days, ulcerations about 5 cm in size were 
developed on her face. She was extremely weak and suffered from high fever up to 40 oC, possibly 
Figure 2-1: Auguste D, Photograph 
dated November, 1902 (Maurer K et al., 
1997) 
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due to pneumonia in both inferior lobes (Alzheimer A, 1906; Alzheimer A, 1907; Alzheimer A. 1911; 
Maurer K et al., 1997).  
 
2.2.3. Definition 
 
In the necropsy report, Alzheimer recorded the presence of numerous miliary foci. In addition, he 
wrote that “almost one-third of the cortical cells had died off, in their places were peculiar, deeply 
stained bundles of neurofibrils” (Alzheimer A, 1906). The miliary foci are now often described as 
plaques, and further studies showed that they were composed of β-amyloid protein aggregates. 
Whereas, the intracellular fibrils that were observed in clumps were later identified as aggregate of 
Tau protein (Bick K, et al., 1987; Berrios GE. 1987; Beach TG. 1987; Mirra SS. 1991).  
 
These two aggregation features (shown in Figure 2-2) are currently being used to define Alzheimer’s 
disease according to ICD-10, DSM-III-R, CERAD standard. For example, ICD-10 states that the diagnosis 
is confirmed by post mortem evidence of neurofibrillary tangles and neuritic plaques in excess of those 
found in normal ageing of the brain. It is worth noting that Alzheimer and many researchers concluded, 
based on the autopsy, that such particular type of dementia is degenerative, not vascular (O’Brien C, 
1996; Bonfiglio F. 1908; Fischer O. 1907; Perusini G, 1909). 
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Figure 2-2: Left, neurofibrillary tangles from Auguste D, drawn by Alzheimer (Alzheimer A. 1911), right, 
sections from the cereral cortex of Auguste D, Beilschowsky silver stained (Goedert M et al., 2006),  
the stained “clouds” were neuritic plaques (intercellular) and the tangles (intracellular) were evident.  
 
2.2.4. Significance  
 
Alzheimer’s disease has been recognised as one of the most common neurodegenerative diseases. It 
accounts for over 80% of dementia cases world-wide among the elderly (typically over the age of 45). 
The disease results in progressive deterioration in mental functionality over approximately 10 years 
and ultimately results in death, commonly as a result of another condition such as pneumonia or lung 
infections. Hence, it is also a major social and economic issue as a significant level of patient care is 
required. In 2015, it was estimated that approximately 200,000 and 5 million AD sufferers were below 
and above 65 years of age respectively. By 2050, the total prevalence is expected to reach 13.8 million 
(Kumar A et al., 2015). According to the Alzheimer’s Society, the average cost of care per patient per 
year in the UK mounts up to £32,250.  
 
2.3. Discovery of the paired helical filament (PHF)—the main constituent of 
neurofibrillary tangles 
 
In the 1960s, the neurofibrillary tangles described by Alzheimer were identified as bundles of 
abnormal cytoplasmic filaments, using electron microscopy (Kidd M, 1963; Kidd M 1964; Terry R.D, 
1963; Terry R.D et al., 1964). In his paper published in 1963, Michael Kidd named the abnormal 
structure, paired helical filaments, based on its morphology, shown in Figure 2-3. The filaments are 
typically several hundred nanometres in length and 20 nanometres in diameter (30 nanometres at the 
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widest point and 15 nanometres at the narrowest point, roughly), whereas, the longitudinal spacing 
between each two crossover points is around 80 nanometres.    
 
It is also worth noting that in 1968, straight filaments (SF) were seen and reported by electron 
microscopy (Hirano A et al., 1968). Some twenty years later, it was revealed that filaments of both 
morphologies were aggregates of the same protein molecule, hence they are of the same biochemical 
identity (Crowther R.A., 1991).  
 
2.4. Protein Tau – the molecular composition of PHF 
 
2.4.1. Discovery of Tau 
 
In the 70s, research on microtubules progressed significantly. The assembly and disassembly 
mechanism was found to be temperature dependent. At 4 degree Celsius, microtubules dissociate  
into tubulin, its building block, whereas, at body temperature, 37 degree Celsius, they assemble back 
into microtubules. The process was monitored by light scattering and allowed co-purification of a 
family of proteins that attach to microtubule through centrifugation (Gaskin et al. 1974; Weisenberg 
1972). This family of proteins were therefore generally referred to as microtubule associated proteins 
Figure 2-3: Filaments extracted form 
Alzheimer disease brian tissue, 
three of them were PHFs, whereas, 
two of them, indicated by arrows, 
were straight filaments. Scale bar, 
100nm (Goedert M et al 2006) 
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(MAPs). Among them, a protein molecule that was isolated via ion-exchange chromatography, was 
named protein Tau (Weingarten et al. 1975).   
 
2.4.2. PHF – Tau aggregate 
 
In the 80s, technical developments in immunoblotting analysis had been made and were applied to 
better study  the protein composition of the tangles. From the assay, the proteins found to share the 
same epitopes with PHF included: neuro-filaments (Miller C.C.J et al., 1986), vimentin (Yen S.-H. et al., 
1983), microtubule-associated protein 2 (Kosik K.S. et al., 1984; Nukina N. and Ihara Y. 1983), 
microtubule associated protein Tau (Brion et al., 1985; Delacourte A et al., 1986; Grundke-Iqbal I et 
al., 1986; Kosik K.S. et al., 1986; Nukina N. and Ihara Y. 1986; Wood J.G. et al., 1986), amyloid-β 
(Masters C.L. et al., 1985) and ubiquitin (Mori H et al., 1987; Perry G et al., 1987). However, three 
issues had to be addressed to verify the candidate proteins: a) The immunoblotting approach cannot 
distinguish between the specific proteins contained in PHF and those associated to it. b) Many 
candidate proteins share the same epitopes to those that were identified. C) There is a possibility that 
although the antibody was designed to bind a specific epitope, it may exhibit non-specificity to other 
protein sequences. Furthermore, PHF is not soluble in water, hence, making it difficult for antibodies 
to adhere to parts of the protein sequence that may be folded contained within the aggregate  
(Mandelkow EM and Mandelkow E., 2012).  
 
Towards the end of 80s, a group of researchers based in Cambridge University managed to uncover 
the amino acid and the DNA sequence of the protein that forms PHF. A collection of monoclonal 
antibodies were developed and used against protease digested and solubilised PHF. The digests were 
then ran on an electrophoresis gel. A 12kDa band was found labelled by the antibodies and 
subsequently sequenced. After screening the protein sequence against a cDNA data bank generated 
from RNA extracts from AD brain tissue, a positive identification was made. Matching the positive 
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against cDNA library generated from healthy brain tissue led to a DNA sequence encoded a 352 amino 
acid protein, one of the six Tau isoforms in neurons. (Goedert M et al., 1988; Wischik C.M et al 1988a; 
Wischik C.M. et al 1988b) 
 
The first challenge, distinguishing the main constituent from the proteins that associates to PHF was 
addressed by the use of electrophoresis gel. The most significant labelled band was identified as the 
fragment derived from the main constituent of PHF as the intensity of the bands indicate relative 
concentration. The second and the third concerns were resolved as the antibody served only as a 
marker: the fragment was then fully sequenced.  
 
2.4.3. Six isoforms of Tau 
 
The Cambridge researchers discovered another isoform of Tau in the repeat of the original experiment. 
In addition, southern blotting analysis has confirmed that there was only one Tau gene in the human 
genome. Hence, a reasonable hypothesis was raised that the Tau mRNA undergoes alternative splicing. 
Follow up work then sequenced a large number of cDNA clones which ultimately revealed six isoforms 
of Tau. Later, all six isoforms were expressed in E.coli successfully and reported in 1990 (Goedert M et 
al., 1990).  
 
To confirm the presence of six Tau isoforms in neuronal cells, a PHF Tau sample was compared to an 
E.coli expressed Tau sample, containing a mix of all six recombinant isoforms, on SDS PAGE gel for 
immunoblotting analysis. As shown in Figure 2-4, the dephosphorylated PHF Tau sample (Lane 3) 
compared to the E.coli recombinant mixture (Lane 1), confirms that all the isoforms were present. 
Phosphorylation appears to significantly slow down the migration of proteins on the gel (Lane 2), i.e. 
phosphorylated Tau exhibited a higher apparent molecular weight (Lindwall G and Cole R.D et al., 
1984). 
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In 1986, it was discovered that the human Tau gene is encoded on chromosome 17q21. Six isoforms 
arise from mRNA alternative splicing and they mainly present in the axons of neurons. The six Tau 
isoforms defer by two sequence sections, illustrated in Figure 2-5. Close to N-terminus, variations arise 
from the number of inserts present (0, 1 and 2), whereas, towards the C-terminus, there is a region 
featured by three or four similar sequences, known as the repeat region. In combination, they can 
make up to six isoforms in total (Lindwall G and Cole R.D et al., 1984). It should be mentioned that 
another Tau isoform, known as “big Tau” (named so because of its greater size) exists, but is only 
present in the peripheral nerve system and allegedly bears no significance in AD pathology (Couchie 
D et al., 1992; Goedert M et al., 1992c).  
 
 
 
Figure 2-4: Immunoblot of PHF Tau compared 
against recombinant Tau mix. Lane 1 was the 
recombinant Tau mix of 6 isoforms, lane 2 and 3 
were PHF Tau before and after dephosphorylation 
respectively. Dephosphorylation was achieved 
through alkaline phosphatase treatment. (Goedert 
M et al., 2006) 
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Figure 2-5: Schematic representation of the six human brain Tau isoforms. N denotes the insert close 
to N-terminus, often known as the N-terminal insert, R denotes the repeat/similar sequences, usually 
referred to as the C-terminal repeat. The number of amino acids in each isoform is also marked in the 
Figure.  
 
2.4.4. Domains and biochemical functionalities of Tau 
 
Tau was discovered as a microtubule associated protein, specifically, it attaches to microtubules and 
stabilises the structure (Weingarten et al. 1975). Figure 2-6 (a) schematically represents the binding 
of Tau to microtubules. Describing the structure of Tau from the C-terminus towards the N-terminus, 
the protein can be considered to consist of two domains, the microtubule binding domain (containing 
3 or 4 repeats) and the projection domain. It has been established that the C-terminal tail binds to 
tubulin while the N-terminal end projects away from the microtubule. However, the specific binding 
sites and the interaction mechanism still remain elusive (Mandelkow EM and Mandelkow E., 2012). 
The C-terminal repeats may play a significant role in the microtubule interaction as it has been 
reported that the four repeat Tau promotes microtubule assembly at a 2.5 – 3.0 times faster rate than 
the three repeat Tau (Ennulat D.J. et al., 1989, Lee G et al., 1989).  
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                a)      b)   
 
Figure 2-6: a) Tau binds to microtubule. For full length Tau, 2N4R, interactions with the microtubule 
mainly occur through residues 200-400 (Mukrasch MD et al., 2005; Sillen A et al., 2007) b) Model of 
the conformation of Tau in solution deduced by ﬂuorescence resonance energy transfer (Mandelkow 
E et al., 2007) 
 
Some biochemical properties of Tau can be predicted theoretically based on its amino acid sequence, 
for example, Figure 2-7 illustrates the sequence of Tau (2N4R) indicating the hydrophobicity or –
phillicity of the amino acid residues and suggests that the protein is hydrophilic in nature due to the 
large number of polar and charged amino acids. This hydrophilic nature is also observed in the 
laboratory. The protein shows a basic character overall, but, within the first 120 N-terminal amino 
acids there are a large number of acidic amino acids, whilst, the 40 C-terminal residues are mostly 
neutral. Additionally, towards the centre of the protein in between the N-terminal inserts and the C-
terminal repeats, there is a proline rich region (Mandelkow EM and Mandelkow E., 2012). 
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Figure 2-7: Full length Tau region denoted, based on the amino acid sequence. The biochemical 
properties of the residues are also marked. (Kolarova M et al., 2012) 
 
The structure of Tau has been characterised using various methods, including circular dichroism, NMR 
and small angle X-ray scattering (Schweers et al. 1994; Mukrasch et al.2009). All findings suggested 
that Tau is natively unfolded or intrinsically disordered. Such interpretation is further backed up by 
the extraordinary thermo-stability of Tau: the protein retains its functionality (i.e. binding to 
microtubules) after boiling. Figure 2-6 (b) is a proposed conformation of Tau deduced by ﬂuorescence 
resonance energy transfer. 
 
2.5. Tauopathies and neurodegeneration 
 
Tauopathy refers to pathology related to the Tau protein. While there is a great number of 
neurodegenerative diseases defined by a specific set of special features, they share many striking 
similarities both in clinical symptoms and in brain deformities. The tangles formed by Tau is one of the 
two features that defines AD, yet, deposit/aggregates of Tau have been found in quite a number of 
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other neurological disease. Table 2-1 summarises neurodegenerative diseases that have been 
discovered featuring Tau deposits.  
 
Table 2-1: Neurodegenerative diseases in which Tau deposits have been described (Goedert M et al., 
2006). 
 
 
2.5.1. Cause or effect? 
 
The senile/neuritic plaques and the neurofibrillary tangles are the two hallmarks that defines AD. 
However, it is critical to identify the cause and effect in understanding the pathology and developing 
a therapy. From 1991 to 1995, it was reported extensively that among the familial cases of AD, an 
abnormal mutation in the amyloid β-protein precursor (the protein that aggregate to form plaques) 
gene was identified (Goate A et al., 1991; Levy-Lahad E et al., 1995; Murrell J R et al., 1991; Rogaev E.I 
et al., 1995, Sherrington R. et al., 1995). Such a finding directly suggested that the ill transformation 
of amyloid β-protein precursor or what triggers it is the causative factor. Whereas, despite the tangle 
formation exhibits a strong correlation against neurodegeneration (Arriagada P.V. et al., 1992; 
Bondareff W et al., 1990; Braak H et al., 1991), its presence in some apparently unrelated conditions 
made it seem more like an effect for a while (Goedert M et al., 2006). 
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In 1994, evidence emerged linking a particular type of frontotemporal dementia with Parkinsonism 
localised to chromosome 17q21.2, where the Tau gene is also found. More interestingly, the cases 
linked to chromosome 17 (FTDP-17) feature no plaque formation or Aβ deposits (Crowther R.A and 
Goedert M et al., 2000; Spillantini M.G. et al., 1996; Spillantini M.G. et al., 1998a; Spillantini M.G. et 
al., 1998b; Wilhelmsen K.C. et al., 1994). Furthermore, in 1998, the first Tau gene mutation for FTDP-
17 cases was identified (Friedhoff P et al., 1998; Poorkai P. et al., 1998; Spillantini M.G. et al., 1998c). 
It is worth noting that most mutations in Tau gene affects the sequencing and splicing of the C-terminal 
repeats (Goedert M et al., 2006). Hence, the pathological pathways associated with both hallmarks 
seem equally likely to be causative.  
 
2.5.2. The pathological changes of Tau 
 
Many abnormal changes on Tau have been characterised. In general, experimental findings suggests 
that the abnormal modifications weaken its binding to microtubules and promote self-assembly into 
filaments. It has been reported that phosphorylation can have inhibitory effects on the microtubule 
binding capability of Tau (Mandelkow EM and Mandelkow E 2012). Moreover, phosphorylation on 
sites that are inside the repeat region was suggested to have a greater impact (Gustke N et al., 1992). 
In particular, phosphorylation on Ser 262 (with respect to full length Tau) was reported to significantly 
inhibit microtubule binding of Tau (Biernat J et al., 1993). Though it has been reported that 
hyperphosphorylation of Tau could lead to aggregation, no PHF structure have been observed via such 
induction route (Avila J et al., 2006) (i.e. no EM image of hyperphosphorylation induced PHF formation 
has been published). Interestingly, an in vitro assembly experiment have provided contrary evidence, 
suggesting that hyperphosphorylation could prevent filaments formation (Friedhoff P et al., 2000).  
 
Hyper-phosphorylation is the most significant feature of AD Tau. Oxidation (Schweers et al. 1995), 
Ubiquitination (Morishima-Kawashima et al. 1993), proteolytic cleavage (Gamblin et al. 2003; 
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Horowitz et al. 2004; Rissman et al. 2004) and glycosylation (Li et al. 2006), as well as some non-
enzymatic modifications (Ledesma et al. 1994) have also been studied intensively. Table 2-2 lists a 
number of known Tau abnormalities in neurodegenerative diseases. Table 2-3 summarises the PTMs 
listed on Universal Protein Resource.  
 
Table 2-2: Abnormal modifications in Tauopathies (Mandelkow EM and Mandelkow E., 2012). 
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Table 2-3: PTMs reported on Universal Protein Resource, sites referring to the full length Tau.  
Site  PTM Type Publication 
2 Acetylation (Hasegawa M et al., 1992) 
18 Phosphorylation (Lee G et al., 2004) 
46 Phosphorylation (Illenberger S et al., 1998) 
50 Phosphorylation (Illenberger S et al., 1998) 
123 Glycosylation Smet-Nocca C et al., 2011) 
153 Phosphorylation (Illenberger S et al., 1998) 
175 Phosphorylation (Illenberger S et al., 1998) 
181 Phosphorylation (Illenberger S et al., 1998; Liu F et al., 2005) 
197 Phosphorylation (Sato S et al., 2005) 
198 Phosphorylation (Sato S et al., 2005) 
199 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Liu F et al., 2005; Sato S et 
al., 2005) 
202 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Liu F et al., 2005; Sato S et 
al., 2005; Li G et al., 2004; Smet-Nocca C et al., 2011) 
205 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Liu F et al., 2005; Li G et al., 
2004; Smet-Nocca C et al., 2011) 
212 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Liu F et al., 2005; Yoshida K, 
2008) 
214 Phosphorylation (Liu F et al., 2009; Yang Y.C et al., 2006; Illenberger S et al., 1998; Liu F 
et al., 2005; Cripps D et al., 2006) 
217 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Cripps D et al., 2006) 
231 Phosphorylation (Illenberger S et al., 1998; Liu F et al., 2005; Cripps D et al., 2006; Cho 
J.H. and Johnson G.V. 2004) 
235 Phosphorylation (Illenberger S et al., 1998; Liu F et al., 2005; Cripps D et al., 2006; Cho 
J.H. and Johnson G.V. 2004) 
237 Phosphorylation (Cripps D et al., 2006; Paudel H.K 1997) 
254 Ubiquitination (Cripps D et al., 2006) 
262 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Liu F et al., 2005; Yoshida H 
and Goedert M et al., 2012; Cripps D et al., 2006; Paudel H.K 1997; 
Drewes G et al., 1995) 
285 Phosphorylation (Paudel H.K 1997) 
293 Phosphorylation (Illenberger S et al., 1998; Drewes G et al., 1995) 
305 Phosphorylation (Paudel H.K 1997; Drewes G et al., 1995) 
311 Ubiquitination (Cripps D et al., 2006) 
324 Phosphorylation (Illenberger S et al., 1998; Drewes G et al., 1995) 
352 Phosphorylation (Paudel H.K 1997) 
353 Ubiquitination (Cripps D et al., 2006) 
356 Phosphorylation (Illenberger S et al., 1998; Yoshida H and Goedert M et al., 2012; Drewes 
G et al., 1995) 
396 Phosphorylation (Liu F et al., 2009; Lee V.M et al., 1991; Illenberger S et al., 1998; Liu F et 
al., 2005; Li G et al., 2004; Smet-Nocca C et al., 2011; Cripps D et al., 
2006) 
400 Glycosylation (Smet-Nocca C et al., 2011) 
404 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Liu F et al., 2005; Li G et al., 
2004; Smet-Nocca C et al., 2011) 
409 Phosphorylation (Liu F et al., 2005) 
416 Phosphorylation (Sato S et al., 2005) 
422 Phosphorylation (Liu F et al., 2009; Illenberger S et al., 1998; Sato S et al., 2005; Cripps D 
et al., 2006) 
427 Phosphorylation (Sato S et al., 2005) 
 
 
 
 
36 
 
2.5.3. Therapeutic availability  
 
The current targets for therapeutic intervention are 1) slowing down the spread of Tau aggregation, 
2) maintaining Tau in a healthy state, by restoring normal PTMs and preventing truncations and 3) 
adjusting the expression level of certain proteins or the overall cell activeness. As the root of cause of 
AD and other neurodegenerative diseases remains unknown, the current treatment development 
strategy is largely to slow down its progression (Huang Y and Mucke L, 2012).  
 
The therapeutic research efforts in slowing the spread of Tau aggregation have been primarily focused 
on identifying Tau-Tau interaction inhibitors. Phenothiazine methylene blue showed promising effect 
in a phase II clinical trial (Gura, 2008). However, it has also been observed that one side effect of the 
chemical is that it also undesirably reduces the level of soluble Tau in the brain. Hence, other 
formulations of methylene blue are being examined (Schirmer et al., 2011). Overall, the understanding 
on the aggregation pathology still requires much more research, as many other Tau aggregation 
inhibitors have been observed to actually enhance the formation of Tau oligomers, which may be 
potentially toxic (Taniguchi et al., 2005).  
 
The abnormal PTM profile and the truncation of AD Tau have inspired various treatment approaches. 
Hyper-phosphorylation, acetylation, truncation and other abnormal changes have received better 
attention (Min et al., 2010; Sahara et al., 2005; Zempel et al., 2010). Hyper-phosphorylation is the 
most distinctive abnormal change of Tau, but no treatment strategy exists for altering kinase or 
phosphatase activities. It is unclear whether hyper-phosphorylation is the cause or the effect of the 
disease. Furthermore, kinases and phosphatases have numerous substrates other than Tau. Universal 
up or down regulation of phosphorylation may very likely affect other mechanism pathways. To date, 
no promising treatments have been developed targeting other Tau abnormalities (mutation and other 
abnormal PTMs) (Huang Y and Mucke L, 2012).  
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Tau aggregation is coupled by many changes in cell, including an overall higher level expression of Tau 
and destabilisation of microtubules (Morris et al., 2011; Brunden et al., 2010). Followed by the report 
that no significant negative impact has been observed after a 50% reduction of Tau expression in 
animal models, chemicals such as dihydropyridines have been studied for down-regulation of Tau 
expression in cells (Evans et al., 2011). Some chemicals that are microtubule stabilisers (e.g. peptide 
NAP) have also been tested (Vulih-Shultzman et al., 2007).  
 
2.6. Hyper-phosphorylation of Tau in neuro diseases  
 
In 1968, it was initially suggested, based on immunoblotting analysis using phosphorylation-
dependent antibodies, that the proteins forming the filaments are extensively phosphorylated 
(Grundke-Iqbal I et al., 1986; Ihare Y et al., 1986). However, at this time the protein identity of the 
filaments had not yet been elucidated. It was later identified, in 1991, that the PHFs can be dissociated 
back into their monomeric building blocks, through surfactant treatment. This progress led 
researchers to confirm that both straight and paired helical filaments were aggregate of Tau protein 
(Crowther R.A et al., 1991). In addition, dissolving the filaments into monomeric Tau provided greater 
access for epitope binding of antibodies, which in turn allowed more phosphorylation sites to be 
identified (Lee V.M.-Y et al., 1991). Apart from immunoblotting analysis, mass spectrometry has also 
been used to identify phosphorylation marks on Tau (Goedert M et al., 1994; Hasegawa M et al., 1992; 
Morishima-Kawashima M et al., 1995).  
 
Phosphorylation of protein is one of many types of post translational modification. The addition and 
removal of a phosphoryl group is regulated by kinases and phosphatases. Residues with a hydroxyl 
group (serine, threonine and tyrosine being the most common) can potentially be phosphorylated. 
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Figure 2-8 describes how the phosphorylation is regulated and the molecular structures of serine, 
threonine and tyrosine. It is worth noting that histidine is often phosphorylated in E.coli (Victor L et 
al., 1999). However, it is not a great concern as Tau protein was not identified in the phospho-protein 
enriched E.coli produced Tau fraction, suggesting that E.coli produced Tau proteins are, at least, not 
significantly phosphorylated endogenously.   
                         
Figure 2-8: Left: reversible phosphorylation of serine residue; Right: the molecular structure of serine, 
threonine and tyrosine. 
 
There are 85 putative phosphorylation sites (colour coded in Figure 2-9) on the 2N4R, full length, Tau 
protein (Martin L et al., 2013). However, a universal agreement on the Tau phosphorylation profile 
(for both the healthy or the disease version) has not yet been reached as the previously published 
findings do not always agree (Gong et al., 1994; Gong et al., 1995; Liu et al., 2005, Lee HG et al., 2005;). 
Such inconsistency is further reflected in Table 2-3: not all the publications revealed the same 
phosphorylation profile.  
 
The candidate kinases identified includes: mitogenactivated protein kinase (MAPK) (Drewes G et al., 
1992), glycogen synthase kinase-3 (GSK3) (Hanger D.P et al., 1992; Mandelkow E.M et al., 1992), cyclin-
dependent kinase 5 (CDK5) (Kobayashi S et al., 1993), microtubule affinity regulating kinase (MARK), 
extracellular-signal-regulated kinases (ERK) (Drewes G et al., 1997) and stress-activated protein 
kinases (SAPK) (Goedert M et al., 1997). Whereas, Protein phosphatase 2A (PP2A) has been identified 
as the major Tau phosphatase in brain (Goedert M et al., 1992b). 
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Figure 2-9: 85 putative phosphorylation sites on full length Tau, 441 residues, serine—yellow, 
threonine—red, tyrosine—blue. 
 
A comprehensive mass spectrometry profiling study was published in 2000 and may serve as a 
reference. Recombinant Tau protein synthesised in E.coli was treated with four kinases in vitro: a) c-
Jun N-terminal kinase (JNK), b) extracellular signal-regulated kinase 2 (ERK2), c) glycogen synthase 
kinases 3 (GSK3), d) P38, a member of the mitogen-activated protein kinase family. The 
phosphorylation sites of these samples and that of PHF-Tau were characterised, the results are 
summarised in Table 2-4. In this study, 17 out of the 85 putative sites were seen phosphorylated 
(Reynolds CH et al., 2000). However, the phospho-peptide spectra supporting their findings were not 
published. In our study, an encyclopaedia for Tau peptides and phospho-peptides was generated. 
Further, a targeted method was built based on such encyclopaedia and was proven capable of 
capturing phospho-peptides in more samples (sample fractions from mammalian cells as opposed to 
E.coli cells).   
 
Hyper-phosphorylation is the most significant abnormal feature of PHF Tau, however, its exact role in 
Tau aggregation remains elusive. No evidence suggest that in vitro phosphorylated Tau is capable of 
self-aggregation, meanwhile, the assembly of Tau into filaments has been successfully facilitated by 
some other chemicals (Goedert M et al., 1996). 
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Table 2-4: Summary of phosphorylation sites on Tau, recombinant Tau treated with ERK2, JNK, P38 
and GSK3β in vitro (Reynolds CH et al.,2000). a) Identified only by antibodies (Iqbal et al., 1989; 
Goedert et al.,1995). b) Nonproline sites. c) Ser184 or Ser185 were found phosphorylated in PHF-tau 
(Hanger et al., 1998). 
 
 
2.7. The spreading of Tau filaments, a nucleation mechanism 
 
A robust AD-like filaments assembly procedure was successfully developed by Goedert and his co-
workers in 1996 by in vitro incubation of Tau protein with sulphated glycosaminoglycans (Goedert M 
et al., 1996). Two years later, a nucleated assembly mechanism was proposed and Tau aggregation 
through seeding (using in-vitro, heparin induced filaments) without presence of chemical inducing 
agent was demonstrated (Fridhoff P et al., 1998). In 2011, Guo and Lee induced Tau filaments 
formation in mammalian cells through incubation with pre-formed Tau aggregates without the help 
of transducing reagent (Guo JL and Lee VM, 2011). A year later, it was proven that AD filaments 
purified from brain tissue was capable of seeding mammalian cells too (Santa-Maria I et al., 2012).  
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2.7.1. In vitro full length Tau filaments synthesis 
 
By the early 90s, it was widely established that hyper-phosphorylation of Tau is the most distinctive 
feature of PHF, the major component of the neurofibrillary deposits (Goedert M et al., 1988; Wischik 
C.M et al 1988a; Kondo J et al., 1988; Lee V.M.-Y et al., 1991; Goedert et al 1992a). Furthermore, 
hyper-phosphorylation had also been reported to disable Tau from binding to microtubules. 
(Bramblett GT et al., 1993; Yoshida H and Ihara Y, 1993). Therefore, such abnormal level of 
phosphorylation was generally perceived to precede PHF assembly. However, the first attempt to 
synthesise Alzheimer-like Tau filaments in vitro was achieved using the bacterially expressed, non-
phosphorylated three repeat fragments of Tau, in 1992(Crowther R.A. et al., 1992; Wille H et al., 1992).  
 
Assembly of Alzheimer-like filaments from complete Tau was first reported in 1996 (Goedert M et al., 
1996). In this study, the application of sulphated glycosaminoglycan (such as heparin) was designed 
to stimulate phosphorylation of E.coli produced recombinant Tau by kinases. Interestingly, though 
Alzheimer-like filaments were observed as anticipated after the treatment, the control experiment 
proved that the aggregation was glycosaminoglycan-dependent and phosphorylation-independent 
(Goedert M et al., 1996).  
 
The publication provided a robust filament assembly protocol for recombinant Tau protein solution at 
2-3 mg/ml concentration: incubation for 48 hours with 200 µg/ml heparin in 30 mM MOPS buffer, 1 
mM AEBSF, at 30 oC and pH 7.4. In addition, through immunoblotting analysis, it was understood that 
heparin sulphate does exist in Alzheimer’s disease brain tissue. This finding, coupled with the fact that 
heparin had already been proven to stimulate Tau phosphorylation by a number of kinases made 
sulphated glycosaminoglycans a focus of AD research (Goedert M et al., 1996).  
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AD Tau filament was described as paired helical filament, PHF, based on its appearance under electron 
microscope. Figure 2-10a shows the EM image of in vitro synthesised Tau reported in 1996. It had a 
similar shape to AD filaments. While the detailed structure of these filaments remains elusive, some 
interesting insights have been revealed over time. Towards the end of 80s, immunoblotting analysis 
suggested that the core of the filament is formed by the microtubule binding region, whereas, the 
amino and carboxy-terminus are not confined and was vividly referred as a “fuzzy coat” (Crowther and 
Wischik 1985; Wischik et al., 1988b). The deduction was made as only the terminus binding antibodies 
were observed on the EM image, Figure 2-10b, c and d shows that the in vitro synthesised filaments 
also has this feature.  
 
The repeat region plays an interesting role in filament assembly. The repeat region is also known as 
microtubule binding region as domain attaches to microtubule. Both 3R and 4R Tau isoforms are 
constituent of PHFs (Jakes R et al., 1991). However, in vitro assembly study showed that 4R isoforms 
take less time to form filaments, whereas, the 3R isoforms could eventually grow longer (Zhong Q et 
al., 2012). In addition, the repeat region has also been proven as the necessary and sufficient domain 
for filaments formation (Friedhoff P et al., 2000).  
 
More recently, multiple characterisation methods were applied to uncover the structure of the 
filament core. To date, its β-structure has been universally verified by circular dichroism and FTIR 
(Barghorn et al. 2004), NMR (Mukrasch et al. 2009), electron diffraction (Berriman et al. 2003), X-ray 
fiber diffraction (Giannetti et al. 2000), and even X-ray crystallography (Sawaya et al. 2007). However, 
it was estimated that the core probably makes up less than 25% of the structure, therefore, a minor 
part of the filament (Alzheimer A. 1911).  
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Figure 2-10: a) EM image of in vitro synthesised Tau filament b), c) and d) are immunoelectron 
microscopy images of the in vitro assembled filaments, mark antibodies were seen as black dots. 
Antibodies directed to the N terminus, C terminus and microtubule-binding regions were applied 
respectively in b), c) and d) (Goedert M et al., 1996)  
 
2.7.2. Tau aggregation, a nucleation mechanism 
 
In 1998, a nucleation mechanism was proposed for Tau aggregation. A thioflavine S assay was 
employed to monitor the extent of polymerisation. The polymerisation rate of Tau was measured at 
the presence and absence of various types of seeds: aggregate formed from truncated Tau, AD-PHF 
and in vitro assembled PHF. Figure 2-11 illustrates that complete Tau protein polymerised in solution 
with the addition of AD-PHF as seed. The study also suggested that the nucleus comprises about 8-14 
Tau monomers (Fridhoff P et al., 1998).  
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Figure 2-11: Complete Tau protein polymerises at the presence of AD-PHF (Fridhoff P et al., 1998).  
 
In 2010, Takashi Nonaka verified the same concept in a cell model (Nonaka T et al., 2010), over a 
decade after the nucleation mechanism was proposed based on in vitro filament assembly experiment. 
In 2011, Virginia Lee developed that work further: recombinant full length (2N4R) Tau, truncated Tau 
and pro-aggregation mutated & truncated Tau were produced in E.coli and induced to form filaments 
in vitro. The in vitro formed filaments were then applied as seeds to QBI 293 cells that expressed the 
various types of Tau (see below for details). Tau deposit formation in cells was accelerated in all 
seeding experiments, but to different extents. In addition, it was also suggested in this particular study 
that the cells can spontaneously take up Tau aggregates, most likely through endocytosis (Guo JL and 
Lee VM, 2011).  
 
A mammalian cell model for Tau aggregation spreading research was developed in this study. The 
longest isoform of Tau (2N4R), truncated Tau containing only the four-repeat region (code named K18) 
and the truncated 4R Tau incorporating a pro-aggregation mutation (K18/P201L) were produced in 
E.coli. The bacterial produced Tau was purified and treated with heparin. Filaments assembled were 
then subsequently pelleted at 100,000 g centrifugation. These seeds were separately applied to QBI 
293 cells that were transiently transfected with five forms of Tau, including 2N4R Tau (wild type), 0N4R 
Tau (wild type) and the 2N4R Tau incorporating P301L, △K280 and R406W pro-aggregation mutation. 
To encourage the uptake of the seeds, cells were placed under starvation medium and, for some 
experiments, BioPORTER reagents or wheat germ agglutinin (WGA) were employed. The Tau filaments 
generated in cell were also pelleted at 100,000 g centrifugation. The variable factors of this particular 
study are summarised in Figure 2-12 (Guo JL and Lee VM, 2011). 
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Figure 2-12: Summary of variable factors for the 2011 publication from Virginia Lee’s group 
 
Tau aggregation in mammalian cells was characterised by immunostaining and electron microscopy. 
Statistical analysis was subsequently conducted on the sampling images. Figure 2-13 shows a series of 
sample images taken on an experiment: K18/P301L seeds were applied to cells expressing P301L 
mutated 2N4R Tau. The variables along three axis shown in Figure 2-12 should generate 45 
experimental combinations (3 x 3 x 5 = 45), however, the publication only provided results to support 
certain arguments (Guo JL and Lee VM, 2011).  
 
Table 2-5 provides the average percentage of cells that exhibited filament formation. It is evident that 
P301L mutation on intracellularly expressed Tau was a key acceleration factor, but the effect of 
mutation and truncation of seeding Tau is unclear as the control experiment using wild type Tau was 
not presented. Furthermroe, Figure 2-14 shows that the addition of WGA significantly had boosted 
the percentage of cells with aggregates. However, the impact of BioPORTER reagent was not discussed. 
It can be interpreted that the numbers in Table 2-5 were generated with the help of BioPORTER 
reagents as the percentage of cells with aggregates for cell expressing P301L Tau treated by K18/P301L 
seeds was 35% compared to 4% for  control (no WGA or BioPORTER reagent) featured in Figure 2-14. 
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Overall, the percentage of cells that showed aggregate after seeding appeared to be significant. 
However, no data was provided on the combination that would be most natural: using the wild type 
Tau formed filaments to seed for aggregate in the cells expressing wild type Tau without the help of 
endocytosis facilitating chemicals or with WGA (Guo JL and Lee VM, 2011). 
 
Figure 2-13: Immuno-EM image of Tau aggregates/filaments being induced in QBI 293 cells through 
seeding with the help of BioPORTER reagents. Cells were transiently transfected to expresses 2N4R 
Tau with P301L mutation and the seeds were prepared from K18/P301L E.coil produced Tau. a) scale 
bar 2000 nm, b)scale bar 500 nm. Arrows indicate mitochondria and/or vesicular structures (Guo JL 
and Lee VM, 2011).  
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Table 2-5: Average percentage of cells exhibited aggregation when seeded with in vitro prepared Tau 
aggregates, NT: not tested.  
 
 
Figure 2-14: Data generated from incubating in vitro assembled K18/P301L Tau aggregates with QBI 
293 cells transiently transfected to express 2N4R Tau with P301L mutation. Four WGA dosages: 0 
µg/ml 5µg/ml, 10µg/ml, 15µg/ml, were experimented. * indicates that P is less than 0.05 and ** 
suggest that P is less than 0.1 (Guo JL and Lee VM, 2011). 
 
2.8. Pathology model system – HEK 293 
 
The AD pathology study currently employs three types of models: in vitro, in cell and in vivo (animal). In 
vitro protein aggregation studies are ideal for investigating the effect of chemical additives, but cannot 
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effectively simulate realistic physiological conditions. Animal models would present the closest similarity 
to a human pathology, but such models are too complex to study the aberrant mechanisms involved. 
Furthermore, the pathological responses found in animal models may be different from those found in 
humans, rendering a number of models unfit for purpose (Games D et al., 2006). Human cell models can 
offer a good compromise between complexity and validity of pathology. They usually deliver good 
reproducibility, well simulated physiological conditions at a low cost (Thomas P and Smart TG, 2005). 
However, two significant differences should be taken into consideration: 1) established cell lines are 
generally immortalised and 2) 2D cultured cells lack the complexity and tissue based responses from 
multiple types of differentiated cells that would normally occur inside the body.  
 
Numerous AD and Tau studies have been done using cell models. In particular, human cell lines are popular 
choices: HEK 293 and neuroblastoma SH-SY5Y (Mandelkow EM and Mandelkow E, 2012; Anderton BH et 
al., 2001, Guo JL and Lee VM 2011; Goedert M et al., 2006). Though it is uncertain if the pathology model 
developed based on human cell line is entirely valid, the healthy phosphorylation profile of Tau expressed 
in HEK 293 is by and large consistent with native Tau in human brain (Anderton BH et al., 2001, Feijoo C et 
al., 2005). In addition, as the protein background in the cell is reasonably complex, sample preparation 
procedure designed for cells may be applied to brain tissue with minor modifications (Guo JL and Lee VM 
2011; Santa-Maria I et al., 2012).  
 
Human embryotic kidney cells, HEK 293, were originally transformed in 1973 (Graham FL et al., 1997). 
It has been widely used as a recombinant protein expression vehicle for its capability of carrying out 
most of the post translational modifications and folding for proteins, i.e. unlike E.coli which is a type 
of bacteria often used to produce recombinant protein in large quantity, HEK 293 has a wide range of 
enzymes and cell machinery to manufacture fully functional mammalian proteins. However, due to its 
relatively complicated background, purification of a target protein is more challenging. Therefore, 
while E.coli is ideal for larger scale recombinant protein production, HEK 293 is more suited to be 
49 
 
developed into a pathology model that studies the role of desired proteins of interest (Thomas P and 
Smart TG, 2005). 
 
Figure 2-15: Healthy HEK 293 cells under microscope. Image taken from ATCC.  
 
HEK 293 cells offer a similar intracellular environment to neuronal cells, but do not express Tau 
natively. For AD studies, a Tau containing plasmid is often transiently transformed into HEK cells as 
Tau is a microtubule stabilising protein and its over-expression can result in microtubule over 
stabilisation which inhibits mitosis. CMV promoters, incorporated in pcDNA and pCIS plasmids, are 
usually preferred as it can effectively “hijack” the protein production facility in HEK cells (Thomas P and 
Smart TG, 2005). 
 
Electroporation and calcium phosphate precipitation are the two common transfection methods. 
Electroporation subjects cells to an intense electric field which causes transient perforations in the 
membrane and allows plasmid to diffuse in. Calcium phosphate precipitation, on the other hand, 
requires no specialist equipment. A spontaneous precipitation is achieved through creating a 
supersaturation of calcium phosphate in solution. DNA plasmids present in the solution are then 
naturally incorporated into the precipitate (if small enough) which can pass through cell membrane. 
Despite a wide range of conditions that can potentially allow precipitation, an optimal window exists 
for decent efficiency of transfection (Jordan M et al., 2004). 
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HEK 293 cells were chosen for cellular model development for its high through put. It was observed in 
preliminary experiments that both neuroblastoma cells and HEK 293 cells do not express Tau protein 
endogenously (verified via mass spectrometry). Comparing to neuroblastoma cells, the doubling time 
of HEK 293 cells is considerably shorter (40hr versus 20hr) and the amount of cells at confluency was 
much greater (roughly twice as much by cell volume per plate upon harvesting).  
 
2.9. Protein structure characterisation – mass spectrometry  
 
The structure of a protein molecule may be studied at four levels: primary (amino acid sequence), 
secondary (local regular sub-structure), tertiary (3D structure of monomeric or multimeric molecules), 
quaternary (3D structure of the functional multi-subunit protein). In addition, proteins are dynamic 
molecules that can undergo conformational changes which are essential for their biological function 
(Lodish H et al., 2003). The various characterisation methods that are available at present for protein 
structural study have their pros and cons, summarised in Table 2-6 (Vandermarliere E et al., 2014).  
 
Classic methods include X-ray crystallography, nuclear magnetic resonance (NMR) and mass 
spectrometry. X-ray crystallography is known for providing comprehensive information on the 3D 
structure of a molecule. However, this technique has two main constrains: 1) the 3D structure 
provided is static and may not be the structure in solution/physiological condition, 2) obtaining a 
crystal of diffraction quality for protein can be extremely challenging (McPherson A, 2003). NMR can 
measure the structure of proteins while they are in solution, but an upper limit on size of the molecule 
exists, around 30kDa (Rudiger S et al., 2002, Horst R et al., 2005; Bertini I et al., 2008, Ishima R and 
Torchia D 2000). Whereas, Mass spectrometry, has been traditionally used to obtain primary 
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structural information. However, as shown in Table 2-6, the method is becoming increasingly powerful 
as the computational capability and resolution of the measurement advances.  
 
Table 2-6: Protein structural determination techniques, advantages and limitations (Vandermarliere E 
et al., 2014) 
 
In particular, mass spectrometry is very suitable for post translational modification, PTM, study. PTM 
study is largely part of primary structural study, though some PTM may result in conformational 
changes. Furthermore, modified peptides tend to have different properties which allow separation by 
chromatography. The sample may be applied through an off-line HPLC(high pressure liquid 
chromatography) or a HPLC-MS for resolution improvement (Vandermarliere E et al., 2014).  
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2.9.1. Mass spectrometry work flow 
 
There are three typical workflow for mass spectrometry: top-down, middle-down and bottom up. The 
top-down approach analyses a protein in its entirety: feeding the whole molecule to the MS. Though 
the method could potentially provide most comprehensive information on the sequence and PTMs of 
the protein of interest, the amount of sample required (in mg quantity) makes it unpractical under 
most circumstances. Middle-down work flow digests the protein molecules into large peptides using 
enzymes such as Glu-C. However, while providing better sequence coverage and more complete PTM 
profile comparing to the bottom up work flow, the separation and analysis of large peptides demands 
high resolution liquid chromatography (LC) and mass analyser. Bottom up is the most commonly 
chosen approach as small peptides are easily separated by LC. An inevitable compromise is the poorer 
sequence coverage as a result of enzymatic cleavage (e.g. trypsin): some extremely small peptides (4 
amino acids or less) are hard to identify (Fenn JB et al., 1989; Gabelica V, 2005; Goodlett DR and Yi EC, 
2002; Chen P, 2003). 
 
A typical bottom up run consist of four stages: 1) sample preparation, 2) peptide separation, 3) 
ionisation, 4) mass spectrometry and 5) computational analysis. As shown in Figure 2-16, the prepared 
peptide/protein sample is ionised via either an electrospray ionisation (ESI) or a matrix-assisted laser 
desorption/ionisation (MALDI) interface. The ions are then selected and detected in the mass 
spectrometer. Finally, the signals are feed into computational program for analysis (Steen H and Mann 
M et al., 2004). 
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Figure 2-16: Illustration of a typical mass spectrometry run  
 
To prepare the sample for a bottom-up work flow, the purified sample solution, with protein of interest at 
a satisfactory concentration level and free of lipid or fat (causes damage to the mass spectrometer), is 
treated with digestion enzyme. As a result, the protein molecules are truncated into peptide fragments, an 
example is shown in Figure 2-17. These peptides may be further separated in an online reverse phase 
column before fed to the electrospray ionisation interface (Demartini D R, 2013; Steen H and Mann M et 
al., 2004). 
 
Liquid chromatography is employed to separate the peptides across time, thus reducing the 
competition at the ionisation source, also allowing the mass analyser to focus on few ions at any given 
time point. In addition, peptides that have different PTMs or have PTMs on different residue could 
also being eluted at different time. The most common type of LC used achieves separation of peptides 
based on their hydrophobicity: the hydrocarbon chains attached to the silica beads (packing) retains 
the hydrophobic molecules longer (known as reverse phase LC). The recent adoption of nano scale LC 
column tubing (column diameter below 0.1 mm and the flow rate in nL/min range) reduced the radial 
diffusion of the sample species in the HPLC, therefore, allowing the analytes being fed to the MS at a 
higher concentration. This advancement effectively improves the resolution of the system and lowers 
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the minimum sample amount required for decent analysis. (Wilson SR et al., 2015; Visser JPC, 1999; 
Makarov a., 2000).  
 
 
Figure 2-17: Enzymatic digestion of 2N4R Tau by trypsin, a digestion enzyme that cleaves at lysine and 
arginine, colour coded red and blue.  
 
Figure 2-18: The sample solution further separated by liquid chromatography is charged positively. 
The  tension is broken by the voltage applied which allows the sample to be sprayed into the analyser.  
 
The mass analyser/mass spectrometer is a device that separate the ions by their mass over charge 
(m/z) ratio. There three main types of mass spectrometers: 1) quadrupole, 2) time of flight and 3) 
trapping. In particular a quadrupole ion trap is a trapping mass analyser that creates a dynamic electric 
field that retains the ions. The selective release/retention of ions can be achieved through tuning such 
dynamic electric field. An improved version of the traditional quadrupole ion trap is linear ion trap 
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which allows three or more tandem mass spectrometry stages. In addition, it also has a higher 
injection efficiency and higher ion storage capacity (Demartini D R, 2013; Steen H and Mann M et al., 
2004). Figure 2-19 provides a schematic drawing of a quadrupole ion trap.    
 
 
Figure 2-19: The ions enter into a linear ion trap quadrupole (LTQ) are confined radially by a 2D radio 
frequency field, created by the quadrupole, and axially by a stopping potential, applied by the capping 
electrodes. Similar to a traditional quadrupole, the ions are suspended and released by tuning the 
electric field, the selected ions are then passed on for fragmentation (Douglas D et al., 2005).  
 
Tandem mass spectrometry allows multiple rounds of MS selection and fragmentation in between, 
illustrated in Figure 2-20. There are three common methods for fragmenting an ion in MS, 1) collision 
induced dissociation (CID), including higher-energy collisional dissociation (HCD), 2) electron capture 
dissociation (ECD) and 3) electron transfer dissociation (ETD). CID is achieved by energetic collision 
with an inert gas, typically helium or argon. The weaker covalent bonds are preferentially cleaved, 
hence, certain PTMs often breaks off during CID, including phosphorylation. The mechanism of ECD is 
not completely understood: the dissociation occurs when low energy electrons are introduced to ions 
in gas phase. In ETD, an electron from a radical anion is transferred to a protonated peptide, causing 
the cleavage of the N-C bond of the peptide backbone. PTMs are usually preserved well by ETD 
(Demartini D R, 2013). CID is better at fragmenting short peptides (compatible with bottom up 
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approach), whereas, ETD and ECD are more suitable for longer peptides. The three mechanisms results 
in different cleavage of peptide, shown in Figure 2-21.  
 
 
Figure 2-20: The ions detected in MS1 for m/z can be selected from the next batch of ions and 
fragmented using CID or/and ETD (or other means), the m/z of the fragments can then be detected in 
MS2. Depending on the sample of interest, MS3 or further may follow.  
 
Figure 2-21: Peptide fragmentation via CID, ETD and ECD; CID and ETD could result in a and x ions, 
whereas, b and y ions are typical products of CID; c and z ions mostly occur from ECD and ETD 
 
Finally, the dissociated ion fragments enter a detector and logged into data file for computational 
analysis. Currently, there are three data acquisition approach: 1) data dependent acquisition (DDA); 
2) selected ion monitoring (SIM); 3) data independent acquisition (DIA). DDA selects peptides based 
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on their intensity, typically the top 5-6 abundant peptides are fragmented. SIM selects the peptides 
with m/z being targeted and ignores any other signals. DIA analyses all peptides within a defined m/z 
window (Doerr A, 2015). SIM is usually preferred for analysis on a particular protein molecule of 
interest.  
 
SIM has number of derivatives. SRM (selected reaction monitoring) selects and fragment ions of 
interest in MS1. In MS2, the ions from fragmentation are then targeted. CRM (consecutive reaction 
monitoring) monitors the selected ions and their product ions in a series of MS stages. MRM (multiple 
reaction monitoring) takes into consideration of different reaction on certain precursor ions, hence, 
the product ions from a number of expected reactions are monitored. PRM (parallel reaction 
monitoring) allows following up on multiple precursor ions and their products. All the derivatives 
above focus on the predicted reaction of certain precursor mass (Doerr A, 2015). However, it is very 
likely that a relatively complex sample contains multiple precursor ions of the same m/z which elutes 
from the HPLC at around the same time. Therefore, the strategy adopted for this study, described in 
details in section 5.2.2, was selecting ions by m/z in certain time window, then applying a full scan of 
all product ions. 
 
A reciprocal profile of the ions is then constructed based on the m/z signals being acquired. The m/z 
differences of the fragmentation products could be matched with amino acid losses (from both N-
terminus and C-terminus). However, the fragmentation spectrum could be discontinuous as some 
bonds are harder to break, which poses challenge to peptide identification. Data analysis is largely 
achieved through matching experimental data against possible fragmentation generated from a data 
bank that contains all the candidate proteins. While well coded computation software is commercially 
available, tailor made program is often capable of delivering a significantly better analysis (Steen H and 
Mann M et al., 2004).   
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2.9.2. Phosphoproteomics  
 
Two main challenges exist in analysing peptides that are phosphorylated. Firstly, phosphorylated 
proteins may be at a much lower abundance compared to the general protein population and may be 
outcompeted by unmodified proteins within the MS if no sample enrichment is utilised. Secondly, the 
precise localisation of phosphorylation on a peptide that have multiple putative sites is difficult (e.g.  
if the same peptide contains more than one serine/threonine/tyrosine residue). These issues have 
resulted in a field of mass spectrometry dedicated to the identification and localisation of 
phosphorylated peptides called phosphoproteomics.  
 
To improve the detection of phosphopeptides over more abundant peptide species enrichment 
strategies can be utilised. The most common are 1) affinity chromatography purification, 2) affinity 
pull down purification and 3) liquid chromatography separation. The first two methods can essentially 
utilise material of same chemical nature while their physical morphology may be adjusted accordingly. 
Chemicals such as TiO2, Fe3+, Ga3+, MOAC with ZrO2 or Nb2O5 are capable of adsorbing 
phosphopeptides under favourable chemical conditions and releasing them less favourable conditions 
(e.g. variation of pH) (Andersson L and Porath J 1986; Nuhse T et al., 2007, Thingholm T E and Jensen 
O N 2009;  Ikeguchi Y and H N 1997; Pinkse M W et al., 2004; Ficarro S B et al., 2008; Kweon H K and 
Hakansson K, 2006). These materials may be synthesised onto porous beads and used either for 
packing in a chromatography column or loose for affinity pull-downs (Ikeguchi Y and H N 1997; Pinkse 
M W et al., 2004). The third approach makes use of the fact that the hydrophobicity of the 
phosphorylated peptides may vary. Offline Liquid chromatography (LC) may be applied to separate 
the peptides into different aliquots. Alternatively, the sample may be loaded on a LC that is connected 
to MS, allowing the phosphopeptide to be loaded on the MS for analysis at a different time point to 
its non-phosphorylated counterpart (Ficarro S B et al., 2011; Villen J and Gygi S P 2008; McNulty D E 
and Annan R S 2008; Gan C S et al., 2008).  
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Phosphorylation site localisation is better distinguished using ETD as a fragmentation method. Unlike 
CID, when used for peptide backbone fragmentation ETD is better at producing a complete series of 
fragment ions, hence provides more extensive peptide sequence information. In addition, PTMs are 
often unpredictably removed by CID while ETD typically preserves them well (Mikesh L M et al., 2006). 
Furthermore, additional help is delivered by algorithms built for the purpose of phospho group 
localisation, including PTM score, Ascore and PhosphScore, etc (Olsen J V et al., 2006; Beausoleil S A 
et al., 2006; Ruttenberg B E et al., 2008).  
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Chapter 3 
 
 
 
 
 
 
Tau Protein Production and 
Plasmid Amplification in E.coli  
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3.1. Introduction 
 
E.coli recombinant protein production and plasmid amplification protocols were created to support 
development of the HEK 293 pathology model described in section 4.2. The main reagents produced 
by the E.coli systems are 1) pcDNA 3.1 plasmid (Figure 3-2, right) containing the Tau sequence on a 
CMV promoter for expression in mammalian cell lines and 2) recombinant Tau protein expressed and 
purified from E. coli for in vitro filament assembly.  
 
The chemical structure of the genetic information carrying material, DNA, is the same in all organisms. 
Furthermore, the fact that the primary protein structure synthesis mechanism is also identical in all 
cells makes recombinant protein expression work extremely practical. Peptide synthesis universally 
involves: 1) transcription of DNA to mRNA; 2) translation of mRNA to peptide sequence, facilitated by 
ribosomes. mRNA and tRNA (involved in the transporting of the peptide building block, amino acid) 
are the same across all organisms. However, post translational events, such as PTMs and folding, relies 
on enzymes and chaperones that are not present in the cells of all species.  
 
Hence, a host cell can be made to express certain target protein molecule upon being transfected with 
a circular DNA construct, known as plasmid or vector, containing its corresponding DNA sequence. 
Typically, a plasmid has three features, 1) a replicon that controls the copy number, 2) a promoter 
that initiates the expression of the recombinant protein, which can usually be induced by the addition 
of a chemical and 3) a selection marker that equips the host organism with resistance against certain 
antibiotics. Figure 3-1 illustrates the typical components in a vector (Rosano GL and Ceccarelli EA, 
2014).   
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Figure 3-1：Typical components in a plasmid. Note: 1) Ori stands for origin of replication. 2) The 
recombinant protein can include an N-/C-terminal peptide tag that allows for affinity purification after 
expression (Rosano GL and Ceccarelli EA, 2014). 
 
E.coli has been one of the most popular choices of host for recombinant protein production. This 
particular type of bacteria can grow rapidly at high density on inexpensive substrate. However, as a 
prokaryotic organism, constrained by its limited cell machinery, it may not be able to synthesis the 
biologically active form of all proteins of interest (e.g. kinases that facilitate the phosphorylation of 
Tau protein are not endogenous in E.coli). Further, the mass production of the target molecule may 
not be taken for granted as some proteins may be toxic to the host (Baneyx F, 1999). It is important 
to choose the right strain of E.coli or other more sophisticated cell lines for a given application (Casali 
N, 1983).  
 
3.1.1  Previous Work on Cloning and Expression of Recombinant Protein Tau 
 
The cDNA sequence of Tau was identified and isolated in the late 80s (Goedert M et al., 1988; Wischik 
C.M et al 1988a; Wischik C.M. et al 1988b). A cDNA library was generated using mRNA extracted from 
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human brain. The Tau cDNA sequence was identified through a series of screening steps, described in 
section 2.3.2 and 2.3.3. Oligonucleotide probes were then designed based on the cDNA sequence and 
was used to isolate the Tau cDNA clones from the library (Goedert M et al., 1988; Wischik C.M et al 
1988a; Wischik C.M. et al 1988b). The clones encoding Tau protein was then subcloned into the EcoRI 
site of M13mp18. In the context of the initiator codon, an Ndel site was introduced through site-
directed mutagenesis. The cleavage with Ndel and EcoRI allowed the cDNA sequence being cloned 
downstream of the T7 RNA polymerace promoter in a pRK172 plasmid (Goedert M et al., 1989). 
 
Recombinant Tau protein was first expressed and reported in 1990 (Goedert M. and R. Jakes, 1990). 
In the original work, Tau was incorporated in pRK172 vector (Figure 3-2, left, is a schematic map of 
pRK172) and transfected into E.coli BL 21 (DE3). The cell culture was grown to an optical density of 0.6 
– 1.0 at 600 nm. Expression was then induced by Isopropyl β-D-1-thiogalactopyranoside (IPTG) at a 
concentration of 0.4 mM. Following the induction, the culture was inoculated for another 2 hours at 
37 oC. The cells were sonicated and purified through a combination of ammonium sulphate 
precipitation and two fast flow ion exchange chromatography steps (phosphocellulose and 
carboxymethyl-Sepharose) (Goedert M et al., 1990). Figure 3-3 is an image of SDS-PAGE gel loaded 
with E. coli lysate and purified Tau protein. 
 
Recombinant Tau protein expression was also described in other publications. (Bandyopadhyay B et 
al., 2007; Guo JL et al., 2011; Nonaka T et al 2010; Lu M and Kosik KS, 2001). Researchers made use of 
the equipment they have access to, hence the protocol varied from case to case. The untagged Tau 
protein was purified through three or four orthogonal chromatography steps (e.g. ion exchange 
followed by size exclusion and HPLC). The commercially available Tau from various suppliers are 
typically tagged to help its purification.  
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Figure 3-2: Schematic map of pRK172 (left) and pcDNA3.1 (right). pRK172 bears an ampicillin 
resistance marker, whereas, pcDNA3.1 contains ampicillin and neomycin resistance markers (Foulcer 
SJ, 2012).  
 
Figure 3-3: SDS-PAGE, Coomassie blue stained, of the E.coli crude lysate and purified Tau. Lane 1 and 
14 were loaded with standard markers with their molecular weight indicated in kDa on the left. Lane 
3, 5, 7, 9, 11 and 13 were loaded with purified 352, 383, 381, 412, 410 and 441 amino acid isoforms. 
Lane 2, 4, 6, 8, 10 and 12 were loaded with their corresponding crude cell lysate (Goedert M et al., 
1990). 
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3.1.2. Technical Challenges in Expression and Purification of Recombinant Tau Protein in E. 
Coli  
 
The main challenge associated with producing recombinant protein Tau in E. coli for in vitro filament 
assembly is that the Tau sequence was not affinity tagged, which prohibits the use of affinity 
purification methods.   While requiring more complicated procedures for purification, the untagged 
sequence of Tau was preferred in these studies so that the observation of successful filament assembly 
could be attributed to native motifs in the Tau sequence and not tag-induced artefacts. 
 
As purification of untagged recombinant proteins is particularly challenging, even from an E. coli 
protein background, this work created a purification strategy that exploited the extraordinarily 
hydrophilic nature and outstanding thermal stability of protein Tau.  
 
3.2. Materials and Methods  
 
3.2.1 Tau constructs 
 
Tau 1N4R constructs containing the untagged 412 amino acid isoform were incorporated into pRK172 
and pcDNA3.1 plasmids, designed for expression of protein Tau in E. coli and mammalian cells, 
respectively.  The constructs (in aqueous solution) were generous gifts from Dr. Micheal Goedert 
(Cambridge).  The overall work flow for both protein and plasmid production is illustrated in Figure 3-
4.  
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3.2.2. Procedures for plasmid amplification in XL10 Gold E. coli 
 
Competent XL10 Gold E.coli stocks were kindly gifted by Dr Till Bartke (MRC Clincal Sciences Centre). 
The procedure described below is equivalent for the amplification of pcDNA3.1 or pRK172 plasmids. 
Heat shock plasmid transfection was performed using the competent XL10 Gold strain E.coli cells. 
Firstly, a plasmid stock was thawed on ice for 30 minutes. No less than 50 ng of plasmid (typically 1 µl 
at a concentration above 100 ng/µl, as measured by a Nanodrop instrument, Jenway, GenovaNano) 
was added to 50 µl of competent XL10 Gold cells in a 1.5 ml centrifuge tube, and then gently mixed 
by flicking.  After incubation for another 30 minutes on ice, the tube was heat shocked in a water bath 
at 42 oC for 90 seconds, then placed back on ice for 90 seconds.  
 
 
Figure 3-4: Plasmid transfection and E.coli culturing were performed for both procedures, whereas, 
the steps taken for the extraction and purification of the protein and plasmid varied. 
 
The content in the 1.5 ml tube was subsequently transferred in to a 15 ml culturing tube and mixed 
with 1 ml of SOC medium. The SOC medium was made in the laboratory. 200 g (Sigma-Aldrich D9434) 
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dextrose was dissolved in 1 L DI water and sterile filtered. 28 g of SOB medium powder was dissolved 
in DI(deionised) water and autoclaved at 120 oC for 50 minutes. For each litre of SOC medium, 18 ml 
of the 20% dextrose solution was added into 1 L of SOB medium.  
 
The 15 ml tube was inoculated for 1 hour at 37 oC, 250 rpm, and then 2 ml of SOC medium, containing 
antibiotics (ampicillin, 100 mg/L, Sigma-Aldrich, A0166), was added. The mixture was then inoculated 
overnight (optimised duration was 15 hours). Successful transfection was visually observed by the 
existence of a cloudy broth on the second day, evidence that the plasmid have equipped the cells with 
the resistance against the antibiotics. The successfully transfected E. coli stock was then transferred 
into 400 µl aliquots (320 µl culture and 80 µl 50% aqueous sterile glycerol) and stored at -80 oC.   
 
For plasmid amplification, one aliquot of the transfected E.coli stock, 400 µl, was thawed on ice and 
added to 200 ml SOC medium in a 1 L conical flask. The flask was then inoculated at 250 rpm and 37 
oC overnight (optimised duration was 16.5 hours). Finally, the cell pellets were harvested by 
centrifugation at 4500 g for 10 minutes. The pellets were stored at -80 oC or immediately processed 
for plasmid purification as described below.  
 
The plasmids were purified from the XL10 Gold cell pellets using commercial Qiagen kits (Miniprep-
27104, Maxiprep-12163, PlusMaxiprep-12963). Although the chemical composition of some Qiagen 
buffers are confidential, the general principle for DNA plasmid purification is well known. The cells 
were re-suspended in a neutral solution that contains RNAase, which will degrade all RNA in the lysate.  
Alkaline lysing buffer was then added to the cell suspension which also irreversibly degraded native 
E.coli genomic DNA. The mixture was subsequently neutralised and centrifuged to precipitate the cell 
debris and genomic DNA. Following centrifugation, the supernatant was then loaded on a mini silica-
gel membrane chromatography column and cleaned with an ethanol based washing buffer. Finally, 
the plasmid was recovered from the column by eluting with an aqueous and neutral buffer. 
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3.2.3. Recombinant Tau protein production in BL 21 E. Coli 
 
Competent BL 21(DE3) E.coli stocks were kindly gifted by Dr Till Bartke (MRC Clincal Sciences Centre).  
These BL 21(DE3) E. coli were transfected with the pRK172 plasmid following the same general 
procedure described above for plasmid amplification in XL10 Gold. 
For each round of recombinant protein expression, one 400 µl aliquot of the transfected BL21 stock 
was thawed on ice. 90 µl of the stock was added to four 2 L conical flasks containing SOC medium 
(ampicillin at 100 mg/L concentration) at an optimised volume, 375 ml. The culture was then 
inoculated at 250 rpm and 37 oC to optical density 0.6 – 1.0 at 600 nm, characterised through UV 
spectrophotometer (Pharmacia Biotech, ultrospec2000) sampling. IPTG (Acros Organics, 327280050) 
induction (0.4 mM) was performed in this particular window and the culture was grown at the same 
condition for another 3 hours to allow for recombinant protein expression. Typically, 0.8 ml sterile 
filtered IPTG solution at 200 mM concentration was added to each 2 L conical flask, containing 375 ml 
culture. The cell pellets were harvested by centrifugation at 4500 g for 10 minutes and stored at -80 
oC or used for purification of protein Tau, as described in section 3.3. 
 
3.2.4. Routine characterisation methods applied  
 
a) SDS-PAGE gel 
SDS-PAGE gel was prepared from time to time, served as a quick visual characterisation method. The 
gel preparation followed the protocol and recipe on At the Bench: A Laboratory Navigator (Barker K, 
2004) and the commercially available Bio-Rad gel casting system was used. The resolving layer was 
casted first, then followed by the stacking layer (45 minutes curing time was allowed for each layer). 
SDS (Fisher Scientific, S/5200153) and acrylamide (the percentage/strength of the gel depends on its 
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concentration)(Bio-Rad, 161-0156) was mixed with Tris buffered solution (pH 7) first, then TEMED 
(Bio-Rad, Amresco, M146) and ammonium persulphate (Fisher Scientific, BP179-25)was added and 
mixed fiercely using pipette. Once the gel was casted, the sample was then mixed with laemmli buffer 
(Bio-Rad, 1610737) typically by a 1:1 volume ratio and heated with 54 mg/ml DTT at 95 oC for 5 minutes. 
The denatured sample and the ladder (Bio-Rad, 161-0374) was then loaded on the gel. Afterwards, 
the gel was transferred into the Bio-Red gel tank (Bio-Rad, MiniPROTEIN) where a voltage of 170 volts 
was applied for 75 minutes to allow separation. Finally the gel was Coomassie blue stained to visualise 
the protein bands.  
 
b) DNA gel 
Agarose DNA gel was run to monitor the transfection of E.coli cells. Agarose (Invitrogen, 16500-500) 
was added to TAE buffer (Sigma Aldrich, 11666690001) based on the formulation by Invitrogen. The 
mixture was then heated by a microwave and casted into the Bio-Red mould (Bio-Rad, MiniSub Cell 
GT System) (30 minutes curing was allowed). Empirically, decent image could be produced if loading 
couple micro grams plasmid in each slot. After the sample solution and the ladder (Thermo Scientific, 
SM0103) was added, the gel was placed in the Bio-Red gel tank (Bio-Rad, MiniSub Cell GT System) 
filled with TAE buffer.  A voltage of 80 volts was applied typically for 70 minutes. The gel was then 
stained with ethidium bromide (Sigma-Aldrich, E1510) for UV imaging.  
 
c) Bradford assay 
Bradford assays provided an estimation of the overall protein concentration at each stage. For each 
measurement, 1 µl protein solution was mixed with 1 ml Bradford reagent solution (Bio-Rad, 5000006). 
Bovine serum albumin (BSA)(Sigma Aldrich, A9306) was used as standard universally. The compromise 
was made as the lyophilised Tau protein was not commercially available. The calibration curve (UV 
absorbance against BSA concentration) was plotted using data points generated from BSA standard at 
the following concentration: 1 mg/ml, 2mg/ml, 5 mg/ml, 10 mg/ml and 20 mg/ml. The UV absorbance 
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reading obtained by the sample solution was then fitted into the calibration curve for the 
corresponding concentration reading. Though the calibration curve plotted was always seen 
reasonably linear, it is worth noting that protein concentration below 0.5 mg/ml was the detection 
limit of our in-house UV spectrophotometer (Pharmacia Biotech, Ultrospec 2000). Besides, Bradford 
assay was also ineffective to samples that are lipid rich. 
 
d) OD 600 measurement 
The optical density at 600 nm wave length was measured for estimation of E.coli cell density in the 
culture broth. Sampling was done immediately after the orbital shaking was stopped (more discussion 
in section 3.4.1). Three samples were typically draw for each measurement to minimise the 
uncertainty due to the sedimentation of E.coli cells. Hence, error bars in Figure 3-8, 9, 11 were 
calculated from triplets.  
 
3.3. Proposed Methodology for Purification of Recombinant Protein Tau 
 
This section describes the workflow created for the purification of the untagged recombinant Tau 
protein from E. coli.   The proposed method aims to purify recombinant Tau without the need for 
expensive FPLC purification steps by exploiting the thermo-stability, intrinsic disordered structure and 
hydrophilicity of protein Tau. Figure 3-5 illustrates the overall framework of the purification 
methodology and each component will be described in detail.  
 
The E.coli pellet was re-suspended in 25 mM Tris (Amresco, 0497), 10 mM EDTA (Promega, H5031), 
0.1 mM DTT (Sigma-Aldrich, 43815) and 0.1 mM PMSF (Sigma-Aldrich, P7626) at pH 7.4 by a 1:1 
volume (pellet to buffer) ratio. The cell suspension was sonicated on ice for 5 minutes at 40% capacity 
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and 5 seconds on and off pulse frequency using a sonication probe (Fisher Scientific, FB-505). 
Following lysis, cell debris was isolated by centrifugation at 20,000 g for 20 minutes.  
 
 
 
Figure 3-5: Downstream separation of recombinant Tau. Cell lysed using a sonication probe, 
preliminary cleaning up by DE52 ion exchange chromatography, product capture through ammonium 
sulphate precipitation, purification achieved by boiling and the product quality was finally polished 
using HPLC.  
 
The nucleic acid and lipid fraction in the supernatant was partially cleaned up using gravity-fed anion 
exchange chromatography.  Briefly, 30 ml of DE 52 resin (GE Health Care, 17-0709-01) was poured 
into a 2.5 x 30 cm column (Biorad, 737-2532): a cake of no less than 5 cm depth was formed after the 
ethanol was drained. 50 ml of the re-suspension buffer (25 mM Tris, 10 mM EDTA, 0.1 mM DTT at 
pH7.4) was run through to equilibrate the column. The supernatant was then added to the column 
and the flow through was collected. Finally, another 50 ml of the re-suspension buffer was loaded on 
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the column and the eluent was combined with the flow through as crude product solution for further 
purification.  
 
It is important to note that the diethylaminoethyl cellulose based weak anion exchange 
chromatography conducted here was vast different from convention. The positively charged DE-52 
resin was used to bind negatively charged nucleic acids and proteins. Typically the proteins retained 
on the column would be washed via salt gradient elution. However, protein Tau, due to its extremely 
hydrophilic nature, mostly does not bind to resin in first place. Hence, only the flow through and wash 
was collected from the column, conveniently leaving behind significant amount of impurities.  
 
The protein content in the crude solution was precipitated from other contaminants in the DE-52 flow 
through using 45% saturated ammonium sulphate (Sigma-Aldrich, A4418). Briefly, 27 g ammonium 
sulphate was dissolved (magnetic stirring) to 100 ml of the solution at 4 oC. The precipitate was 
pelleted by centrifugation for 40 minutes at 20,000 g. The pellet was later re-suspended in 10 – 15 ml 
of distilled water and dialysed overnight against 30 mM Tris at pH 7 (dialysis tubing 14kDa MW, Fisher 
Scientific, BID-010-020H).  
 
Further purification of Tau from the enriched protein fraction is required for in vitro filament assembly.  
Instead of using the previously reported series of orthogonal FPLC purification steps (Goedert M et al., 
1990), the proposed method is based on exploiting the unusual thermal stability of Tau. Thus, the 
resulting protein fraction from ammonium sulphate precipitation was boiled to precipitate the 
majority of heat sensitive proteins in the background. Specifically, the dialysed protein fraction in 30 
mM Tris (pH7) was boiled for 2 hours and subsequently cooled to room temperature. The aggregates 
formed by denatured heat sensitive proteins was pelleted at 20,000 g for 40 minutes, and the 
supernatant was then filtered by 0.2 µm sterile filter (Millipore, SLMP025SS) to remove any remaining 
aggregates.  
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An optional final product polishing step could be achieved using reversed phase HPLC. The filtered 
supernatant recovered from boiling the protein solution was first concentrated to 5-10 mg/ml 
(monitored through BSA assay) using a 30 kDa molecular weight cut off filter (Amicon, UFC903024).  
200 µl of this concentrated protein was fractionated using reversed phase HPLC (Ascentis Express C18, 
Sigma-Aldrich, 53829-U) with the gradient shown in Figure 3-6.  Initially, 20 3-minute fractions were 
collected across the 60-minute run, and the 11th fraction (corresponding to 30-33 minutes) was rich in 
Tau protein, verified using SDS-PAGE gel. Tau at ultrahigh purity was empirically observed to elute 
between 30 to 32.5 minutes, reflected by the width of the Tau peak in chromatogram (see Figure 3-
15).  
 
 
Figure 3-6: HPLC gradient illustration. Mobile phase A was made of 5% MeCN (Fisher Scientific A955-
212), 2% TFA (Sigma-Aldrich, 14264) and 93% H2O, Mobile phase B was made of 95% MeCN, 1.88% 
TFA and 3.22% H2O. The flowrate was 0.5 ml/min. 
 
The effectiveness of each of the aforementioned separation steps for purifying recombinant protein 
Tau were evaluated at each downstream step (discussed below).  Briefly, a 10 µl aliquot was sampled 
at each step, and a Bradford essay was conducted on 1 µl to determine protein content and the 
remaining 9 µl was loaded on a 12% SDS-PAGE gel. When applicable, gel bands were identified via 
tandem mass spectrometry.  
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3.4. Results and Method Optimisation 
 
A reproducibly robust series of protocols were created to generate sufficient quantities of Tau-
expressing plasmids and recombinant Tau protein for conducting studies using the HEK 293 pathology 
model.  This section provides an empirical evaluation of the methods utilised and a discussion of the 
critical steps is provided. In total, 8 mg of pcDNA 3.1 and 79mg of recombinant Tau protein were 
produced to support the HEK 293 pathology model. 
 
3.4.1. Plasmid amplification  
 
a) Transfection of E. coli  
Successful E. coli transfection was initially confirmed by the observation of growth in the presence of 
antibiotics.  To optimise the XL10 Gold E.coli culturing, a series of pilot runs were conducted. E.coli 
growth was monitored through characterising the optical density of the broth. Doubling time was 
measured to help predict growth. More importantly, harvesting was timed when the culture reaches 
its stationary phase, which is indicated by stable plasmid output over time. The plasmid was purified 
by using a Qiagen mini prep kit from the cells and its concentration was measured using a Nanodrop. 
The purity of the plasmid recovered was then tested by running a DNA agarose gel with ethidium 
bromide staining. 
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Figure 3-7: 1% agarose gel stained by ethidium bromide. Image on the left was pKR 172 and the image 
on the right was pcDNA 3.1 plasmid. It is clear that both plasmid stocks were pure, but did not match 
well with the ladder (Thermo Scientific, SM0103) as the plasmid was not perfectly linearized.  
 
b) Sampling and doubling time measurement for E. coli 
The concentration of E.coli cells in culturing medium can be reflected by its optical density (OD) at 600 
nm wavelength. At relatively low concentration, below 8 x 108 cell/ml, the relation between OD 600 
reading and cell concentration is reasonably linear (Barker K, 2004). Hence, the culture was diluted 
when its OD 600 reading exceeded 1.0 (equivalent to 8 x 108 cell/ml). The diluted OD measurement 
was then multiplied by its dilution factor to give a better reflection of the E.coli concentration.   
 
The uncertainty of this concentration measuring technique arises from the uneven distribution of 
E.coli in the broth. The sampling was conducted by pipetting from the growing culture. However, the 
cells settled to the bottom of the flask rather quickly once the orbital shaking stops. As illustrated in 
Figure 3-8, samples were drawn to quantitatively analyse the sampling error from a 200 ml broth in a 
1 L conical flask.  The results for triplicate sampling  are  shown for sampling 1) the broth randomly; 2) 
the upper half of the culture; 3) the pipette tip touching the bottom; and 4) the flask immeditately 
after repeated stirring and mixing, respectively.  
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Figure 3-8:  Variation in E. coli concentration measurement associated with different sampling 
techniques.  
 
It is observed that, even immediately sampling after the shaker was stopped, the OD reading 
difference between surface and bottom sampling could be as significant as 25%. The standard 
deviation in multiple random sampling was also around 25% of the average reading. Though the 
mixing while sampling approach had slightly reduced the observed variation, the uncertainty was still 
around ±10%. To mitigate these issues, multiple samples were drawn at more than two time points 
for each batch. In addition, doubling time of the two strains were also measured to help anticipate 
the growth pattern.  
 
Knowing the doubling time of the two strains enabled for the estimation of cell concentrations at time 
points other than when the sampling was conducted. Figure 3-9 shows the growth curve of XL10 Gold 
E. coli. It is apparent from the plot that the doubling time of XL10 Gold is around 40 minutes, which is 
consistent with the literature (Green MR and Sambrook J, 2012). From 440 minutes to 480 minutes 
into culturing, the average OD 600 reading computed from three sampling increased from 0.119 to 
0.195, almost doubled. However, as discussed above, the uncertainty of such manual sampling 
operation is inevitable.  
0.25
0.27
0.29
0.31
0.33
0.35
0.37
0.39
0.41
O
D
 6
0
0
Random                         Bottom                      Close to surface                   Sampling right
sampling                        sampling                            sampling                            after mixing 
77 
 
 
c) Maximum yield achieved when harvesting in stationary phase  
Three Qiagen plasmid purification kits were utilised in this work: 1) Mini prep; 2) Maxi prep; 3) Maxi 
plus prep. Though the purification principle of all three products are the same, the observed 
performance considerably varied. 400 ml culture were grown in two 1 L conical flasks (200 ml in each 
flask) and mixed well. 5 ml was sampled and purified using the Qiagen Mini prep kit, and the remaining 
395 ml were split evenly and processed using the Qiagen Maxi prep and Maxi plus prep kits, 
respectively.  
 
 
Figure 3-9: XL10 Gold, transfected with pcDNA3.1 incorporating Tau 1N4R gene. 
 
Table 3-1 summarises the yield, determined via Nanodrop, by the three Qiagen plasmid purification 
units. The overall recovery cannot be computed as the total amount of plasmid produced is unknown. 
However, it is evident that though the Qiagen Miniprep kit is useful for quality control for its time and 
resource efficiency, the Qiagen Maxi plus prep was preferred as the operation time required per cycle 
was only a third in comparison. Though the yield of Maxi plus prep was over two times greater than 
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that of Maxi prep, further trials must be conducted for statistical analysis to provide conclusive 
evidence. The pattern may be verified if the error bars of the yield by two kits show no overlap. 
Alternatively, the yield may be assumed to follow normal distribution and the confidence may be 
calculated to provide quantitative information of the performance of the kits.  
 
Table 3-1: Comparing the purification performance of different Qiagen products 
 Culture 
volume 
Plasmid 
concentration 
Plasmid solution 
volume 
Yield—Plasmid/culture 
volume  
Operation 
time 
Mini prep 5 ml 107 ng/ µl 50 µl 1.07 µg/ml 1 hr/cycle 
Maxi prep 197.5 ml 307 ng/ µl 1000 µl 1.55 µg/ml 6 hr/cycle 
Maxi plus prep 197.5 ml 978 ng/ µl 800 µl 3.96 µg/ml 2 hr/cycle 
 
The maximum yield of plasmid from XL10 Gold at culturing stage can be achieved by harvesting in 
stationary phase.  However, it is hard to estimate the culturing time required based on the OD 600 
reading of the starting stock and its volume ratio to the broth. The complication arises as 1) not all the 
transfected cells survive -80 oC storage; 2) the cells may take some time to revive before starting to 
grow in population, known as the lag phase. Hence, the approach taken to deliver consistency was to 
1) generate stocks as homogeneous as possible; 2) determine a stationary phase time window, as 
described in Figure 3-10.  
 
Figure 3-10 shows the plasmid yield remained at the same level from the 15th to 18th hour in to 
culturing, proving that this interval was within the stationary phase. Hence, the harvesting time for 
the broth grew from that particular batch of seeding stock was set at 16.5 hours into culturing. All the 
plasmid production work was done within a month, hence, the quality of the seeding stocks did not 
vary from batch to batch significantly due to degradation over time. 
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Figure 3-10: Determining the harvesting time. For each run, 400 µl of seeding stock was added to 200 
ml SOC medium in 1 L conical flask. The three runs were cultured at 37 oC and 250 rpm. For sampling 
at each time point, 5 ml of culture was sampled and the plasmid purified using a Qiagen mini prep kit. 
The plasmid concentration reading was acquired using a Nanodrop. OD 600 measured at stationary 
phase, after 1:8 dilution, was 0.8 (OD is linear to cell concentration only from 0 to 1.0, hence, dense 
culture needed dilution to reflect cell concentration, however, at below 0.1 OD, the measurement 
uncertainty is intrinsically significant) 
 
3.4.2. Recombinant protein Tau production   
 
a) Transfection of pRK172 in E coli 
The transfection was initially visually confirmed as described in (see section 3.4.1. above), including 
harvesting of transformed E coli followed by plasmid purification and DNA gel imaging.  After induction 
of protein expression, the success of the transfection was ultimately verified via mass spectrometry 
identification of the Tau sequence in the BL 21(DE3) lysate.  
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b) Doubling time and IPTG induction  
Being able to forecast the cell concentration is critical for BL 21(DE3) cultures as IPTG expression 
induction has to be performed in a specific window corresponding to an OD 600 between 0.6 – 1.0. 
Figure 3-11 shows the growth curve of BL 21(DE3). It is evident from the plot that the doubling time 
of BL 21 was around 20 minutes which was consistent with literature (Green MR and Sambrook J, 
2012). As plotted in Figure 3-11, from 260 minutes to 280 minutes into culturing, the average OD 
density measured doubled from 0.211 to 0.434. However, the earlier data points were invalid as the 
cell density changes were buried by the measurement uncertainty. 
 
Figure 3-11: BL 21(DE3) growth curve. The cells were transfected with pKR172 plasmid, incorporating 
Tau 1N4R gene. Note:  the OD 600 measurement was not effective at low concentration either, the 
reading at 100 minutes and 150 minutes were not very different.  
 
c) Crude yield depends on the timing of IPTG induction 
The timing of IPTG addition for induction of protein expression is critical in optimising Tau yield at the 
culturing stage. Addition of IPTG outside of the OD 600 0.6 – 1.0 window had resulted in poor or no 
expression of Tau (results not shown). Thus, multiple samples were drawn at more than two time 
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points for each batch to minimise measuring uncertainty. Typically, the optical density window was 
observed around 5 hours into culturing based on adding 90 µl of seeding stock to 375 ml SOC medium 
(2 L conical flask). 3 hours (kindly advised by Dr. Micheal Goedert) after IPTG induction, the cells were 
harvested at OD 600 reading 0.8- 0.9, 1:4 dilution. 
 
The first OD measurement was usually taken around 4 hours and 20 minutes into culturing. Based on 
the reading, the IPTG induction timing was then estimated. 10 minutes before the anticipated 
induction timing, another OD measurement was sampled to confirm the prediction. IPTG was then 
added if the estimation was accurate, else the scheduled induction time was revised based on the 
second reading and a third sampling was performed for final verification prior to induction.  
 
In addition to IPTG induction timing, the culturing volume was also determined to be a critical 
parameter. In 2 L conical flasks, the maximum SOC medium volume for effective Tau production was 
found to be 400 ml.  Scaling up the media volume had resulted in poor expression of Tau (data not 
shown), possibly due to insufficient aeration and changing of the mixing dynamics.  Figure 3-12 
presents a SDS-PAGE protein gel corresponding to the E. coli lysates from three independent 
expression runs (starting from the same stock). It is observed that the relative concentration of Tau to 
the background E. coli proteins are variable from run to run, despite following the same procedure in 
each.  
82 
 
 
Figure 3-12: 12% SDS-PAGE gel loaded with 5µl of E.coli lysate. Note that the apparent molecular 
weight on SDS-PAGE gel of Tau 1N4R is around 60 kDa (Goedert M et al., 1990), whereas its theoretical 
molecular weight is 42.9 kDa, computed based on its amino acid sequence.  
 
d) Protein purification 
The overall protein concentration (measured by Bradford protein assay) and the relative 
concentration of Tau protein (visualised from SDS-PAGE gel) was monitored throughout the 
purification workflow described in Section 3.3. Tau protein has been previously reported to be: 1) 
extremely thermal stable as it is natively unfolded and 2) highly hydrophilic (Goedert M et al., 2006). 
Hence, no-salt anion exchange chromatography, boiling and reverse phase chromatography were 
employed in its purification. 
 
Three pilot Tau expression runs are compared in Figure 3-13 and their yields in terms of total protein 
content at each step of the purification workflow (see Figure 3-5) are summarised in Table 3-3.  Briefly, 
the cell pellets from 3 L of culture were processed as an individual batch. The purification protocol 
begins with a no-salt DE 52 chromatography step, where Tau is in the flow-through and wash fraction, 
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and is followed by ammonium sulphate precipitation and dialysis. It is important to note that Tau 
protein does not bind to DE 52 resin under salt-free conditions due to its excessively hydrophilic nature. 
Lipid and nucleic acid content was mostly removed by these conventional steps along with a significant 
fraction of the overall E. coli protein background, which requires salt elution from DE-52 resin.  The 
boiling step exploits the extraordinary thermal stability of Tau and precipitated over 90% of the E. coli 
proteins in the background. Figure 3-15 shows a typical reversed phase HPLC chromatogram: Tau was 
the first protein eluted through the column due to its super hydrophilic nature. Earlier fractions were 
also characterised, the fact that no band was observed on SDS-PAGE gel suggested that the peaks (at 
5 min, 6 min and 15 min) were not corresponding to protein structures.  
 
From Figure 3-13 there is an observed inconsistency in the amount of protein recovered by boiling. 
The dramatic variation may be explained by the image of E.coli lysate on SDS-PAGE gel in Figure 3-12: 
Tau expression level varied from batch to batch. Hence, overall protein level measurement was paired 
with SDS-PAGE gel to provide information on the relative concentration of Tau. The protein gel image 
for Run 2 is presented in Figure 3-14 as an illustration.   It is observed that the background is reduced 
after DE 52 and ammonium sulphate cleaning up, as much of the “streaking” observed in the lysate 
lanes has been removed.   Importantly, the boiling step eliminated almost all remaining E. coli proteins 
(see Table 3-2) and an ultrapure sample was produced after reversed phase HPLC fractionation.  
 
Table 3-2: The Top ranked proteins identified via MS after boiling. 
Protein Score Ranking 
Microtubule-associated protein tau, Homo sapiens  737.0 1 
Cold-shock DNA-binding domain protein, E.coli, strain B / BL21-DE3) 115.4 2 
Cold-shock DNA-binding domain protein, E.coli, strain B / BL21-DE3) 77.4 3 
30S ribosomal protein S1, E.coli, strain B / BL21-DE3) 72.1 4 
Ribonuclease E, E.coli, strain B / BL21-DE3) 65.8 5 
Peptide synthase, E.coli, strain B / BL21-DE3) 53.0 6 
Phosphatidylserine decarboxylase proenzyme, E.coli, strain B / BL21-
DE3) 32.0 7 
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Table 3-3: Protein recovery at each stage of purification. Crude yield was calculated by dividing the 
overall protein level at each step of purification by the total amount of protein in the lysate 
  Lysate Post dialysis Post Boiling Post HPLC 
Run 1 Protein concentration (mg/ml) 12.1 7.9 1.9 2 
 Volume (ml) 30 19.5 3 1 
 Total protein (mg) 363 154.1 5.7 2 
 Crude yield N/A 42.3% 3.7% 35.1% 
Run 2 Protein concentration (mg/ml) 13.7 8.1 4.2 3.1 
 Volume (ml) 30 17.3 3 2 
 Total protein (mg) 411 140.1 12.6 6.2 
 Crude yield N/A 34.1% 9.0% 49.2% 
Run 3 Protein concentration (mg/ml) 11 6.7 3.1 2.2 
 Volume (ml) 30 20.7 3 2 
 Total protein (mg) 330 138.7 9.3 4.4 
 Crude yeld N/A 42% 6.7% 47.3% 
Average Crude Yield  N/A 38.4% 6.5% 43.9% 
Standard deviation of yield in 
percentages 
N/A 9.7% 33.5% 14.3% 
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Figure 3-13: The overall protein content, as measured using a Bradford assay, following each 
purification step. Note: the lysate contains a crude background of macromolecules, hence its protein 
concentration was not directly measured using the standard Bradford assay as it would not be 
accurate.  Instead a partially lysed sample (prepared via sonication) was analysed against BSA standard. 
This lysate was then loaded onto a SDS-PAGE protein gel with a series of diluted lysates from complete 
lysis.  Lastly, the estimated concentration of the full lysate was computed by multiplying the 
concentration (measured by Bradford assay) of the partial lysate and the dilution factor that generated 
a lane of similar intensity to the partial lysate on the SDS-PAGE gel. 
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Figure 3-14: SDS-PAGE gel image of the sampling after each purification step 
 
 
Figure 3-15: Chromatogram corresponding to the reversed-phase HPLC fractionation of the purified 
sample after boiling and dialysis. The peak corresponding to protein tau eluted in the 30 min – 32.5 
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min interval, which corresponds to a %B of 50%. The fractions corresponding to the 2.5 minute 
intervals before and after were also collected, in case minor variations were observed from run by run.  
 
3.5. Summary 
 
In this chapter an E. coli system for production of Tau plasmids and recombinant protein were 
developed.  On average, 1 mg vector and 8 mg Tau protein were produced per experiment, 
respectively. Every preparation round was monitored by optical density measurement for culturing, 
whereas, Bradford assay coupled with SDS-PAGE gel and Nanodrop were used to characterise the yield. 
The material produced by E.coli were later used in cell pathology model building and MS discovery 
method design. Some critical points worth noting are:  
 
a) Timing IPTG induction 
Timing of IPTG induction is critical for recombinant protein production in E.coli. Addition of IPTG 
outside of the OD 600 0.6 – 1.0 window had resulted in poor or no expression of Tau. Therefore, 
multiple samples were drawn at more than two time points for each batch. Typically, the optical 
density window for induction was observed around 5 hours into culturing based on adding 90 µl of 
seeding stock to 375 ml SOC medium (2 L conical flask).  
 
b) Optimal XL10 Gold culturing duration  
Observed from multiple runs that the plasmid yield remained at the same level from the 15th to 18th 
hour in to culturing, proving that this interval was within the stationary phase. Hence, the harvesting 
time for the broth grew from that particular batch of seeding stock was set at 16.5 hours into culturing. 
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c) Tau protein purification can be achieved through boiling  
Boiling was incorporated as a purification step as Tau was reported to be extremely thermal stable 
and natively unfolded. Braford assay and SDS-PAGE gel showed that boiling precipitated over 90% of 
the E. coli proteins in the background. The microtubule binding assay conducted afterwards verified 
that Tau protein purified via this route preserves its functionality.  
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Chapter 4 
 
 
 
 
 
 
The Development of a 
Tauopathy Cellular Model 
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4.1. Introduction 
 
The primary objective of this work package was to generate samples for the Tau protein targeted MS 
method, described in Chapter 5. An attempt on developing a cellular AD Tauopathy model was made. 
In this work, HEK 293 cells was transiently transfected to express wild type Tau (1N4R). Exogenous 
wild type Tau (1N4R) filament was applied to seed for intracellular filament formation. The healthy 
Tau protein, exogenous and intracellular filament sample fractions were purified for MS 
characterisation. The Tau fractions preparation procedure was further developed based on the 
methods reported in previous publications. 
 
Researchers had started to investigate how to turn healthy Tau protein into the filament structures 
characteristic of AD in more complex environments after such was demonstrated in vitro in 1996 
(Goedert M et al., 1996). The effort to develop cellular model started around 2000 (see Table 4-1). 
The physiological condition in a cellular model is certainly closer to reality (in an AD brian) than in vitro, 
hence, the aggregate generated in cell is supposedly more similar to the actual pathological Tau 
compared to the in vitro assembled filaments.  
 
Typically, Tau protein was expressed in the cell line of choice and the filament formation was triggered 
by the addition of a reagent that induced aggregation or simply by the overexpression of a genetically 
modified Tau sequence. The model can be used to study the disease pathology or to examine potential 
drug molecule targeting on Tau aggregation inhibition (Lim S et al., 2014). Table 4-1 lists some 
examples of the in cell models developed for Tau protein aggregation.  
 
4.1.1. Significance and limitations of the existing cellular models 
 
The proposed AD mechanism is far from complete (Kumar A et al., 2015), so is that of Taupathy 
(Goedert M et al 2006; Mandelkow EM and Mandelkow E., 2012). However, it is well established by 
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the overwhelming evidence that the aggregation of Tau filament is associated with the progression of 
AD. In addition, a series of abnormal PTMs on filament Tau have been reported (see section 2.4). 
Hence, a decent model should: 1) allow the study of Tau aggregation mechanism; 2) allow the study 
of Tau PTMs and 3) provide a valid physiological condition. 
 
Table 4-1: Examples of cellular models for Tauopathology study, HEK 293, QBI 293, SH-SY5Y and SIH 
3T3 cells are human cells.  
Cell line Aggregation inducer Reference 
HEK 293 Congo red (Bandyopadhyay B et al., 2007) 
QBI 293 Exogenous Tau filaments (Guo JL et al., 2011) 
SH-SY5Y Exogenous Tau filaments (Nonaka T et al., 2010) 
SIH 3T3 P301L, V337M, R406 mutations (Lu M and Kosik KS, 2001) 
N2a △K280, PP, I277P, I308P mutations and truncation (Khlistunova I et al., 2006) 
CHO N279, △K280, P301L, S305N, V337M, R406W (Vogelsberg-Ragaglia V et al., 2000) 
 
a) Mutation induced aggregation model 
The first cellular model on Tauopathy was developed using Tau protein with mutations. Tau protein 
with mutations suspected to cause AD was expressed in animal cells and human neuroblastoma cells 
(Lu M and Kosik KS, 2001; Khlistunova I et al., 2006; Vogelsberg-Ragaglia V et al., 2000). Tau 
aggregation was visualised by immunoelectron microscopy using Tau monoclonal antibodies. 
However, while some mutations have been shown to significantly induce aggregation, based on the 
statistics from Alzheimer’s Association and ALZFORUM, only less than 5% of Alzheimer’s and other 
neurodegenerative diseases are familial. Furthermore, the mapping of the gene sequences and 
mutations responsible for AD is far from conclusive (Kumar A et al., 2015). Therefore, cellular model 
that relies strongly on Tau pro-aggregation mutations do not represent the most common AD cases.  
 
b) Chemicals induced aggregation model 
Chemicals had also been applied to Tau expressing cell line, free of any mutations, to induce 
aggregation. It was discovered by coincidence that anionic molecules such as heparin could induce 
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Tau aggregation in vitro (see section 2.6.1). Following the discovery, it was found that a number of 
similar chemicals, polyanions, were also able to cause Tau aggregation (Friedhoff P et al., 2000). 
Therefore, these molecules, including Congo red, an anionic dye, was applied to build cellular model 
(Bandyopadhyay B et al., 2007). However, since the aggregation was induced by chemicals that are 
not naturally present in cells, the underlying aggregation mechanism of the cellular model was invalid. 
In addition, since the aggregation could result purely by these polyanionic chemicals as proven in vitro, 
the PTMs identified on Tau protein in such models were most likely the effect, rather than the cause, 
to aggregation.  
 
c) Seeding through exogenous Tau filaments  
Tau filaments that were assembled in vitro had also been used to induce Tau aggregation in cellular 
model (Nonaka T et al., 2010; Guo JL et al., 2011). It was discovered, that Tau aggregate itself could 
seed for further filament formation of healthy Tau in vitro (see section 2.6.2). Hence, a nucleation 
mechanism was proposed for the spreading of Tau filaments in AD.  
 
However, the cellular model developed based on such argument typically made use of in vitro 
assembled mutated Tau filaments to induce the aggregation of the intracellular expressed Tau protein 
(also incorporating mutations). Figure 4-1(Guo JL et al., 2011) shows that fibril induction significantly 
increased the amount of insoluble Tau protein in cells. However, it is worth noting that the Tau protein 
expressed in QBI 293 cells and that employed for the synthesis of in vitro filament were both mutated. 
It is questionable if wild type Tau filaments (image not shown in the publication) can have such a 
dramatic impact on cells expressing natural Tau protein. Hence, it is unclear if the aggregation was 
simply a result of the mutations on Tau. 
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Figure 4-1: Immunoblotting band of Tau protein. T stands for Triton soluble Tau which water soluble 
functional Tau, S stands for SDS soluble Tau which is fibril Tau and insoluble in water. The cells were 
incubated without and with Tau filaments alone, no chemicals were applied to facilitate the uptake of 
the aggregate. The filaments were assembled in vitro from Tau produced in E.coli, incorporating Myc-
K18 and P301L mutations. The cells were transfected to express Tau protein with P301L mutation (Guo 
JL et al., 2011). 
 
Among the cellular models for studying Tau pathology that have been developed, the induction of 
aggregation via the addition of exogenous Tau filaments carries most pathological significance based 
upon the spreading model, where neurodegenerative disease progression is suspected to follow a 
nucleation mechanism (reviewed in section 2.6). In contrast, the use of anionic dyes such as Congo 
red effectively generates Tau filaments using an artificial chemical that is not naturally present in the 
brain or any cell line. The mutation induced Tau protein aggregation only simulates familial AD which 
accounts for less than 5% overall. To best simulate the most common type of AD for Tauopathy study, 
in our work, a human cell line that expresses wild type Tau was induced with exogenous wild type Tau 
filament.   
 
4.1.2. Challenge: Tau purification from the cellular model 
 
Tau protein has to be purified from the cellular model for decent mass spectrometry characterisation. 
Ideally, healthy/functional Tau protein, intracellular assembled filament Tau and the in vitro 
synthesised Tau seeds should be recovered in different fractions. Furthermore, the relative purity of 
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Tau must be MS satisfactory in each fraction. For all the works summarised in Table 4-1 and most Tau 
protein PTM mapping efforts, immunoblotting analysis, a much less sample purity demanding 
characterisation method, was applied. The reported Tau purification (from mammalian cell line) 
approaches are reviewed below, but needs to be polished for decent MS study. 
 
a) Functional Tau  
The purification of functional Tau protein may take advantage of its microtubule binding capability. 
Tau protein was discovered in the microtubule fraction from porcine brain in 1975 (Weingarten et al. 
1975). Hence, Tau protein can be enriched from cell lysate through inducing microtubule assembly. 
Typically, cells were lysed in a neutral buffer that contained protease inhibitors using surfactant or 
sonication. The lysate was then centrifuged at 20,000 g and 4 oC to remove the nuclear content and 
other cell debris. Magnesium ions, glycerol and GTP (or Taxol) were then added to the supernatant 
and incubated at 37 oC for 45 minutes. Finally, the microtubule fraction was pelleted by centrifugation 
at 20,000 g, room temperature (Lodish H et al., 2000). 
 
b) Intracellular assembled Tau filament  
The intracellular filament Tau can be purified through multiple cycles of centrifugation. Typically, the 
cell lysate was centrifuged at 20,000 g to remove the nuclear content and other cell debris. Then a 
100,000 g – 200, 000 g centrifugation was performed and the pellet that contains the filament could 
be solubilised in surfactant such as SDS (Guo JL et al., 2011; Santa-Maria I et al., 2012; Goedert M et 
al., 1996).  
 
c) Exogenous Tau filament 
It was reported that, observed via immunoelectron microscopy, a significant fraction of the exogenous 
Tau filament was attached to the cell membrane (Guo JL et al., 2011). Previous work had not focused 
on the PTMs of the exogenous Tau filament that served as aggregation inducing agent. However, 
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comparing the PTMs on exogenous and intracellular filament Tau might help distinguish the cause and 
effect PTMs to aggregation.  
4.2. Material and Methods: Tau aggregation cellular model development 
 
The Tauopathy cellular model created in this study utilised recombinant protein Tau (see Chapter 3) 
to produce exogenous Tau filaments for treating HEK293T (generally just referred to as HEK293 cells 
later for convenience, because it's the only cell line used) cells expressing Tau to induce intracellular 
aggregation. The overall workflow was inspired by previous models developed based on the filament 
spreading mechanism (Nonaka T et al., 2010; Guo JL et al., 2011), and is illustrated in Figure 4-2. The 
recombinant Tau produced from E. coli (Chapter 3) was assembled into filaments in vitro. The Tau 
filaments were added to the culture medium of HEK293T cells that had been transiently transfected 
with the pcDNA 3.1 plasmid (Chapter 3) to express intracellular tau.  The spreading hypothesis being 
tested is that the endocytosis of the exogenous Tau filaments seeds the aggregation of the 
intracellular Tau in HEK 293 (Guo JL et al., 2011).  
 
The soluble/functional (intracellular synthesised Tau) and insoluble (exogenous and intracellular 
assembled filament) Tau were then purified separately and characterised using mass spectrometry. 
This chapter focuses on the development of the cellular model and the methods developed for the 
purification of untagged, intracellular tau from HEK293 cells; how the Tau protein sample fractions 
were prepared into mass spectrometry samples and the targeted mass spectrometry method for tau 
analysis is described in Chapter 5.  
 
4.2.1. Filament assembly 
 
The Tau protein purified from E.coli was treated with heparin (Sigma Aldrich, H3393) and the filaments 
formed were subsequently separated via centrifugation. Typically, filament assembly was achieved at 
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2-3 mg/ml concentration of Tau in 2ml of 30 mM MOPS buffer (Sigma Aldrich, M1254), 300 µg/ml 
heparin (average MW 28 kDa), 1 mM 4-(2-aminoethyl)benzene-sulphonyl-fluoride (AEBSF), pH 7.4 at 
30 oC. The solution was divided into 100 µl aliquots for incubation; evaporation was allowed to take 
place spontaneously as it drove the equilibrium in the favoured direction by further concentrating the 
Tau protein in solution.  
 
 
Figure 4-2: Work flow of the in cell model. Isotope labelling technique may be applied to distinguish 
the E.coli Tau and in cell synthesised Tau protein 
 
Following incubation, the solution was subjected to ultracentrifugation (100,000 g, 150,000 g and 
200,000 g) to pellet the filaments. Electron microscopy (EM) was performed to verify the formation 
and separation of these structures. The filament pellet was then washed and re-pelleted to remove 
heparin. Prior to addition to the culture medium of the HEK 293 cells, the re-pelleted filaments were 
re-suspended in PBS (Sigma Aldrich, D4031) and sonicated in an effort to break down any higher order 
aggregation of the individual filaments. The pellet yielded from 1 ml of Tau protein solution (2-3 mg/ml 
prior to filament assembly incubation) was re-suspended in 1 ml of PBS. Preparation of the filaments 
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for the seeding experiments were performed and stored at 4 oC less than 24 hours earlier to their 
application to the HEK293 cell cultures.  
 
4.2.2. HEK 293 culturing  
 
HEK 293 cells were thawed from 1 ml aliquots (stored in liquid nitrogen) and plated into 50 cm2 plates 
using a 1:20 split ratio. All seeding aliquots used for data generation were previously prepared from 
one passage of cells. The cells were grown in Dulbecco’s modified eagle medium (DMEM, Gibco, 
61965), with 10% fatal bovine serum (FBS, 16000-044, Lot: 1723615), 1% penicillin/streptomycin 
(Gibco, 15140-122) and 4 mM L-glutamine (Gibco, 25030-024). A typical culturing procedure is listed 
in Table 4-2, the cells were grown in twenty 50 cm2 culture plates per round of experiment. Though 
cell growth was carefully monitored, the distribution of cell density did vary between plates.  
 
Table 4-2: HEK 293 culturing time table, doubling time of the cell line is roughly 20 hours 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Action Resuscitati-
-on in the 
morning 
(e.g. 10 am) 
None None 1) Transfection in the 
morning (e.g. 8 am) 
2) Filament addition in 
the evening (e.g. 8 pm) 
Harvesting 
In the 
morning (e.g. 
8am) 
Culturing Time 0 hr 
(10 am) 
20 hr 
(6 am) 
40 hr 
(2 am) 
1) 70 hr (8 am) 
2) 82 hr (8 pm) 
92 hr 
Estimated 
confluency 
5% 10% 20% 1) 60% 
2) 80% 
100% 
 
a) Transient transfection  
Calcium phosphate transfection was performed to incorporate the pcDNA3.1 plasmid containing 
untagged Tau 1N4R into HEK 293T cells. Around 70 hours into the culturing, the cells were examined 
under light microscope to estimate its percentage of confluence was in the appropriate range of 50% 
- 70%. To prepare the transfection buffer, 240 µg of plasmid was mixed with 10 ml 0.5 M CaCl2 (Sigma 
Aldrich, C1016) solution. 10 ml of 1 M HEPES (Fisher Scientific, BP299-1), 280 mM NaCl (Sigma Aldrich, 
S5886), 1.5 mM Na2HPO4 (Sigma Aldrich, S7907) and 12 mM dextrose (Sigma Aldrich, D9434) pH 7 
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were then added to the mixture in a 50 ml conical tube and extensive air was bubbled through using 
50 ml pipette. The solution was further mixed with air via vigorous shaking and left at room 
temperature for 15 minutes. For transient transfection, 1 ml of this mixture was added to each 50 cm2 
plate of HEK 293 cells. 
 
Antibiotic selection was not performed on the transient transfected cells. The HEK 293T cells express 
large T antigen which enhances the replication of plasmid containing SV40 origin (pcDNA3.1 plasmid). 
However, the large T antigen expression gene was incorporated alongside with neomycin resistance. 
Hence, the pcDNA3.1 plasmid and HEK 293T cells have the same antibiotic markers: ampicillin (present 
in all HEK 293 strains) and neomycin.  
 
b) Addition of in vitro filaments to cell culture 
Filaments were added to the HEK293 cells 12 hours after transfection. Firstly, the medium was 
exchanged to a “starvation” medium, which consisted of Dulbecco’s modified eagle medium with 0.5% 
fatal bovine serum, 1% penicillin/streptomycin  and 4 mM L-glutamine. 100 µl of the filaments in PBS 
and 1.5 mg/ml wheat germ agglutinin (WGA, Sigma Aldrich, C9640), which reportedly mediates 
endocytosis, was then added to each culture plate (Guo JL et al., 2011). The plates were left to grow 
for another 12 hours before harvesting.  
 
4.3. Proposed Methodology for purification of Tau protein from HEK293 cells 
 
 
This section describes the workflow created for the purification of the untagged protein Tau from 
HEK293 cells.  This aspect of the work is particularly challenging, as the task is not only to enrich for 
untagged Tau as much as possible from a complex mammalian protein background, but also to be able 
to distinguish cytosolic protein tau (referred to as “soluble tau”) from the tau filaments (referred to 
as “insoluble tau”) formed via aggregation.  
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The proposed method for the purification of soluble Tau will exploit its biological function in binding 
microtubule structures, followed by TiO2 phospho-enrichment procedure. The purification of insoluble 
Tau will exploit the extraordinary stability of tau filaments and utilise ultracentrifugation. The overall 
workflow of the initial purification routes to recover and separate soluble and insoluble Tau are 
presented in Figure 4-3. Typically, cell harvesting was performed early in the morning and the entire 
purification process was completed on the same day.  
 
 
 
Figure 4-3: The work flow of Tau purification from HEK 293, soluble Tau attaches to the microtubules 
and the insoluble Tau can be pulled down by ultracentrifugation.  
 
a) Soluble/cytosolic protein Tau purification from HEK293 
Soluble untagged protein Tau was enriched from cytoplasmic lysates of HEK293 cells using 
microtubule assembly, which was originally used in the identification of protein tau. The harvested 
and washed HEK 293 cells were re-suspended in a lysis buffer consisting of 150 mM sodium glutamate 
(Sigma Aldrich, G1626), 30 mM NaH2PO4 (Sigma Aldrich, S9638), 0.5 mM CaCl2 (Sigma Aldrich, C1016), 
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0.25 mM DTT (Sigma Aldrich, 43815), 0.2 mM GTP (Sigma Aldrich, G8877), 10% glycerol (Sigma Aldrich, 
G5516), AEBSF(Fisher Scientific, 30827-99-7), phosphatase inhibitor cocktail (Thermo Fisher, 78428) 
and 1% Triton X-100 (Sigma Aldrich, T8787) at pH 6.8. The lysate was then centrifuged at 1,000 g for 
10 minutes and 20,000 g for 30 minutes to remove the nuclear content and the cell debris, respectively.   
The remaining supernatant is referred to as the cytoplasmic fraction.  
 
Temperature dependent microtubule assembly (Weingarten et al. 1975) was induced by incubation 
of the cytoplasmic fraction at 37 oC after adjusting the buffer to final concentrations of 0.5 mM MgCl2 
(Sigma Aldrich, M8266), 1 mM GTP, 25% glycerol and 1 mM EGTA (Sigma Aldrich, 34596).  The 
microtubule, along with any microtubule-associated proteins (MAPs; including Tau) was pelleted via 
centrifugation at 20,000 g for 1 hour at room temperature.  The corresponding pellet can be brought 
through a second round of microtubule disassembly and assembly for improved MAP enrichment, 
however there is a trade-off in terms of significant sample loss.  
 
The Tau protein in the microtubule fraction could be further enriched. Typically, the pellet was 
reconstituted in 100 µl DI water. A straightforward option was loading an aliquot, 10 µl, on a 12% SDS-
PAGE gel for separation by molecular weight. Alternatively, exploiting the fact that Tau protein is 
phosphorylated, TiO2 phospho-enrichment was performed on the pellet solution. Though the 
phospho-species were enriched at protein level, the protocol followed was exactly the same to 
phosphopeptide enrichment described in part c of section 5.2.1 
 
b) Insoluble/filament Tau protein purification 
The supernatant remaining from the microtubule assembly and pull-down (Fig 4-3) was further 
processed using ultracentrifugation to recovery any insoluble Tau filaments (Santa-Maria I et al., 2012; 
Goedert M et al., 1996). Two rounds of ultracentrifugation were performed: 100,000 g to further 
remove impurities and 200,000 g to collect the filaments. The pellet and supernatant from both 
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rounds of ultracentrifugation were all processed for further analysis using SDS-PAGE, followed by in-
gel tryptic digestion as described in 5.2.1.  
 
c) Tau protein in the 600 g pellet (exogenous filaments) 
 
Membrane and other cell debris were pelleted at 600 g to reduce the complexity of the protein 
background (Fig 4-3).  However, as discussed earlier in 4.1.2, the endocytosed Tau filaments may 
present as they were reported attaching to the membrane (Guo JL et al., 2011).  In addition, it is 
possible that this fraction potentially contains the newly translated Tau protein associated with the 
endoplasmic reticulum. Thus, the 600g fraction that usually contained membrane and cell debris were 
resolved using SDS-PAGE, and the protein bands corresponding to protein Tau were excised and 
processed for in-gel digestion as described in 5.2.1. 
 
Phospho-enrichment efforts on the exogenous and intracellular assembled insoluble Tau fractions 
were described in Chapter 5.3.1. It was rather straightforward to conduct TiO2 enrichment on the 
microtubule fraction as functional Tau were individual protein molecules. The complication arose as 
the Tau aggregates were folded and much bigger structures (20-30 nm diameter, 100-300 nm length, 
fibre structure) which inhibits them from binding to porous TiO2 particles (average pore size 10 nm).  
4.4. Results and discussion 
 
The proposed methodology for purification of cytosolic and filament-associated Tau from HEK293 cells 
was optimised before use in the cellular model for studying tau pathology. HEK 293 cells were 
transiently transfected with the pcDNA 3.1 plasmid to express Tau, and a Tau expression control set 
(without the addition of filaments) and an exogenous Tau filament treated set were processed in 
parallel to evaluate the nucleation mechanism hypothesis.   
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4.4.1. Purification of insoluble Tau filaments  
 
The main procedure for recovery of insoluble Tau filaments relies upon ultracentrifugation, as shown 
in Figure 4-3. Therefore, it is important to identify the optimal centrifugation speed that can 
differentially pellet the targeted aggregate. Hence, a study was conducted using the exogenous 
filament assembled from E.coli synthesised Tau. After incubation, as described in section 4.2.1, The 
solution was subjected to three rounds of ultracentrifugation, at 100,000g, 150,000g, 200,000g (as 
discussed in section 4.1, the reported ultracentrifugation rate varies from publication to publication). 
As shown in Fig 4-4b, electron microscopy analysis of the resulting 100,000 g pellet (reconstituted in 
DI water) revealed mostly particle-like structures, and not the expected filaments observed from in 
vitro filament assembly.   The corresponding supernatant was therefore presumed to contain any tau 
filament structures, and was subjected to ultracentrifugation at increased speeds of 150, 000 g and 
200, 000 g. 
 
No pellets of significant size were observed after 150,000 g, however a pellet at 200,000 g was 
identified and reconstituted with DI water for examination using electron microscopy. In Figure 4-4 it 
was seen that the EM images for in vitro filament assembly using recombinant Tau (Fig 4-4a) and the 
filaments purified using 200,000 g ultracentrifugation (Fig 4-4c) have the same morphology. The same 
EM results were observed for triplicate experiments, in which consistent patterns were observed. In 
addition, the pellet was dissolved in laemmli buffer (2% SDS) and loaded on a 12% SDS-PAGE gel 
(further described in section 5.2.1). The band corresponding to the apparent molecular weight of Tau 
was processed and characterised by MS to verify the biochemical identity of these filaments seen 
under EM. Tau protein was identified by MS and ranked the first in the Sequest general protein search 
with a decent score of over 500.   
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Thus, the optimal procedure for purification of insoluble tau filaments from HEK 293 cells was 
achieved via two rounds of ultracentrifugation of the supernatant remaining after the first stage of 
microtubule pull-down: impurities were removed at 100,000 g and tau filaments were pelleted at 
200,000 g.  
 
 
Figure 4-4:  a) Exogenous assembled filaments observed in Tau solution after incubation with heparin; 
b) Particles that were around 500 nm in diameter pulled down at 100,000 g centrifugation; c) 
Exogenous assembled Tau filaments pelleted at 200,000 g  
 
4.4.2. Purification of soluble (cytosolic) untagged tau from HEK293 via microtubule assembly 
 
The protocol for microtubule assembly for MAP purification was first optimised using HEK 293 cells 
not transfected with protein Tau. The supernatant and the pellet from centrifugation at 20,000 g after 
the first and second round of microtubule assembly were examined on a SDS-PAGE gel, as shown in 
Figure 4-5. The strongest Coomassie band in lane 4 of Figure 4-5 was excised, in-gel digested and 
identified to be a collection of tubulin (Alpha-1C, 1A, 4A and Beta-4B, 2B, 6) with molecular weight 
around 50 kDa via tandem mass spectrometry, which verified the effectiveness of assembling 
microtubules from cytoplasmic fractions and pelleting them at 20,000 g.  
 
It is worth noting that 1) microtubule assembly is temperature dependent; 2) the protein background 
is still quite complex after first round microtubule assembly as evidenced by a messy column on gel 
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(lane 2). Actin, another abundant cytoskeleton protein, also assembles into tubular polymer at 
elevated temperature and the presence of glycerol.  Further, the lysate was incubated at 37 oC for 45 
minutes and kept at room temperature while being centrifuged for another hour, it is very likely that 
some thermally unstable proteins denatured and formed aggregate in the meantime, and as a result 
made the pellet background more complicated.  
 
Figure 4-5: 12% SDS-PAGE gel: lane 1-4 were loaded with the supernatant and the pellet from 
centrifugation at 20,000 g after the first (1) and second (2) round of microtubule assembly, 
respectively. Evidently, the sample loaded on lane 2, microtubule pellet from first assembly, was fairly 
concentrated but still complex. Whereas, lane 4, loaded with the pellet from the second round of 
assembly re-suspended in DI water was particularly enriched in tubulin.  
 
Phosphoprotein enrichment using porous TiO2 and SDS-PAGE gel separation by molecular weight were 
applied to increase the relative concentration of Tau in the microtubule fraction. Table 4-3 compares 
the ranking and the score calculated by Sequest for the microtubule fraction being digested in solution 
against that being enriched using TiO2 then digested in solution. Evident from the table, TiO2 
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enrichment delivered outstanding sample quality even compared to the ranking and the score of the 
gel band excised from lane 2 (corresponding the apparent molecular weight of Tau 1N4R isoform, 
60kDa), where the pellet from first round of microtubule assembly was loaded. Hence, the better 
approach to further purify Tau protein from the microtubule fraction was phosphoprotein enrichment 
using TiO2. 
 
Table 4-3: Sequest ranking and score comparison for soluble Tau enriched via different approaches 
 Reconstituted 
microtubule pellet 
digest in solution 
Reconstituted microtubule 
pellet phosphoprotein 
enriched then digest in 
solution 
75kDa to 50kDa region gel band 
excised from the lane loaded 
with the microtubule fraction 
(in gel digestion) 
Tau ranking 177 5 64 
Tau score 31.12 207.05 81.41 
 
4.4.3. Pilot-scale validation of cellular model 
 
The cellular model was designed to mimic the spreading of AD via endocytosis of extracellular tau 
filaments to seed further nucleation. Therefore, to validate the hypothesis, samples purified from a 
control set (HEK 293T cells transient transfected with Tau plasmid but were not treated with 
exogenous filaments) was compared against that from the cellular model. 
 
a) Inconclusive evidence on the effect of seeding 
Insoluble and soluble Tau fractions prepared as described in 4.2 and 4.3 were resolved on a SDS-PAGE 
gel. A band corresponding to the expected molecular weight region for Tau, 50-75 kDa, was then 
excised from all lanes on the gel and processed for MS protein identification (following in gel digestion 
protocol, described in section 5.3.1). Figure 4-6 provides an example image of the resulting protein 
gel, which illustrates the protein background typically observed in each fraction. The strongest band 
in the apparent molecular weight range of 50-75 kDa was identified to be a 60 kDa heat shock protein, 
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which is presumed to be upregulated in response to the overexpression of Tau resulting from transient 
transfection on a CMV promoter.  
 
Figure 4-6:  12% SDS-PAGE gel: fractions collected from processing HEK 293 cells. Lane 1: 600 g cell 
debris pellet; Lane 2: microtubule pellet; Lane 3: cytoplasmic extract after microtubule assembly; Lane 
4: 100,000 g pellet; Lane 5: 200,000 g pellet.  
 
The MS run data was summarised in Table 4-4. Tau protein was identified in all fractions, but the 
ranking and score of Tau in each search were vastly different. The fact that Tau, in the targeted 
fractions (600 g, 200,000g and microtubule fractions) scored and ranked significantly higher suggested 
that the purification efforts were effective.  
 
However, as discussed in 4.4.2, soluble Tau protein in the microtubule fraction could be enriched using 
TiO2, instead of SDS-PAGE gel separation by molecular weight. In addition, the enriched sample could 
be digestion in solution subsequently, giving a higher yield of peptide (in gel digestion incurs great 
sample loss during extraction, discussed in section 5.3.1), hence, as seen in Table 4-3, achieving a 
better sample quality. TiO2 enrichment efforts were also made on other fractions which were 
described in section 5.3.1.  
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Table 4-4: Comparing the relative concentration of Tau in each fraction from control and filament 
addition experiment, measured by their ranking and score calculated by Sequest 
 Control HEK 293 treated with filaments 
 Ranking Score Ranking Score 
600 g cell debris pellet 12 149.61 12 178.07 
Microtubule pellet 64 79.63 57 90.14 
Cytoplasmic extract 211 31.91 189 27.25 
100,000 g pellet 104 10.11 134 8.98 
200,000 g pellet 30 121.44 11 131.56 
 
The relative concentration of Tau in all targeted fractions showed difference to certain degree as 
measured by the ranking and score.  Based on the hypothesis, solid positive identification of Tau 
protein was expected for the insoluble Tau fractions in the seeded group, in contrast to the absence 
of Tau protein in the corresponding fractions for the control group. However, no significant seeding 
effect could be deduced based on the ranking and score for the insoluble Tau fractions. Hence, the 
peak area (MS1) for three peptides that have been identified with confidence for the insoluble 
fractions is compared in Table 4-5 for futher analysis.  
 
Table 4-5: Peak area comparison for the three confident identified peptides in common; Note: base 
level for all runs were at E3-E4. 
  Control Filament treated 
 Peptide Peak area Average Peak area Average 
600 g pellet TPSLPTPPTR 2.54E5 4.77E6 7.56E4 1.29E6 
 LQTAPVPMPDLK 5.12E6 1.34E6 
 IGSLDNITHVPGGGNK 8.93E6 2.44E6 
200,000 g pellet TPSLPTPPTR 3.77E5 3.44E6 9.78E4 1.54E6 
 LQTAPVPMPDLK 4.66E6 1.07E6 
 IGSLDNITHVPGGGNK 5.28E6 3.45E6 
 
 
 The filament treated samples contained less amount of Tau protein compared to the control ones, 
based on the comparison of peak area presented in Table 4-5. However, such difference is also 
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insignificant. In fact, the difference might even be a result of uneven sample loss during post 
harvesting processing. Hence, further work is required for the development of the cellular model. 
Characterisation methods in addition to protein gel and MS may also be applied 
 
4.4.4. Further work on cellular model development  
 
The MS data on the sample fractions suggests that the cellular model is not functioning as designed 
yet. There are couple potential issues to be scrutinised: 1) the effect of Tau overexpression; 2) 
endocytosis of the filaments; 3) effects of the filaments in Tau expressing cells.  
 
a) The effect of Tau over expression 
It is possible that the transient transfection resulted in over expression of Tau and intracellular Tau 
aggregates were formed even without the addition of an inducing agent. Hence, no significant 
difference could be made via the addition of filaments as seed. In fact, it had been reported that 
overexpression of the repeat domain of Tau protein in N2a neuroblastoma cells led to aggregation 
formation (Bergen M et al., 2006).  
 
To verify this hypothesis, a fluorescence dye, ThS, may be applied for aggregation detection. 
Alternatively and more directly, the 200,000 g pellet from a control set may be subjected to TEM 
imaging instead of MS characterisation. Observation of filaments could confirm that the insoluble Tau 
aggregates in the 200,000 g was a result of overexpression. Furthermore, a cell line that stably 
expresses Tau at moderate level (no virus promotor) may be examined. Absence of Tau protein in the 
200,000 g fraction could also prove the point. Cell line that stably expresses Tau at moderate level 
may be preferred if investigation of overexpression proves it could trigger significant level of 
aggregation. 
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b) Endocytosis of the filaments 
The endocytosis of the filaments was not proven. It is also possible that the insignificant difference 
between the control and the seeded group was due to the failed or poor uptake of the filaments. The 
cellular model was simply designed to take the previous work to the next stage: investigating the 
intracellular aggregation of the wild type Tau, instead of the mutated Tau (Guo JL and Lee VM 2011; 
Santa-Maria I et al., 2012). We took for granted that WGA, as it was reported, is sufficient to mediate 
the endocytosis of the Tau filaments as they claimed. Further, we assumed that the filaments would 
arrive and stay in cytoplasm to induce aggregation as described previously (Guo JL and Lee VM 2011, 
anchored on the membrane, projected itself into the cytoplasm). However, these matters have to be 
scrutinised in future work.  
 
The in vitro assembled filaments may be fluorescence marked for its fate to be monitored.  
Alternatively, immuno-microscopy could be performed. It is important to keep track of the filaments, 
making sure it is up-taken by the cells and stays long enough in the cytoplasm to induce nucleation. 
Filament treatment may be considered a success if it is visualised that considerable amount of the Tau 
aggregates were endocytosed and managed to maintain their presence in the cells. Micro-injection or 
other more aggressive bio-porter reagents might be applied if WGA is proven powerless in facilitating 
the endocytosis of Tau filaments. However, the hypothesis may be proven false if it was observed that 
the filaments are destroyed quickly (in a matter of minutes) upon entering the cells, either by 
lysosomes or other metabolic pathway. 
 
c) Effects of the filaments in Tau expressing cells 
The in vitro nucleation experiment may not be reproducible in cells. Though it was solidly 
demonstrated that the Tau filaments could be used to induce aggregation of originally extremely 
water soluble Tau in vitro (Friedhoff P et al., 1998), it is questionable if the cytoplasmic background 
would support such reaction, with the presence of numerous enzymes and possibly cofactors that can 
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inhibit the assembly of Tau. Furthermore, the concentration of both the seed and Tau protein is much 
lower in cells. Hence, the time frame for nucleation might change from hours to days.  
 
The nucleation event may be monitored via immuno-microscopy visually and MS quantitatively, once 
the first two issues are cleared. Immuno-microscopy should allow the visualisation of the spreading 
mechanism. Whereas, if the quantity of Tau aggregates changes significantly overtime, measuring 
peak area of the Tau peptides from the 200,000 g fraction should provide quantitative evidence of 
filaments accumulation.  
 
4.5. Summary 
 
Three fractions, one soluble and two insoluble fractions of Tau protein have been purified from HEK 
293 cells, ready for MS characterisation. A cellular model is in development to test the Tau filament 
nucleation spreading mechanism.  pcDNA 3.1 plasmid produced by XL10 Gold E.coli strain enabled the 
synthesis of Tau protein (1N4R, wild type)  in HEK 293T cells via transient transfection. BL 21 E.coli 
strain produced Tau protein (1N4R, wild type) were assembled into filaments and applied to HEK 293 
cells as exogenous seed.  
 
a) Successful soluble Tau protein purification 
An effective purification protocol was developed for soluble Tau. Microtubule was reassembled in the 
lysate and pulled down via centrifugation. Among other microtubule associated proteins, Tau was also 
isolated from the complex cytoplasmic extract background. The relative concentration of Tau protein 
which is naturally phosphorylated was further increased through TiO2 phosphoprotein enrichment 
protocol. More efforts on further purifying the insoluble Tau samples were described in Chapter 5. 
 
b) Inconclusive results on the nucleation mechanism hypothesis 
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No obvious effect of exogenous seeding was observed using the cellular model so far. Every effort has 
been taken to develop a cellular model that is most physiological relevant: mutation and polyanions 
were not incorporated/applied as aggregation inducing agent. However, as observed clinically, the 
spreading of Tau filaments might take a fairly long period of time under natural condition. The 
timeframe of the experiment could be expanded further. Furthermore, the endocytosis of the Tau 
filaments was yet to be confirmed. In addition, transient transfection may have already resulted in 
aggregation as Tau protein was overexpressed. These hypothesis needs to be verified in future study. 
 
c) Proper candidate sample to test the MS Tau protein targeting method 
 
The Tau proteins extracted from such pathology model developed in human cells should have the 
same or similar PTM profile to that in the neurons of an AD patient, hence, serving as proper candidate 
samples to support the development of the MS based Tau PTM characterisation method. A tailored 
MS method designed to better identify Tau protein and its phosphorylation profile was developed, 
described in Chapter 5. Further, an attempt (SILAC) to differentiate the filaments applied for seeding 
and the in cell synthesised Tau aggregate were made to better understand the nucleation mechanism. 
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Chapter 5 
 
 
 
 
 
 
Tau Protein Targeted MS 
Method Development 
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5.1. Introduction 
Mass spectrometry has become significantly more sensitive and accurate (due to nano scale LC and 
ESI interface, etc. see section 2.9) and is now in good shape to serve as a characterisation method to 
discover and validate protein post-translational modifications (PTMs). In this chapter, a targeted MS 
method to study the phosphorylation of Tau protein from an in cell model was developed. The 
targeted method was designed and tested using high purity Tau protein produced from E.coli 
(described in Chapter 3) for application in the analysis of untagged Tau partially purified from complex 
mammalian cell backgrounds (described in Ch 4).  A nice feature of this workflow is that it could be 
immediately adapted for analysing Tau recovered from human tissue. In addition, a SILAC (stable 
isotope labelling with amino acids in cell culture) experiment trial was conducted in effort to 
understand the role of PTMs in aggregation.  
 
5.1.1. Mass spectrometry: an alternative to immunoblotting analysis for PTM study 
 
Immunoblotting analysis has been the standard tool to study post translational modifications (PTMs) 
by default in biochemistry. The method has indeed identified numerous phosphorylation sites on AD 
protein Tau, while being not so demanding with respect to both the quantity and the purity of the 
sample. However, mass spectrometry may serve as a characterisation method to cross check the PTMs 
being reported. In addition, MS allows the development of an unbiased discovery method that can be 
directly used to analyse any sample, whereas, antibodies need to be raised first to enable 
immunoblotting analysis (Mann M 2006).  
 
In 2009 (DiMaggio PA et al., 2009), it was reported that the PTMs of the proteins purified from 
mammalian cells was successfully analysed by mass spectrometry via targetd approach.  In their work, 
histone proteins were purified to a certain extent, digested by trypsin, then loaded to a liquid 
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chromatography unit that was connected to a state of art mass spectrometer. The liquid 
chromatography unit allowed the peptides to be separated across time based on their hydrophobicity, 
hence, making the background less complex at any time point for the MS, achieving a greater 
sensitivity. Moreover, the m/z ratio, charge state and the retention time of the peptides were 
recorded. A histone targeted method was developed based on these information, allowing better 
analysis of the protein of interest in a less pure sample. 
 
5.1.2. Mass spectrometry phosphorylation characterisation on protein Tau 
 
The investigation on the phosphorylation profile of Tau protein using mass spectrometry techniques 
started in 1992 (Hasegawa M et al., 1992), after the hyperphosphorylation of the protein came to light 
in 1986 (Grundke-Iqbal I et al., 1986; Ihare Y et al., 1986). However, despite of all the effort that was 
made, the state of art mass spectrometry allowed only the prediction of peptide sequence based on 
their charged mass (MHn+). The peptides were not fragmented and confirmed, hence, the findings of 
the study were not conclusive.  
 
Mass spectrometry based proteomics technologies have improved over time in terms of both 
sensitivity and resolution. An attempt to comprehensively study the phosphorylation of Tau protein 
using MS was made in 2000 (Reynolds CH et al., 2000). It was demonstrated that the phosphorylated 
Tau peptide could be identified by their m/z (MS1) and the m/z of the individual amino acids (with 
their modified residue, the PTMs) after fragmentation (MS/MS). The study was conducted using in 
vitro phosphorylated recombinant protein Tau purified from E.coli. Kinases applied for in vitro 
phosphorylation includes extracellular signal-regulated kinases 2, glycogen synthase kinase 3 and c-
Jun N-terminal kinase, microtubule affinity regulating kinase and stress-activated protein kinase.  
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The MS method suppose to provide solid proof for the presence of the peptide and the PTMs on it. 
However, extremely limited number of spectra with poor quality were shown: one MS1 spectrum and 
two MS2 spectra (two of them shown in Figure 5-1b).It is worth noting that analysing protein Tau 
sample from a more complex background is more challenging as the MS based methods are, in general, 
a lot more demanding in sample purity compared to immunoblotting analysis. 
 
 
Figure 5-1: a) MS1 spectrum reported in 1992: two doubly charged peptides and one singly charged 
peptide were identified based on their m/z ratio (Hasegawa M et al., 1992). Two of them are predicted 
to be phosphorylated. b) MS1 (top) and MS2 (bottom) spectra published in 2000. The continuous 
coverage of Y ions detected in MS2 provided convincing prove that the peak spotted in MS1 is indeed 
what was predicted (Reynolds CH et al., 2000).  
 
Brain tissue in gram quantity had been characterised using MS. Hanger and his co-workers purified 
PHFs from human brain via extensive centrifugation and ion exchange chromatography in 2007 
(Hanger DP et al., 2007). More recently, in 2015, the method was applied to mice brain tissue (Morris 
M et al., 2015). In both studies, extensive phosphorylation sites were uncovered, but the sample 
consumption for each run was spectacular: the work flow may not be applied to cultured cells 
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economically. MS work on Tau protein using smaller sample amount was also conducted (Bros P et al., 
2015), Tau protein concentration in cerebrospinal fluid was proposed as a biomarker for AD, however, 
only general Tau peptides were successfully discovered (via SIM approach), phospho-peptides which 
are at a much lower relative concentration were not reported. None of the works described above 
contain spectra as evidence, in the article or in the supplementary material.  
 
Importantly, for all the MS work on Tau protein, extremely limited spectra have been made 
available, hence, the validity of their findings could not be evaluated. Our aim is to a) create a 
comprehensive spectral library that contains the retention time, the m/z and spectra (MS1 and MS2) 
for the Tau general peptides and phosphopeptides; b) develope a targetd MS method for Tau 
protein using such encyclopedea.  
 
The analysis of phosphopeptide, especially site localisation, using MS remains a challenge. The MS 
method must cope with low sample amount as the purification of protein from complex background 
is also problematic. In addition, Tau protein sample that bears physiological significance is either 
purified from mammalian cells or human/aminal tissue, hence the quantity of the “raw material” is 
also extremely limited and precious. Therefore, bottom up work flow was choosen for our work as a) 
it is less demanding in sample amount than the top down approach; b) shorter peptides resolve better 
than longer peptides (if middle down approach is choosen) on the online LC, therefore providing 
better sensitivity. CID is the fragmentation method compatible with bottom up work flow as it works 
better on smaller peptides. In addition, the Velos Pro LIT in our lab is a low resolution equipment, 
hence, not suitable for ETD and ECD which are better for phosphopeptide analysis as they preserve 
the weak covalent bond attaching the phospho group (discussed in section 2.9.1).  
5.2. Materials and methods 
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The purified protein fractions were processed for MS analysis, overall work flow shown in Figure 5-3. 
In the process of preparing MS sample, efforts in further purifying Tau via TiO2 phospho-enrichment 
in the insoluble Tau sample, the fractions collected at 600 g and 200,000 g centrifugation, was made. 
Some pilot studies using E.coli produced Tau were conducted to gather the data for the development 
of a method that targets the peptides of interest, overall work flow demonstrated in Figure 5-2. The 
spectra generated was first analysed by the commercially available software, Sequest (Thermo), then 
analysed using an in-house unconstrained mass sequencing software for manual validation of site 
localisation. Finally, The targeted method was tested on a soluble Tau protein sample purified from 
the cellular model. In addition, a SILAC (stable isotope labelling with amino acids in cell culture) 
experiment trial was conducted in effort to understand the role of PTMs in aggregation through 
differentiating the exogenous filament against the intracellular generated insoluble Tau. 
 
 
 
Figure 5-2: The overall work flow for the Tau protein spectra liberary building 
 
 
Figure 5-3:The overall work flow for HEK 293 Tau protein sample MS run 
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5.2.1. MS sample preparation 
 
Peptides consist of 8-10 amino acids are ideal for bottom-up MS analysis as they typically fragment 
rather well via CID.  The recovered Tau may be digested in-solution (for the soluble Tau fraction, after 
being enriched using TiO2) directly or loaded on the gel to be further purified and digested depending 
upon sample complexity. For the insoluble Tau samples, the peptides with the PTMs of interest, 
phosphorylation, were further enriched using TiO2. The digestion enzyme chosen in this study was 
trypsin, as it could cleave to give peptides of satisfactory length and for its compatibility with many 
existing software for data analysis.  The MS sample processing work flow largely follows the protocol 
developed by Prof. Mattias Mann (Rappsilber J 2003). 
 
a) In-solution digestion of soluble, microtubule-binding Tau 
The soluble and wild type Tau, after phosphoprotein enrichment by TiO2, was digested in-solution 
directly. In-solution digestion is significantly more efficient than in-gel (SDS-PAGE) digestion, due to 
the absence of gel hindrance. The overall recovery by in-solution digestion was tremendously better 
as the incomplete extraction of peptides from the gel is avoided. The overall work flow of in-solution 
digestion is illustrated in Figure 5-4.  
 
 
Figure 5-4: In-solution digestion: the disulphide bonds were reduced and thiols carbamidomethylated, 
then the proteins were digested into peptides. 
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Disulphide bond was reduced prior to digestion to give unbridged peptides. Typically, 10 µl of the 
sample solution was mixed with 50 µl of 100 mM NH4HCO3 (Sigma Aldrich, 09830), to bring the 
solution to pH 7-8. 10 µl of 30 mM DTT and 100 mM NH4HCO3 solution was then added to the sample. 
After mixing, the sample was incubated at 51 oC for an hour. To prevent the disulphide bridge from 
forming again, the cysteine residue was labelled by iodoacetamide (Sigma Aldrich, I1149). 10 µl of 100 
mM iodoacetamide and 50 mM NH4HCO3 was added and the sample was then kept in dark for 45 
minutes. Finally, 2 µl of the 30 mM DTT and 100 mM NH4HCO3 was added to quench the iodoacetamide.  
 
Trypsin digestion was performed by adding trypsin (Promega, V5111) at 1:50 mass ratio to the total 
protein in the sample. The digestion was carried out in NH4HCO3 solution due to the intrinsic 
disordered structure of Tau protein (the conventional 4M urea condition was not needed to denature 
the proteins). Typically, the sample was incubated at 37 oC for 6 – 8 hours. The resulted solution was 
then made up to around 200 µl with acetic acid wash (0.1% acetic acid, 99.9% water, Sigma Aldrich, 
320099), to adjust the pH to 2-3. Then the sample solution was stage tipped, shown in Figure 5-5. The 
solution was loaded on C18 putty (3M, 2215), washed with methanol (Fisher Scientific, A456-212) and 
equilibrated by acetic acid wash. The peptides stuck to the putty was washed with 200 µl of acetic 
wash, then eluted by 200 µl of 75% MeCN (Fisher Scientific, A955-212), 20% water and 5% acetic acid. 
The eluent was dried on the vacuum centrifuge to 1 µl and reconstituted in, typically, 10 µl of TFA 
(Sigma Aldrich, 14264) load (99.4% H2O, 0.5% MeCN and 0.1%TFA).  
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Figure 5-5: Stage tipping removes the salt content in the sample, making it MS friendly.  
 
b) In-gel digestion of Tau from complex backgrounds 
The water insoluble Tau aggregate, corresponding to Tau assembled into filament structures 
(potentially anchored to the plasma membrane), was solubilised in SDS and loaded on protein gel. Tau 
has to be liberated from the filament structure to be well digested, before fed to the MS. In previous 
publications (Santa-Maria I et al., 2012; Goedert M et al., 1996), it has been reported that these 
aggregates are soluble in 2% SDS. Hence, mixing the Tau filament sample with 2 x concentrated 
Laemmli buffer (4% SDS) should allow dissolution. Further, the peptide recovered from in-gel digestion 
is SDS free, therefore, MS friendly. The idea was tested on filaments assembled from E.coli produced 
Tau and verified using EM; a gel image and the sample preparation are shown in Figure 5-6. 
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Figure 5-6: a) The filament (pellet) assembled form E.coli Tau (as described in section 4.2.1) was loaded 
on SDS-PAGE gel. Evidently, the filament effectively dissolved back to Tau monomers b) The filament 
pellet, yielded from 200,000 g centrifugation, of 5-10 µl by volume, was washed with 100 µl DI water 
twice to remove any Tau monomer left. Then the pellet was mixed with 10 µl Laemmli buffer and 
incubated at 95 oC for 5 minutes. Finally, after mixing by pipetting, the sample was loaded on the gel.  
 
 
 
Figure 5-7: In-gel digestion work flow: disulphide bond reduction and labelling were performed prior 
to digestion. The proteins were digested in-gel and then extracted from the gel through multiple 
rounds of rehydration and dehydration cycles  
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The insoluble fraction (pellet from centrifugation at 600 g and 200,000 g) were treated with Laemmli 
buffer (2% SDS) to dissolve the filaments into monomer Tau. The samples were then loaded on SDS-
PAGE gel for further separation by molecular weight. Figure 5-7 summarises the in-gel digestion work 
flow.  
 
The SDS-PAGE gel served as a separation and SDS cleaning tool. Typically, 10 µl of sample solution was 
mixed with 10 µl of 350 mM DTT laemmli buffer. The mixture was incubated at 95 oC for 5 minutes, so 
that the disulphide bonds were reduced and the protein molecules were linearised. Then 20 µl of the 
solution was loaded into each lane of a 12% gel. The gel was run at 170 volts for 75 minutes. Once the 
proteins were well separated, the gel was then stained in Coomassie blue and destained in 40% water, 
40% methanol and 20% acetic acid.  
 
The section of the gel falls into the molecular weight range corresponding to the protein of target (Tau 
has an apparent molecular weight of around 60 kDa, discussed in chapter 3) was excised and diced 
into pieces smaller than 1 mm in any dimension. The gel pieces were washed with 100 mM NH4HCO3 
couple times to neutralise the acidic destaining buffer left in the gel. The gel was then dried on the 
vacuum centrifuge for disulphide bond reduction and labelling. Typically, 100 µl of 10 mM DTT and 
100 mM NH4HCO3 was added to the gel pieces and allowed incubation at 51 oC for an hour. The 
solution was subsequently replaced with 100 µl of the 55 mM iodoacetamide and 50 mM NH4HCO3 
solution, followed by incubation at room temperature for 45 minutes in dark.  
 
The proteins were digested in-gel. The gel pieces, post disulphide bond reduction and labelling were 
dehydrated by MeCN and dried on vacuum centrifuge. Trypsin stock was diluted to 12.5 ng/µl and 
added to the dried gel pieces (enough to cover all pieces). The mixture was kept on ice for 45 mins to 
allow the absorption of trypsin. Then the temperature was elevated to 37 oC to promote the activity 
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of trypsin. After 8-10 hours, the proteins in the gel were cleaved into peptides and could diffuse out 
from the gel.  
 
Four rehydration and dehydration cycles were performed on the gel pieces to extract as many 
peptides as possible, detailed in Figure 5-8. 50 mM NH4HCO3 was used to rehydrate the gels for all 
four cycles, whereas, 75% MeCN, 20% water and 5% formic acid (Sigma Aldrich, 56302) was employed 
to dehydrate the gel pieces for the first two cycles and 100% MeCN was used for the last two 
dehydration cycles. The extract was dried to around 10 µl and made up to 200 µl with 0.1% acetic acid 
and 99.9% water for stage tipping, the procedure followed was the same to that described previously. 
Alternatively, TiO2 phosphopeptide enrichment was performed on the vacuum centrifuge 
concentrated extract prior to stage tipping.  
 
 
Figure 5-8: Rehydration dehydration cycles: 4 cycles were conducted in total, the amount of reagent 
applied in each cycle depends on the amount of gel pieces. Rehydration and dehydration can be 
observed visually as the gel pieces swell and shrink.  
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c) Phospho-peptide enrichment using TiO2 beads 
The phospho-peptides were enriched from the peptides generated from enzymatic digestion using 
TiO2 beads (GL Science, 5020-75010). In addition, the enrichment procedure is also effective for 
phosphorylated protein molecules (structures that are smaller than the average pore size, 10nm, of 
the beads). Hence, the enrichment was performed on the soluble Tau fraction at protein level (post 
microtubule enrichment) and on the insoluble Tau fraction after in-gel digestion. 
 
The porous TiO2 adsorbs phosphorylated peptides at acidic conditions and desorbs them at basic 
conditions. Therefore, typically, 10 mg of the beads were incubated with 500 µl of loading buffer, 
saturated glutamic acid (Sigma Aldrich, G1251), 65% MeCN, 2% TFA (Sigma Aldrich, 14264), for 15 
minutes. The sample solution (concentrated to 10 µl or so using the vacuum centrifuge) was made up 
to 500 µl of the loading solution and shaken with the beads for 30 minutes.  The beads were then 
pelleted through centrifugation and the liquid content was replaced with another 800 µl of loading 
buffer. Another two rounds of washing were done with 65% MeCN, 0.5% TFA and 65% MeCN, 0.1% 
TFA respectively, also mixed by shaking, but for 15 minutes only.  
 
 
Figure 5-9: Phospho-peptide enrichment using titanium dioxide beads: the sample solution was 
loaded on the beads, gradient washed three times and then gradient eluted three times.  
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Elution was then performed after washing, again following a similar procedure, but with 200 µl eluent. 
The first round of elution was done with 300 mM NH4OH (Sigma Aldrich, 320145) and 50% MeCN, 
whereas, the second and third round of elution were done with 500 mM NH4OH and 60% MeCN, pH 
13-14. Finally, the three elution aliquots were pooled and centrifuged at 15,000 g.  550 µl of the 
supernatant was collected, leaving behind TiO2 beads carried over from previous steps. To prepare 
the phospho-peptides for MS characterisation, the solution was dried down and stage tipped as 
described in part a of this section.  
 
5.2.2. Targeted MS method 
 
The background of the untagged Tau samples purified from HEK 293 was still fairly complicated, 
despite the purification scheme developed in Ch 4. To improve the level of sensitivity, the sample was 
loaded to a LC-MS complex (with a trap column, C18 nana, 20 mm x 75 µm I.D. particle size 2 µm, 
11352013). The flow through the LC column (C18 nano, 150 mm x 75 µm I.D. particle size 2 µm, 
11342013, Fisher Scientific) started with 1% eluent B (95% MeCN, 5% H2O and 0.1% FA) and 99% 
eluent A (99.9% H2O and 0.1%FA) at 0.3 µl/min. Then the percentage of eluent B was increased to 50 
within the first 88 minutes. Later, from the 88th minute to the 116th minute, eluent B reached to 95%. 
In the end, the composition was adjusted back to 1% eluent A in the last 4 minutes of the 120 minutes 
run. The LC was connected to a Velos Pro dual-pressure linear ion trap mass spectrometer (Thermo 
Fisher) where CID fragmentation was performed.  
 
In addition to the LC, the MS method was instructed to fragment only the targeted m/z in MS1. To 
determine the targeting m/z, multiple mass spectrometry run on Tau protein purified from E.coli and 
HEK 293 were performed (the peptides being targeted are summarised in section 5.3.2, part a). For 
the data collecting pilot runs (mostly using high purity E.coli produced Tau protein), a general protein 
discovery MS method was applied. CID collision energy was set at 35% and a 120 minute acquisition 
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time frame was employed with a 240-1800 m/z scan range. The top 5 most intense ions from MS1 
were identified and further fragmented in MS2. Repeat count of 2 was set for the dynamic exclusion 
list which has a repeat duration of 10 secs. To prevent repeat sampling of a previously fragmented 
peptide, exclusion list size 100 and exclusion duration of 100 secs was employed.   
 
To determine the targeted m/z, a fragmentation spectra encyclopaedia (see appendix) was built based 
on the peptides discovered from both Tau samples prepared via the in-gel and in-solution digestion 
route. An additional reference phosphorylated peptide spectra encyclopaedia (see appendix, also 
summarised in section 5.3.2, part a)  was then built based on the data generated from the in vitro 
phosphorylated E.coli purified Tau (incubated with 0.5 mg/ml ERK, 10 mM MgCl2 and 200 µM ATP at 
pH 7 for 2 hours).  
 
The encyclopaedia was then used to verify the peptide hits from multiple data set generated from HEK 
293 samples via general discovery method. Eventually, the targeted m/z values included in the MS 
method file were corresponded to 5 non-phosphorylated peptides and 6 phospho-peptides. Tau 
samples purified from HEK 293 was then analysed using the targeted method for better signal capture. 
The same LC gradient was employed. Furthermore, for the targeted method, 6 scanning events were 
incorporated for MS1. The first five scanning events targeted only the m/z for the peptide of interest, 
whereas, the last scanning event looked for the top 5 most intense ions. Other parameter such as the 
CID collision energy and acquisition time remains the same. In the context of the SILAC labelled 
experiments, the targeted method was adjusted to incorporate the mass shift for the peptides that 
supposed to be heavy labelled.  
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5.2.3. SILAC labelling: differentiating between cellular Tau and in vitro filaments 
 
There has been a debate on whether the hyper-phosphorylation of Tau protein is a cause or an effect 
of its aggregation. The lately emerged stable isotope labelling by amino acid in cell culture (SILAC) 
technique (Ong, S. E. et al., 2002, Blagoev, B. et al., 2003) would enable the analysis of the spreading 
mechanism of Tau aggregates in AD. MS could distinguish the proteins that were grown in different 
culture by their mass shift resulted from incorporating amino acids containing heavy isotopes, such as 
13C6. Therefore, allowing the study of PTMs developed in the seeding Tau filaments which were 
produced from E.coli and that of the Tau proteins that were synthesised in the mammalian host cells. 
If the Tau filaments assembled using E.coli Tau was also hyper-phosphorylated, then such abnormal 
PTM would more likely be an effect of the aggregation, rather than a cause. 
 
Trypsin digestion resulted in peptides ending with either lysine or arginine (in the case of miss-
cleavage, more than one lysine or/and arginine might be found in the peptide). In addition, some of 
the peptide targeted (see Table 5-2 contained only lysine or arginine. Therefore, both SILAC labelled 
lysine (M+4, hydrogen labelled, Sigma Aldrich, 616192) and arginine (M+6, carbon labelled, Sigma 
Aldrich, 643440) were applied. The isotope labelled lysine (25.6 mg in 500 ml) and arginine (124.6 mg 
in 500 ml) were added to the DMEM medium free of these two amino acids (Gibco, A14431). The 
SILAC medium was then used just as the standard DMEM full medium. Alternatively, the E.coli 
produced Tau could be labelled instead, however, the amount of SILAC reagents required for the 
culture medium makes the option economically infeasible.  
5.3. Results and discussion 
The purification procedure coupled with the targeted method developed in this study allowed efficient 
analysis of phosphorylation on untagged Tau protein purified from mammalian cells. The sample 
preparation protocol was optimised after conducting several rounds of pilot studies. An encyclopaedia 
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was put together based on the data generated from purified E.coli Tau.  It was a foundation for the 
building of a method targeting on Tau peptides of interest. The preliminary data generated using the 
Sequest general protein discovery MS method on HEK 293 Tau protein sample was also taken into 
consideration.  
 
The targeted method was applied to the microtubule fraction from HEK cells which resulted in better 
peptide/phosphorylation sites discovery. In this study the in vitro prepared filaments were 
differentiated from the in cell synthesised Tau aggregate through SILAC labelling. But, unfortunately, 
the attempt was failed as the expression of Tau protein was inferred.  
 
5.3.1. Pilot studies for method development 
 
Pilot studies were conducted to optimise the sample processing route and to understand the 
background complexity. Ideally, phospho-peptides should be enriched for the insoluble Tau protein 
samples. Unfortunately, phospho-peptides enrichment had failed for the insoluble Tau peptides, 
extracted from the SDS-PAGE gel. the MS sample preparation pathway for the different fractions are 
summarised Table 5-1.  
 
Table 5-1: MS sample preparation route summary 
 600 g membrane fraction Microtubule pellet 200,000 g Filament 
In-solution digestion              N/A                Yes             N/A 
In-gel digestion              Yes        Not chosen             Yes 
TiO2 enrichment              Failed                Yes             Failed 
 
The in cell pathology model described in Chapter 4 was built to be as physiologically relevant as 
possible. Mutation was not incorporated in neither Tau protein expressed in HEK cells nor the E.coli 
produced Tau that were employed to synthesis filament/seed in vitro. Only WGA was applied to 
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facilitate the endocytosis of the filaments. However, such design posed great challenge to purification, 
as the amount of filament Tau produced would not be as much compared the mutation based models. 
 
In general, in-solution digestion is preferred for its greater cleavage efficiency and higher sample 
recovery. However, attempts to use in-solution digestion on the insoluble tau fractions often resultin 
column blocking, therefore SDS-PAGE was used to clean up the samples before Ms analysis. One 
possible cause was that the Tau aggregate could not be broken down completely by trypsin as some 
cleavage sites might be hindered. Therefore, all samples that potentially contained filament Tau were 
dissolved in 2% SDS (Laemmli buffer) and the in-gel digestion protocol was then followed.  
 
Phospho-peptide enrichment was not compatible with in-gel digested samples. To improve the signal 
of the analytes of interest, enrichment is necessary for decent MS analysis as the phosphorylated 
proteins were significantly minor to the unmodified proteins. However, all three attempts made were 
failed, despite that in-gel digestion followed by TiO2 enrichment was reported previously (Jorg V H, 
2011). Loading of TiO2 phospho-peptide enriched samples post trypsin digestion in-gel resulted in 
irreversible LC column clogging. The retention time of all peptides were delayed for around half an 
hour comparing to normal runs, illustrated in Figure 5-10.  
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Figure 5-10: Retention time shift. The peptide extracted from the gel was subjected to phospho-
peptide enrichment using TiO2. However, the LC column was clogged when the resultant sample was 
loaded. Peptides started eluting off from the column around 30 minutes later.  
 
Though wild typeTau protein and insoluble Tau aggregates were both successfully produced, the 
preliminary data generated was not satisfactory. Four rounds of pilot studies on the microtubule 
fraction were conducted, only one solid phospho-peptide discovery was made (see Table 5-3). Hence, 
to improve the sensitivity of the MS characterisation, a Tau protein targeting method was developed. 
No difference, with regard to the overall coverage of the phospho-peptide sequence and the spectra 
quality, was observed between the samples being enriched by TiO2 at protein level and peptide level. 
Therefore, enrichment at protein level was preferred as it allows the analysis of the none-
phosphorylated Tau peptides. 
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5.3.2. Targeted method  
 
Targeting on the m/z corresponding to the peptide of interest is a means commonly employed to 
improve the sensitivity of the MS protein characterisation. Typically, DDA approach (described in 
section 2.9.1) is applied for general protein discovery which tend to miss the peptides that are minor 
by quantity. Hence, to better analyse the phosphopeptide of Tau which are not relatively abundant, 
SIM (described in section 2.9.1) approach is preferred. Though SIM approach had been applied on Tau 
protein previously (Bros P et al., 2015), only general peptides were targeted. Hence, there is no 
database available recording the retention time, mass over charge ratio and spectra for the 
phosphopeptides of Tau protein.  
 
a) Buliding the targeted method 
The targeted MS method for Tau protein has two uses: a) the general peptides being targeted aims to 
help better identify Tau protein from the samples that are not ideal (i.e. low relative concentration of 
Tau); b) the phospho peptides being targeted aims to better capture their signal which are easy to 
miss if DDA approach is taken.  
 
Tau protein purified from E.coli was processed and examined to determine the m/z values that can be 
potentially targeted. The solution prepared from E.coli was at high purity and concentration which 
allowed best general peptide discovery. Table 5-2 summarises the key information of the general 
peptides uncovered, including if they were spotted in the HEK 293 fractions on the MS.  
 
E.coli produced Tau was intrinsically non-phosphorylated, as no discovery was made post TiO2 
enrichment. Hence, in vitro phosphorylation was performed by ERK. The spectra generated were 
edited into an phosphopeptide encyclopaedia (see appendix). Table 5-3 lists the phospho-peptide hits 
generated from the in vitro phosphorylated run.  
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In summary, shown in Figure 5-11, over 70% of Tau sequence was covered in the data generated from 
E.coli Tau run. In addition, 6 phosphorylation sites were identified from the in vitro phosphorylated 
E.coli Tau sample. It is not clear from the preliminary data whether T374 or S375 were phosphorylated 
(both may also well be phosphorylated). 7 key general peptides (out of 29 hits summarised in Table 5-
2) were targeted to achieve positive identification of Tau in samples that contained only quantities of 
Tau that are below the level of quantitation in a DDA experiment. Whereas, all phosphopeptides (8 in 
total, shown in Table 5-3) were targeted as all phosphorylation sites on Tau are of interest. The 
targeted m/z values and their retention time were input into the Tau targeted MS method (Table 5-
4): 7 and 8 m/z values are targeted corresponding to the key general peptides and the phospho-
peptides respectively.  
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Table 5-2: Peptide discovered from purified E.coli Tau runs. Z stands for charge state, RT stands for 
retention time (in minutes). The base line of the MS run was around E3 intensity, all the convincing 
peptide hit had an over E6 corresponding MS1 intensity. Some peptide were not seen in the HEK 293 
fractions from the pilot run. The peptide (highlighted) that were seen in all three fractions had an over 
E8 intensity in the E.coli protein run, hence, are targeted for Tau protein discovery (see Table 5-4).  
  Peptide m/z Z RT  PTM Sample fraction 
1 QEFEVMEDHAGTYGLGDR(6-23) 1026.9 2 36 / M 
2 QEFEVMEDHAGTYGLGDR(6-23) 1036 2 30 M6-Oxidation M 
3 DQGGYTMHQDQEGDTDAGLK(25-44) 728.3 3 20 M7-Oxidation M 
4 ESPLQTPTEDGSEEPGSETSDAK(45-67) 1196.5 2 27 / 200,000g, 600g 
5 STPTAEAEEAGIGDTPSLEDEAAGHVTQAR(68-97) 1004.5 3 36 / 200,000g, 600g, M 
6 SKDGTGSDDKK(102-112) 570.0 2 6 / / 
7 GAAPPGQK(127-134) 725.4 1 6 / / 
8 TPPAPK(146-151) 610.4 1 6 / M 
9 TPPSSGEPPK(152-161) 498.8 2 14 / 600g, M 
10 TPPSSGEPPKSGDR(152-165) 706.3 2 6 / 600g 
11 SGYSSPGSPGTPGSR(166-180) 697.3 2 15 / 600g 
12 TPSLPTPPTR(183-192) 533.8 2 25 / 200,000g, 600g 
13 TPSLPTPPTREPK(183-195) 710.9 2 23 / / 
14 KVAVVR(196-201) 671.5 1 13 / / 
15 TPPKSPSSAK(202-211) 500.3 2 6 / / 
16 LQTAPVPMPDLK(214-225) 663.3 2 29 M8-Oxidation 200,000g, 600g, M 
17 LQTAPVPMPDLK(214-225) 655.3 2 33 / 200,000g, 600g 
18 IGSTENLK(231-238) 430.8 2 16 / 200,000g, 600g 
19 VQIINK(246-251) 714.4 1 17 / 600g 
20 KLDLSNVQSK(252-261) 1131.6 1 20 / 200,000g, 600g 
21 HVPGGGSVQIVYKPVDLSK(270-288) 991.0 2 30 / 200,000g, 600g 
22 SEKLDFK(312-318) 433.25 2 18 / M 
23 IGSLDNITHVPGGGNK(325-340) 789.9 2 26 / 200,000g, 600g, M 
24 IGSLDNITHVPGGGNKK(325-341) 854.4 2 23 / 600g 
25 KIETHK(341-346) 378.3 2 7 / / 
26 TDHGAEIVYK(357-366) 566.8 2 18 / 200,000g, 600g 
27 SPVVSGDTSPR(367-377) 551.3 2 17 / / 
28 
HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(378-
409) 1082.3 3 54 / 600g, M 
29 
HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(378-
409)  1087.5 3 52 
M13-
Oxidation 200,000g, 600g, M 
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Table 5-3: Phospho-peptide discovered from the in vitro phosphorylated E.coli Tau protein MS run. 
Only one peptide was also discovered from four rounds of the HEK 293 microtubule fraction pilot runs 
(highlighted in green). The discovery of phospho-peptide is harder as a) only a minor sub group of the 
protein in the overall population are phosphorylated, making the identification of them harder than 
the non-modified peptides, b) the peptide might undergo dephosphorylation, facilitated by 
phosphatases, in the cell lysate. It is worth noting that the last phospho-peptide in the table (colour 
coded blue) was not seen on the MS run. It was included in the list because the second peptide had a 
miss-cleavage and one of the sub peptide, the 8th peptide, was quite abundant in the E.coli run. All the 
phospho-peptide identified were logged into the targeted list. 
  Peptide m/z Z RT PTM 
1 ESPLQTPTEDGSEEPGSETSDAK(45-67) 1236.5 2 29 T6-Phospho 
2 TPPAPKTPPSSGEPPK(146-161) 835.0 2 19 T7-Phospho 
3 SGYSSPGSPGTPGSR(166-180) 737.3 2 22 S8-Phospho 
4 TPPKSPSSAK(202-211) 540.3 2 11 S5-Phospho 
5 SPVVSGDTSPR(367-377) 591.1 2 17 S9/T8-Phospho 
6 SPVVSGDTSPR(367-377) 1181.5 1 18 S9/T8-Phospho 
7 
HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(378-
409) 1114.1 3 55 M13-Oxidation, S16-Phospho  
8 TPPSSGEPPK(152-161) 538.79 2 14 T1-Phospho 
 
Figure 5-11: Tau coverage and key sites: Grey represents the sequence covered, yellow highlights the 
phosphorylation sites. Red and blue coloured “K” and “R” are the cleavage sites by trypsin.  
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Table 5-4: Summary of peptides targeted in each time interval. Peptide 5 and 6 in the 46-60 minutes 
time interval were not seen from the in vitro phosphorylated trial. They were included as the minimum 
number of m/z ratios for each segment was six. The blue colour coded M represent oxidation on 
methionine. 
Time Interval Peptide (m/z) 
8-23 1.TPPKSPSSAK(+2, 540.3) 
2.TPPSSGEPPK(+2, 538.8) 
3.SPVVSGDT(S)PR(+2, 591.1) 
4.SPVVSGDT(S)PR(+1, 1181.5) 
5.TPPAPKTPPSSGEPPK(+2, 835.0) 
6.SGYSSPGSPGTPGSR(+2, 737.3) 
24-33 1.SGYSSPGSPGTPGSR(+2, 737.3) 
2.ESPLQTPTEDGSEEPGSETSDAK(+2, 1236.5) 
3.TPSLPTPPTR(+2,533.8) 
4.IGSLDNITHVPGGGNK(+2, 789.9) 
5.LQTAPVPMPDLK(+2, 655.3) 
6.LQTAPVPMPDLK(+2, 663.3) 
34-45 1.TPSLPTPPTR(+2,533.8) 
2.IGSLDNITHVPGGGNK(+2, 789.9) 
3.LQTAPVPMPDLK(+2, 655.3) 
4.LQTAPVPMPDLK(+2, 663.3) 
5.STPTAEAEEAGIGDTPSLEDEAAGHVTQAR(+3, 1004.5) 
6.HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(+3, 1087.5) 
46-60 1.HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(+3, 1082.3) 
2.HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(+3, 1087.5) 
3.HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(+3, 1114.1) 
4.HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(+3, 1135.5) 
5.HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(+3, 1108.8) 
6.HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(+3, 1140.6) 
 
b) Phosho-peptide analysis using the targeted method 
The targeted method was applied to characterise endogenous levels of tau phosphorylation in the 
microtubule fraction isolated from HEK293 cells. The HEK 293 cells were harvested 48 hours after 
transfection. Microtubule pellet was suspended and chilled on ice, allowing the disassembly to fully 
take place. The mix was then subjected to TiO2 phospho-protein enrichment. Finally, the enriched 
sample was digested by trypsin and prepared for MS analysis.  
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The application of the targeted method identified four out of six phosphorylation being targeted. Four 
pilot runs had been conducted on the microtubule fraction (sample processed in the same manner: 
microtubule pull down followed by TiO2 enrichment) using the general discovery method. In these 
runs, only one Tau phosphopeptide was found: SPVVSGDTSPR (T8 position was phosphorylated). The 
other three peptides spotted using the targeted method had an intensity that was lower by two orders 
of magnitude, shown in Figure 5-16 and 5-17. Hence, they were previously not sampled for 
fragmentation due to the complex protein background. The spectra of the four peptide which have 
been cross compared with the phosphopeptide encyclopedia established using E.coli produced Tau, 
are attached in Figure 5-12 to 5-15 (the unlabelled base level peaks are results of internal 
fragmentation, instead of breaking amino acids off one by one from the end). 
 
The phosphorylation profile of the functional Tau protein is not universal. The intensity of the 
phosphopeptides discovered from the E.coli in vitro phosphorylation trial were roughly in line with 
that of the unmodified peptides from E.coli, shown in the first two columns in Table 5-5. However, the 
peak intensity of SPVVSGDTSPR seen from the HEK 293 microtubule was couple orders of magnitude 
higher than the others. Such pattern was not seen from the E.coli samples, suggesting that the 
difference may not be contributed to enzymatic digestion or MS fragmentation.  
 
Table 5-5: Phosphopeptide peak intensity (PI) comparison. It was not difficult to capture the in vitro 
phosphorylated E.coli phosphopeptides, as there were hardly any other species despite the peak 
intensities were low. However, the HEK 293 microtubule sample had a much complex background, 
thereby making the targeted method necessary.  
Peptide PI E.coli 
PI E.coli in vitro 
phosphorylated  PI HEK microtubule 
ESPLQTPTEDGSEEPGSETSDAK(45-67) 2E8 7E3 2E4 
SGYSSPGSPGTPGSR(166-180) 1.5E8 1.5E3 6E4 
TPPKSPSSAK(202-211) 2E6 6E2 9E3 
SPVVSGDTSPR(367-377) 2E7 8E2 1.5E6 
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Figure 5-12: Spectrum for ESPLQTPTEDGSEEPGSETSDAK, phosphorylated at T6 (50T) 
 
Figure 5-13: Spectrum for SPVVSGDTSPR, phosphorylation site confirmed, S9(S375) 
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Figure 5-14: Spectrum for TPPKSPSSAK, phosphorylated at S5(S206) 
 
Figure 5-15: Spectrum for SGYSSPGSPGTPGTPGSR, phosphorylated at S8(S173) 
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Figure 5-16: The MS 1 peak intensity of ESPLQTPTEDGSEEPGSETSDAK, phosphorylated at T6(T50), HEK 
293 microtubule sample 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-17: The MS 1 peak intensity of SPVVSGDTSPR, phosphorylated at S9(S375), HEK 293 
microtubule sample 
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c) Further Kinase phosphorylation site mapping efforts 
Miss. Jia Charleen Peer, has extended the target method building work to two more kinases, CDK5 and 
GSK3β. The work flow was the same to what described in section 5.2.2, except the type of kinase being 
applied. The peptide/phosphosite discovered corresponding to CDK5 and GSK3β were listed in Table 
5-6 and 5-7 respectively. Further, an ERK repeat trialed uncovered three additional phospho-peptides, 
summarised in Table 5-8. Therefore, expanding the number of peptide that could be targeted in future 
work from 8 to 15, shown in Table 5-9.  
 
Table 5-6: Phospho-peptide discovered from the in vitro CDK5 phosphorylated E.coli Tau protein MS 
run. 
 Peptide m/z  Z RT PTM 
1 ESPLQTPTEDGSEEPGSETSDAK (45-67) 1236.55  2 32 T6-Phospho 
2 IPAKTPPAPK (142-151) 550.26  2 19 T5-Phospho 
3 TPPSSGEPPKSGDRSGYSSPGSPGTPGSR (152-180)  982.87  3 24 S22-Phospho 
4 SGYSSPGSPGTPGSR (166-180) 737.35  2 23 T11-Phospho 
5 TPSLPTPPTR (183-192) 573.84  2 33 T6-Phospho 
6 TPPKSPSSAK (202-211) 540.26  2 12 S5-Phospho 
7 IGSTENLK (231-238) 471.25  2 24 S3-Phospho 
8 HLSNVSSTGSIDMVDSPQLATLADEVSASLAK (378-409) 1135.63  3 65 S3-Phospho 
S6-Phospho 
9 HLSNVSSTGSIDMVDSPQLATLADEVSASLAK (378-409)  1108.96  3 58 S16-Phospho 
 
Table 5-7: Phospho-peptide discovered from the in vitro GSK3β phosphorylated E.coli Tau protein MS 
run. 
 Peptide m/z Z RT PTM 
1 ESPLQTPTEDGSEEPGSETSDAK (45-67) 1236.55 2 32 T6-Phospho 
2 SGYSSPGSPGTPGSR (166-180) 777.36 2 28 S1-Phospho 
S5-Phospho 
3 KLDLSNVQSK (252-261) 607.26 2 25 S9-Phospho 
4 LDLSNVQSK (253-261) 542.26 2 30 S8-Phospho 
5 SPVVSGDTSPR (367-377) 591.51 2 22 S9-Phospho 
6 HLSNVSSTGSIDMVDSPQLATLADEVSASLAK (378-409) 1114.13 3 46 M13-Oxidation, 
S16-Phospho 
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Table 5-8: Additional phospho-peptide discovered from a repeat in vitro ERK E.coli Tau protein 
phosphorylation trial. 
 Peptide m/z Z RT PTM 
1 TPSLPTPPTR (183-192) 573.84 2 35 T6-Phospho  
2 LQTAPVPMPDLK (214-225) 695.43 2 40 T3-Phospho  
3 IGSTENLK (231-238) 471.17 2 24 S3-Phospho  
 
Table 5-9: Summary of all phospho-peptide discovered from all the in vitro phosphorylated E.coli Tau 
protein MS run. ERK, CDK5 and GSK3β were applied to the in vitro phosphorylation trial. The 
highlighted peptides may be added to the targeted method in the future.  
  Peptide m/z Z  RT PTM 
1 ESPLQTPTEDGSEEPGSETSDAK(45-67) 1236.5 2 29 T6-Phospho 
2 IPAKTPPAPK (142-151) 550.26 2 19 T5-Phospho 
3 TPPAPKTPPSSGEPPK(146-161) 835.0 2 19 T7-Phospho 
4 TPPSSGEPPKSGDRSGYSSPGSPGTPGSR (152-180)  982.87 3 24 S22-Phospho 
5 SGYSSPGSPGTPGSR(166-180) 737.3 2 22 S8-Phospho 
6 TPSLPTPPTR (183-192) 573.84 2 33 T6-Phospho 
7 TPPKSPSSAK(202-211) 540.3 2 11 S5-Phospho 
8 LQTAPVPMPDLK (214-225) 695.43 2 40 T3-Phospho  
9 IGSTENLK (231-238) 471.17 2 24 S3-Phospho  
10 KLDLSNVQSK (252-261) 607.26 2 25 S9-Phospho 
11 LDLSNVQSK (253-261) 542.26 2 30 S8-Phospho 
12 SPVVSGDTSPR(367-377) 1181.5 1 18 S9/T8-Phospho 
13 SPVVSGDTSPR(367-377) 591.1 2 17 S9/T8-Phospho 
14 
HLSNVSSTGSIDMVDSPQLATLADEVSASLAK(378-
409) 1114.1 3 55 
M13-Oxidation, 
S16-Phospho  
15 TPPSSGEPPK(152-161) 538.79 2 14 T1-Phospho 
 
d) The implication of the Tau targeted MS method 
The study of PTMs has historically relied on immunoblotting analysis. Especially for Tau protein, as 
discussed in section 2.9, due to its molecular size and configuration, NMR (too big) and crystallography 
(practically impossible to crystallise) are not compatible with Tau. Though that immunoblotting 
analysis was a brilliant invention and has made invaluable contribution towards the phosphorylation 
profiling of Tau protein, many experimental findings via such route are contradictory. The recent 
development of MS has allowed it to serve as an equally effective characterisation method for PTM 
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study. Hence, providing a measure to clear up the contradictions when there did not exist an actual 
alternative.  
 
The effect of various kinases on Tau was studied via immunoblotting analysis. Specific antibodies were 
generated each time to verify couple phosphorylation sites. The procedure was extremely time 
consuming and, to certain extent, subjective. Table 5-10 summarises the sites (reference to the full 
length Tau isoform, 2N4R) that have been phosphorylated by the three kinases from 14 publications 
across 2 decades (including review, and the summary is by no means exhaustive). It is not practical for 
others to reproduce such experiment and cross check what was reported.  
 
On the other hand, MS fragmentation spectra could provide solid evidence of phosphorylation.  
Through in vitro phosphorylation trial described in section 5.2.2, the effect of any kinase could be 
studied thoroughly within a matter of months.  In our work, Tau 1N4R isoform was studied instead of 
Tau 2N4R, the isoform that all PTM sites were made reference to in publications. Figure 5-18 compares 
the sequence of Tau 2N4R to Tau 1N4R: the red coloured sequence is the N terminal insert, the only 
difference between the two isoforms. Table 5-11 shows the phosphorylation sites (with reference to 
both isoforms) uncovered from the in vitro study against the three kinases being studied.  
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Table 5-10: Summary of phosphorylation sites reported for the three kinases studied. (Illenberger S et 
al., 1998; Liu F et al., 2005; Sato S et al., 2005; Liu F et al., 2009; Li G et al., 2004; Smet-Nocca C et al., 
2011; Cripps D et al., 2006; Yang Y.C et al., 2006; Cho J.H. and Johnson G.V. 2004; Paudel H.K 1997; 
Yoshida H and Goedert M et al., 2012; Drewes G et al., 1995; Lee V.M et al., 1991; Martin L et al., 2013) 
Kinase Phosphorylation sites 
GSK3 S46,T50,T69,T149,T153,T175,T181,T184,S195,S198,S199,S202,T205,S210,T212,S214, 
T217,T220,T231,S235,S237,S241,T245,S258,S262,S285,S289,S305,S324,S352,S356,T373, 
S396, S400, T403, S404, S409, S412, S413, S414, S418, S422. 
ERK S46, T50, T69, T153, T175, T181, S199, S202, T206, T212, T217, T231, S235, S356, S396, 
S404, S422 
CDK5 T153, T181, S195, S199, S202, T205, T212, S214, T231, S235, S396, S404 
 
 
Figure 5-18: Sequence of Tau 2N4R (top) and sequence of Tau 1N4R, the phosphorylation sites 
identified from the in vitro study are highlighted 
 
 
 
 
 
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPL
VDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAP
PGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSR
LQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGS
LGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPR
HLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL 
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEAEEAGI
GDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEP
PKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPG
GGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSK
IGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASL
AKQGL 
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Table 5-11: Summary of the phosphorylation sites uncovered from the in vitro study against the three 
kinases being studied. 
 Tau 1N4R Tau 2N4R Kinase 
1 T50 T50 ERK,CDK5,GSK3β 
2 T146 T175 CDK5 
3 T152 T181 ERK 
4 S173 S202 CDK5,ERK,GSK3β 
5 T188 T217 ERK,CDK5 
6 S206 S225 ERK,CDK5 
7 T216 T245 ERK 
8 S233 S262 ERK,CDK5 
9 S260 S289 GSK3β 
10 T374 T403 ERK 
11 S375 S404 ERK 
12 S393 S422 ERK,CDK5 
 
It was discovered that the three kinases could phosphorylate couple additional sites. Sites S225, T245, 
S262 and T403 were not previously linked to ERK. CDK5 was seen capable of phosphorylating sites T50, 
T175, T217, S225, S262 and S422. In contrast, many sites that were reported putative to the three 
kinases were not identified. Especially for GSK3β, only 3 out of 42 sites that were previously linked to 
GSK3β has been verified by MS in our study. The extra sites being discovered in previous publications 
may be explained as the sites listed in Table 5-9 includes the ones identified from human sample and 
in vitro phosphorylation study (i.e. phosphorylation of some residue may be subjected to certain PTMs 
or cofactors that only exist in human). However, with regard to GSK3β in vitro study, out of three 
phosphorylation sites being identified using MS (in our work), only T50 was also reported previously 
via immunoblotting analysis. Whereas, 9 other sites that were linked GSK3β through in vitro 
phosphorylation experiment have not been seen in our study (T50, T149, T220, S241, T245, S285, S305, 
S324, S352, T373, Sato S et al., 2005; Yang Y.C et al., 2006; Martin L et al., 2013).  
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5.3.3. SILAC experiment   
 
Tau protein expression was inhibited in the SILAC labelled experiment. Lysine (4, 4, 5, 5-D4) and 
arginine (13C6) were added to the arginine and lysine free DMEM medium as described earlier. Three 
fractions, the membrane, the microtubule and the filament pellet, were collected and processed. Two 
aliquots of each fraction were run on the MS using the general peptide discovery and the Tau targeting 
method.  
 
The data file was analysed taking into consideration of the heavy labelled proline (as a result of 
reported arginine to proline conversion) (Bendall SC et al., 2008), as well as the heavy labelled lysine 
and arginine. However, no trace of Tau peptide was found. The functionality of the searching program 
was tested by a peptide that contained proline and lysine, shown in Figure 5-19. Evident from the 
spectra, peptide containing both heavy and light proline were discovered, proving that the analysis 
tool was competent. One speculation is that the jeopardised Tau expression was possibly due to the 
fact that almost one fourth of the protein was made up by lysine, arginine and proline. 
 
Non-labelled Tau protein was also not discovered in the all the fractions. The heavy labelled amino 
acid might have inhibited the expression of recombinant Tau protein, therefore, resulted in negative 
identification of HEK 293 Tau, the heavy labelled Tau. However, the filaments applied to the HEK 293 
cell culture as seeds were assembled from E.coli produced, non-labelled Tau protein. Hence, only 
minute quantity, if at all, of filaments, below MS detection limit, were endocytosed.   
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Figure 5-19: Heavy labelled peptide, SPAGLQVLNDYLADK was a peptide the Elongation factor protein. 
The top spectrum was derived from the sequence labelled with both heavy proline and lysine, whereas, 
the bottom spectrum correspond to the peptide contained only heavy lysine.  
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5.4. Summary 
In this study, for the first time, a comprehensive set of spectra for Tau protein is documented. Spectra 
as evidence of positive identification are presented for all phosphopeptides of Tau protein, including 
the ones discovered in the HEK 293 sample.  
a) Effective MS Tau protein targeting method 
 
The targeted MS Tau phospho-peptide discovery method has been proven a success. An 
encyclopaedia (see appendix) including both general Tau peptides and phosphopeptides (may be 
further expanded in the future) were built. The database was then used for the development of a Tau 
protein targeted MS method. For the soluble Tau sample, on top of one phosphopeptide that was 
discovered using the Sequest general method, three more phosphopeptides with two orders of 
magnitude lower peak intensity were uncovered. The targeted m/z ratios and retention time can be 
determined through an in vitro phosphorylation trial as described. Alternatively, the values can also 
be deduced from the non-modified peptide encyclopaedia by taking into consideration of the mass 
shift and the delay in retention time, assuming the charge state remains the same. For a decent MS 
characterisation run, HEK 293 cells confluent in 5-10 plates (50 cm2) are required to be fed to the 
sample processing procedure. Typically, it takes 4-6 days to prepare the cells into MS samples.  
 
b) The insoluble Tau fractions needs further processing 
 
The MS sample preparation procedure may be further improved for the membrane and the filament 
fractions. The in-gel digestion protocol was followed for the two fractions as the Tau filaments can 
only be dissolved in SDS. However, the in-gel digestion technique has been seen incompatible (results 
in LC column clogging) to phospho-peptide enrichment by TiO2. Hence, no efficient phospho-peptide 
discovery can be made. In-solution digestion trials had resulted in HPLC blocking samples, possibly due 
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to the incomplete digestion of the filaments. A potential option, is to centrifuge the in-solution 
digested sample and taking only the supernatant forward.  
 
c) SILAC reagents interfered the expression of Tau protein  
 
The SILAC experiment outcome is inconclusive as Tau protein expression was blocked at the presence 
of heavy labelled lysine and arginine. A trial with only lysine labelling may be performed. Less labelling 
might reduce the stress and allow the expression of Tau protein. Hyper-phosphorylation may be 
suggested as an effect to Tau filament if the exogenous Tau applied as seeds were also seen 
phosphorylated in the same manner.  
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Chapter 6 
 
 
 
 
 
 
                   Conclusion  
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6.1. Overall summary 
 
The Tau protein targeting mass spectrometry method was successfully developed: for the first time, a 
comprehensive set of spectra for Tau protein is presented. In addition, a compatible protocol that 
purifies soluble/functional and untagged Tau protein from HEK 293T cells was described. It was 
demonstrated that the application of the targeted MS method allowed solid identification of 
phosphopeptides at two orders of magnitude lower than that discovered via the Sequest general 
method. In the future, the targeted method may be expanded to include other PTMs of interest. In 
addition, a phosphopeptide enrichment work flow must be established for the insoluble Tau fraction. 
The method may be widely applied to both pathology model and human tissue. 
 
a) Successful development of a targeted MS method for Tau protein phosphopeptide discovery 
 
A mass spectrometry method targeting on Tau protein for phosphorylation profile study has been 
developed. For a decent MS characterisation run, transient transfected Tau expressing HEK 293 cells 
confluent in 5-10 plates (50 cm2) are required to be fed to the sample processing procedure. Typically, 
it takes 4-6 days to prepare the cells into MS samples. The targeting approach was able to discover 
peptides with MS1 peak intensity weaker by two orders of magnitude than that spotted using the 
general discovery method. For the soluble Tau sample, on top of one phosphopeptide that was 
discovered using the Sequest general method, three more phosphopeptides with two order of 
magnitude lower peak intensity were uncovered. Spectra as evidence of positive identification are 
presented for all phosphopeptides being reported, including the ones discovered in the HEK 293 
sample. 
 
It is important to bear in mind that the heavy isotope labelled amino acid might interfere with the 
protein expression. The SILAC trial failed completely as the production of the Tau protein in HEK cells 
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was jeopardised. However, the expression may be less affected if lysine or arginine was applied alone 
in the culturing, at the cost of being unable to distinguish the origin of some peptides (the ones have 
only lysine or arginine and proline). 
 
The targeting method is compatible with the cellular model work: the amount of sample required is 
fairly modest for decent peptide discovery. Thus, allowing high throughput PTM characterisation 
studies. However, the sample preparation procedure for the fractions containing Tau filament can be 
further improved. Digesting the protein in solution is generally preferred than in gel as the sample loss 
is significantly less.  
 
b) Effective protocol for soluble Tau protein purification from human cellular model  
A cellular model has been developed to test the proposed nucleation mechanism for Tau filament 
spreading.  pcDNA 3.1 plasmid produced by XL10 Gold E.coli strain enabled the synthesis of Tau 
protein (1N4R, wild type)  in HEK 293T cells via transient transfection. BL 21 E.coli strain produced Tau 
protein (1N4R, wild type) were assembled into filaments and applied to HEK 293 cells as exogenous 
seed. An effective purification protocol was developed for soluble Tau. Microtubule was reassembled 
in the lysate and pulled down via centrifugation. Among other microtubule associated proteins, Tau 
was also isolated from the complicated cytoplasmic extract background. The relative concentration of 
Tau protein which is naturally phosphorylated was further increased through TiO2 phosphoprotein 
enrichment.  
 
c) Efficient E.coli Tau protein and plasmid production system 
The material produced by E.coli was used in cell pathology model building and MS discovery method 
design.  On average, 1 mg vector and 8 mg Tau protein were produced per experiment, respectively. 
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A robust protocol for purifying untagged recombinant protein Tau from E.coli was developed, taking 
advantage of its unusual hydrophobicity and outstanding thermal stability.  
 
6.2. Future work 
 
a) An improved PTM targeting MS method 
The Tau targeting MS method may be further developed. In this work, only ERK phosphorylated Tau 
peptides were targeted. The modifications being targeted may be extended to phosphorylations by 
other kinases and other PTMs such as Acetylation. It is worth noting that the total number of peptides 
being targeted in each time segment should be controlled. The inclusion of too many m/z values make 
the method less efficient as less background noise is filtered out.   
 
The targeted method can be built via two approaches. The E.coli produced recombinant protein of 
interest may be artificially modified in vitro and subjected to LC-MS. The retention time of the 
modified peptides being discovered may then be recorded. Hence, the following information for each 
peptide being discovered may be recorded into the encyclopaedia: retention time, modification, 
charge state and m/z.  Alternatively, a basic encyclopaedia may be built using the unmodified 
recombinant protein. The m/z and retention time may be calculated and estimated based on the 
expected/putative modifications. In addition, the charge state may be assumed the same to their non-
modified counterparts. The first approach involves some extra experimental efforts, but delivers the 
best performance by allowing the targeting being more accurate as the retention time and charge 
state is known.  
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The target method may include the sites that can be phosphorylated by some key kinases. More 
kinases of interest, summarised in Chapter 2, may also be incubated with recombinant and non-
modified E.coli Tau. Firstly, the phosphorylation sites responsible by each kinase can be confirmed. 
Then the more accurate targeted method developed via this approach can then be applied to Tau 
samples for a more thorough phosphorylation profiling study.  
 
b) A better filament containing sample preparation pathway 
 
An in solution digestion procedure can be developed for the filament containing fractions. The in gel 
digestion route was chosen in this work originally to allow the solubilisation of the filament by SDS, 
hence, no cleavage sites may be blocked. Application of SDS is not compatible with the in solution 
digestion work flow as the SDS (MS unfriendly) cannot be removed. The filament containing fraction 
may be enzymatically digested for longer time frame, allowing the cleavage sites that are folded in the 
aggregate to be reached. The digested solution may than be subjected to TiO2 porous beads for 
phospho-peptide enrichment. Hopefully, the aggregate remained in the solution would not be 
adsorbed in the porous structure in first place and, therefore, being washed away. However, an 
additional filtration step may be taken to prevent possible LC column clogging.  
 
c) Further develop the cellular model testing the proposed nucleation mechanism for filament 
spreading 
No obvious effect of exogenous seeding was observed using the cellular model so far. Every effort has 
been taken to develop a cellular model that is most physiological relevant: mutation and polyanions 
were not incorporated/applied as aggregation inducing agent. However, as observed clinically, the 
spreading of Tau filaments might take a fairly long period of time under natural condition. The 
timeframe of the experiment could be expanded further. Furthermore, the seeding filament being 
applied should be tracked (to verify if endocytosis was successfully facilitated and understand its fate 
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in cells). In addition, transient transfection may have already resulted in aggregation as Tau protein 
was overexpressed. These hypothesis needs to be verified in future study.  
 
d) Application of the method  
The targeted method may be applied to better study the role of PTM in the pathology and drug 
discovery. The MS method does not demand large amount of sample and can verify the findings by 
immunoblotting analysis. Collaborations may be built with research groups dedicated to Tauopathy 
research or drug discovery targeting on protein Tau. Efficient and definite PTM characterisation can 
be conducted using the targeted MS method on their sample.  
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General Peptides 
1. Sequence: QEFEVMEDHAGTYGLGDR,  
Charge: +2,   Monoisotopic m/z: 1027.96055 Da (+511.12 mmu/+497.22 ppm),    
MH+: 2054.91383 Da,    
RT: 35.64 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
 
y₂⁺
290.07
b₁₅⁺-NH₃
1690.72
b₁₃⁺-NH₃, y₁₄⁺
1520.61
b₅⁺-NH₃
616.19 y₁₂⁺
1290.58
b₁₇⁺-NH₃
1862.90
b₄⁺-NH₃, y₅⁺
517.24
y₁₃⁺
1421.61
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
1018.71
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #5854   RT: 35.64
     ITMS, CID, z=+2, Mono m/z=1027.96055 Da, MH+=2054.91383 Da, Match Tol.=0.8 Da
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2. Sequence: QEFEVMEDHAGTYGLGDR, M6-Oxidation (15.99492 Da) 
Charge: +2,   Monoisotopic m/z: 1035.37767 Da (-69.51 mmu/-67.13 ppm),    
MH+: 2069.74806 Da,    
RT: 30.13 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₃⁺
347.15
b₁₅⁺-NH₃
1706.67y₁₂⁺
1290.67
b₁₃⁺-NH₃, y₁₄⁺
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y₁₃⁺
1437.56
y₆⁺
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b₁₇⁺-NH₃
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b₄⁺-NH₃, y₅⁺
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b₇⁺, y₉⁺
909.42
y₈⁺
838.36
[M+2H]²⁺-NH₃-H₂O
1017.98
400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
1
2
3
4
5
6
7
In
te
n
s
it
y 
[c
o
u
n
ts
] 
(1
0
^6
)
     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #4946   RT: 30.13
     ITMS, CID, z=+2, Mono m/z=1035.37767 Da, MH+=2069.74806 Da, Match Tol.=0.8 Da
171 
 
3. Sequence: DQGGYTMHQDQEGDTDAGLK, (25-44) 
M7-Oxidation (15.99492 Da) 
Charge: +3,   Monoisotopic m/z: 728.34595 Da (+375.1 mmu/+515 ppm),    
MH+: 2183.02329 Da,    
RT: 19.47 min, 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₃⁺
1413.76
b₁₀⁺-H₂O, y₁₁⁺-NH₃
1131.51
y₁₉²⁺, b₉⁺
1034.47
b₁₀⁺
1149.47
y₄⁺, y₈²⁺
388.32
y₅²⁺-NH₃, b₂⁺
244.07
b₆⁺-H₂O, y₆⁺
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y₁₇²⁺
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[M+3H]³⁺-NH₃-H₂O
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     Extracted from: C:\Xcalibur\data\Ecoli_H_24_May_14.raw   #3141   RT: 19.47
     ITMS, CID, z=+3, Mono m/z=728.34595 Da, MH+=2183.02329 Da, Match Tol.=0.8 Da
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4. Sequence: ESPLQTPTEDGSEEPGSETSDAK, (45-67) 
Charge: +2,   Monoisotopic m/z: 1196.52933 Da (+509.96 mmu/+426.2 ppm),   
MH+: 2392.05138 Da,    
RT: 26.70min 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₁₈⁺
1870.88
y₁₇⁺-H₂O
1717.81
y₁₉²⁺, b₉⁺
983.49
y₁₃²⁺-H₂O, b₆⁺-H₂O, y₁₃²⁺-NH₃
638.28
y₁₄⁺
1408.65
b₁₄⁺
1500.64
y₁₈⁺
1836.77
y₁₃⁺
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y₉⁺
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b₂₁²⁺, y₂₁²⁺
1088.13
400 600 800 1000 1200 1400 1600 1800 2000
m/z
0.0
0.5
1.0
1.5
2.0
2.5
In
te
n
s
it
y 
[c
o
u
n
ts
] 
(1
0
^6
)
     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #4274   RT: 26.23
     ITMS, CID, z=+2, Mono m/z=1196.47071 Da, MH+=2391.93415 Da, Match Tol.=0.8 Da
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5.   Sequence: STPTAEAEEAGIGDTPSLEDEAAGHVTQAR, (68-97) 
Charge: +3,   Monoisotopic m/z: 1004.52248 Da (+388.76 mmu/+387.01 ppm),    
MH+: 3011.55287 Da,   
RT: 35.84 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₈⁺-H₂O
1835.69
b₁₉⁺
1856.24
b₁₈⁺
1727.92
b₁₃³⁺
405.14
b₁₃²⁺-H₂O, y₁₇³⁺
599.27
y₁₆³⁺
561.20
y₂₈²⁺, b₁₅⁺-H₂O
1412.29
y₂₃²⁺
1177.27
y₂₅²⁺
1277.65
b₉⁺-H₂O, y₁₇²⁺
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     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #6353   RT: 38.68
     ITMS, CID, z=+3, Mono m/z=1004.45914 Da, MH+=3011.36285 Da, Match Tol.=0.8 Da
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6.  Sequence: SKDGTGSDDKK, (102-112) 
Charge: +2,   Monoisotopic m/z: 570.00696 Da (+734.83 mmu/+1289.16 ppm),    
MH+: 1139.00665 Da,    
RT: 5.65 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₉⁺-NH₃
905.45
b₇⁺-H₂O
615.33
y₆⁺
622.23
b₉⁺
863.27
b₂⁺
216.07
y₃⁺-H₂O
359.07
y₂⁺
262.08
y₇⁺
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y₃⁺
377.14
b₈⁺
748.25
y₈⁺
794.25
[M+2H]²⁺-NH₃-H₂O
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #811   RT: 5.59
     ITMS, CID, z=+2, Mono m/z=505.17904 Da, MH+=1009.35080 Da, Match Tol.=0.8 Da
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7.   Sequence: GAAPPGQK, (127-134) 
Charge: +1,   Monoisotopic m/z: 725.42918 Da (+35.07 mmu/+48.34 ppm),    
MH+: 725.42918 Da,    
RT: 6.18 min, 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₄⁺
297.09
y₃⁺
332.18
[M+1H]⁺-NH₃
708.34
y₄⁺
429.23
y₆⁺
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y₅⁺
526.29
200 400 600 800 1000 1200 1400
m/z
0
50
100
150
200
In
te
n
s
it
y 
[c
o
u
n
ts
] 
(1
0
^3
)
     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #902   RT: 6.48
     ITMS, CID, z=+1, Mono m/z=725.35898 Da, MH+=725.35898 Da, Match Tol.=0.8 Da
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8.   Sequence: TPPAPK, (146-151) 
Charge: +2,   Monoisotopic m/z: 305.66701 Da (+14.61 mmu/+47.81 ppm),    
MH+: 610.32674 Da,    
RT: 6.18 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₃²⁺
158.08
y₁⁺-NH₃
130.09
b₅⁺
464.34
y₅⁺
509.37
b₃⁺, [M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
296.74
b₂⁺
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     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #858   RT: 6.20
     ITMS, CID, z=+2, Mono m/z=305.66701 Da, MH+=610.32674 Da, Match Tol.=0.8 Da
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9.   Sequence: TPPSSGEPPK, (152-161) 
Charge: +2,   Monoisotopic m/z: 498.75442 Da (+0.93 mmu/+1.87 ppm),    
MH+: 996.50156 Da,    
RT: 13.64 min, 
Example MS/MS: 
 
Example XIC and MS1: 
 
 
y₉⁺
895.48
b₉⁺
850.33
y₈⁺-H₂O
780.41
y₇²⁺-H₂O, y₇²⁺-NH₃
342.23
b₂⁺
199.04
y₃⁺
341.22
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
489.89
y₉²⁺
448.39
y₈²⁺
399.84
y₈⁺
798.40
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     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #1819   RT: 12.28
     ITMS, CID, z=+2, Mono m/z=498.76198 Da, MH+=996.51669 Da, Match Tol.=0.8 Da
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10.   Sequence: TPPSSGEPPKSGDR, (152-165) 
Charge: +2,   Monoisotopic m/z: 706.27449 Da (-69.83 mmu/-98.87 ppm),    
MH+: 1411.54171 Da,    
RT: 6.19 min 
 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₃⁺
1311.39
b₁₀⁺
978.44
b₃⁺-H₂O
278.08
y₈⁺
885.40
y₄⁺, y₈²⁺-H₂O, y₈²⁺-NH₃
434.17
y₁₀⁺
1029.43
b₁₃⁺
1237.52
y₉⁺
942.41
y₁₂⁺
1213.54
y₇⁺
756.34
y₁₂²⁺
607.40
y₁₃²⁺, b₇⁺
656.02
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #949   RT: 6.46
     ITMS, CID, z=+2, Mono m/z=706.27449 Da, MH+=1411.54171 Da, Match Tol.=0.8 Da
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11.   SGYSSPGSPGTPGSR, (166-180) 
Charge: +2,   Monoisotopic m/z: 697.27395 Da (-46.87 mmu/-67.22 ppm),    
MH+: 1393.54062 Da,    
RT: 14.88 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₁₃⁺-H₂O
1114.50 y₁₃⁺
1249.78
b₁₄⁺
1219.50
y₃⁺-H₂O
301.18
b₃⁺
308.14
y₉⁺
815.37
y₁₂⁺
1086.49
y₅⁺-NH₃, y₁₁²⁺
500.39
y₁₁⁺
999.48
b₅⁺-H₂O
464.18
b₁₁⁺
978.41
b₈⁺
723.31
y₄⁺
416.24
y₇⁺
671.36
y₁₀⁺
912.46
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #2291   RT: 14.88
     ITMS, CID, z=+2, Mono m/z=697.27395 Da, MH+=1393.54062 Da, Match Tol.=0.8 Da
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12.  Sequence: TPSLPTPPTR, (183-192) 
Charge: +2,   Monoisotopic m/z: 533.84743 Da (+49.25 mmu/+92.25 ppm),    
MH+: 1066.68759 Da,    
RT: 25.25 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₉⁺
966.05
b₇⁺
694.38
b₉⁺
892.59
y₈⁺-H₂O
850.57
y₄²⁺
235.89
b₆⁺
597.45
y₇⁺
781.44
b₂⁺
199.02
b₃⁺-H₂O
268.11
y₈⁺
868.51
y₉²⁺
483.41
y₄⁺
470.28
y₆²⁺
334.82
b₄⁺
399.23
b₄⁺-H₂O
381.21
y₆⁺
668.38
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #4417   RT: 27.01
     ITMS, CID, z=+2, Mono m/z=533.84743 Da, MH+=1066.68759 Da, Match Tol.=0.8 Da
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13.   Sequence: TPSLPTPPTREPK, (183-195) 
Charge: +2,   Monoisotopic m/z: 710.85810 Da (-35.32 mmu/-49.69 ppm),    
MH+: 1420.70893 Da,    
RT: 23.16 min  
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₁⁺-H₂O, y₁₁⁺-NH₃
1204.89
y₁₀⁺
1135.81
y₉⁺-H₂O
1004.51
y₄⁺-H₂O, y₉²⁺, y₄⁺-NH₃
511.95
b₁₁⁺
1177.60
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
702.06
y₉⁺
1022.52
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #3754   RT: 23.16
     ITMS, CID, z=+2, Mono m/z=710.85810 Da, MH+=1420.70893 Da, Match Tol.=0.8 Da
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14.   Sequence: KVAVVR, (196-201) 
Charge: +1,   Monoisotopic m/z: 671.43906 Da (-17.25 mmu/-25.69 ppm),    
MH+: 671.43906 Da,    
RT: 12.64 min 
 Example MS/MS: 
 
Example XIC and MS1: 
 
y₂⁺
274.18
b₃⁺
299.19
b₄⁺
398.25
b₅⁺
497.30
[M+1H]⁺-NH₃
654.40
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #1906   RT: 12.60
     ITMS, CID, z=+1, Mono m/z=671.43906 Da, MH+=671.43906 Da, Match Tol.=0.8 Da
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15.   Sequence: TPPKSPSSAK, (202-211) 
Charge: +2,   Monoisotopic m/z: 500.76210 Da (+485.46 mmu/+969.45 ppm),    
MH+: 1000.51693 Da,    
RT: 6.23 min 
 Example MS/MS: 
 
Example XIC and MS1: 
 
 
y₉⁺
898.47
b₆⁺
608.31
y₂⁺-NH₃
201.13
b₇⁺
695.32y₇²⁺-H₂O
343.14
b₃⁺-H₂O
278.23
y₈⁺-H₂O
783.48
b₉⁺
853.45
y₇⁺
704.44
b₂⁺
199.04
y₈⁺
801.38
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
491.38
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #914   RT: 6.25
     ITMS, CID, z=+2, Mono m/z=500.76210 Da, MH+=1000.51693 Da, Match Tol.=0.8 Da
184 
 
16.   Sequence: LQTAPVPMPDLK, (214-225) 
M8-Oxidation (15.99492 Da) 
Charge: +2,   Monoisotopic m/z: 663.35524 Da (-5.12 mmu/-7.71 ppm),   MH+: 1325.70320 Da,    
RT: 29.04 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₁₁⁺
1179.70
b₃⁺-H₂O
325.20
y₈⁺-H₂O
894.22
b₂⁺
242.10
y₉⁺
983.53
b₄⁺
414.23
b₄⁺-H₂O
396.23
y₁₀⁺
1084.61
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
654.55
y₈⁺
912.50
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     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #4713   RT: 28.80
     ITMS, CID, z=+2, Mono m/z=663.35524 Da, MH+=1325.70320 Da, Match Tol.=0.8 Da
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17.  Sequence: LQTAPVPMPDLK, (214-225) 
Charge: +2,   Monoisotopic m/z: 655.43809 Da (+75.26 mmu/+114.82 ppm),    
MH+: 1309.86891 Da,    
RT: 33.08 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₁₁⁺
1163.67
y₂⁺
260.17
b₂⁺
242.10
b₈⁺
838.40
b₁₀⁺, y₁₀⁺-H₂O
1050.51
b₄⁺
414.24
b₄⁺-H₂O
396.23
y₁₀⁺
1068.56
y₈⁺
896.47
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
646.53
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #5414   RT: 32.93
     ITMS, CID, z=+2, Mono m/z=655.43809 Da, MH+=1309.86891 Da, Match Tol.=0.8 Da
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18.   Sequence: IGSTENLK, (231-238) 
Charge: +2,   Monoisotopic m/z: 431.25791 Da (+20.47 mmu/+47.46 ppm),    
MH+: 861.50855 Da,    
RT: 15.71 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₆⁺-NH₃
585.30
y₅⁺
604.34
b₄²⁺-H₂O, b₂⁺
171.10
y₆²⁺-H₂O, y₆²⁺-NH₃
337.32
y₇⁺
748.38
y₆⁺
691.36
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
422.43
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #2581   RT: 16.54
     ITMS, CID, z=+2, Mono m/z=431.25791 Da, MH+=861.50855 Da, Match Tol.=0.8 Da
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19.   Sequence: VQIINK, (246-251) 
Charge: +1,   Monoisotopic m/z: 714.44165 Da (-9.23 mmu/-12.92 ppm),    
MH+: 714.44165 Da,    
RT: 16.99 min 
 Example MS/MS: 
 
Example XIC and MS1: 
 
b₅⁺-NH₃
551.38
b₄⁺
454.29
b₂⁺
228.14
[M+1H]⁺-NH₃
697.41
y₄⁺
487.32
b₃⁺
341.19
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     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #2473   RT: 16.06
     ITMS, CID, z=+1, Mono m/z=714.44165 Da, MH+=714.44165 Da, Match Tol.=0.8 Da
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20. Sequence: KLDLSNVQSK, (252-261) 
Charge: +2,   Monoisotopic m/z: 566.26605 Da (-56.07 mmu/-99.01 ppm),    
MH+: 1131.52483 Da,    
RT: 19.71 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₂⁺
242.10
b₈⁺-NH₃
881.50
y₂⁺
234.13
b₈⁺
898.49
y₉⁺
1003.52
y₈⁺
890.45
y₅⁺-H₂O, [M+2H]²⁺-H₂O, b₅⁺, [M+2H]²⁺-NH₃, y₅⁺-NH₃
557.67
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #3236   RT: 20.23
     ITMS, CID, z=+2, Mono m/z=566.26605 Da, MH+=1131.52483 Da, Match Tol.=0.8 Da
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21.   Sequence: HVPGGGSVQIVYKPVDLSK, (270-288) 
Charge: +2,   Monoisotopic m/z: 990.54163 Da (-7.7 mmu/-7.77 ppm),    
MH+: 1980.07598 Da,    
RT: 29.69 min 
 Example MS/MS: 
 
Example XIC and MS1: 
 
y₄⁺-NH₃
445.55
b₈⁺-H₂O
673.57
y₁₈⁺
1843.06
y₄⁺
462.31
b₁₅⁺
1519.07
y₆⁺-H₂O
640.50
y₁₇⁺-H₂O
1725.99
b₁₆⁺
1633.98
y₃⁺
347.28
y₁₅²⁺
795.59
b₁₂⁺
1194.70
b₁₁⁺, y₉⁺-NH₃
1031.57
b₁₃⁺
1322.77
y₁₈²⁺
922.27
y₆⁺
658.40
y₁₇⁺
1744.01
y₁₇²⁺
872.69
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     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #4798   RT: 29.30
     ITMS, CID, z=+2, Mono m/z=990.54163 Da, MH+=1980.07598 Da, Match Tol.=0.8 Da
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22.   Sequence: SEKLDFK, (312-318) 
Charge: +2,   Monoisotopic m/z: 433.67473 Da (-59.91 mmu/-138.14 ppm),    
MH+: 866.34217 Da,    
RT: 17.53 min 
 Example MS/MS: 
 
Example XIC and MS1: 
 
y₆⁺
779.41
y₁⁺, y₂²⁺
147.14
b₂⁺
217.07
y₂⁺-NH₃
277.12 b₆⁺
720.38
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
425.00
y₅⁺
650.39
y₂⁺
294.14
b₅⁺
573.30
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #2764   RT: 17.56
     ITMS, CID, z=+2, Mono m/z=433.67473 Da, MH+=866.34217 Da, Match Tol.=0.8 Da
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23.   Sequence: IGSLDNITHVPGGGNK, (325-340) 
Charge: +2,   Monoisotopic m/z: 789.86287 Da (-52.57 mmu/-66.55 ppm),    
MH+: 1578.71845 Da,    
RT: 26.07 min  
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₅⁺-NH₃
1448.83
b₁₄⁺
1318.80
b₁₅⁺
1433.01
b₉²⁺-NH₃, b₅⁺-H₂O
468.30
b₅⁺
486.24
y₁₂⁺
1208.66
y₁₁⁺
1093.54
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
781.14
b₁₀⁺
1050.54
y₆⁺
529.27
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #4244   RT: 26.00
     ITMS, CID, z=+2, Mono m/z=789.86287 Da, MH+=1578.71845 Da, Match Tol.=0.8 Da
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24.   Sequence: IGSLDNITHVPGGGNKK, (325-341) 
Charge: +2,   Monoisotopic m/z: 853.95006 Da (-12.83 mmu/-15.02 ppm),    
MH+: 1706.89285 Da,    
RT: 23.15 min 
 Example MS/MS: 
 
Example XIC and MS1: 
 
b₁₆⁺-NH₃
1543.80
b₄⁺-H₂O
353.58
b₁₆⁺
1560.93
y₁₃⁺
1336.80
y₁₁⁺
1107.65
b₅⁺, y₅⁺-NH₃
486.27
b₁₅⁺, y₁₄⁺-NH₃
1432.72
y₆⁺
560.31
y₇⁺-NH₃
640.34
y₁₂⁺
1221.68
b₁₆²⁺
781.10
y₈⁺
756.39
b₉⁺
951.44
b₁₀⁺
1050.54
y₇⁺
657.35
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #3763   RT: 23.22
     ITMS, CID, z=+2, Mono m/z=853.95006 Da, MH+=1706.89285 Da, Match Tol.=0.8 Da
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25.   Sequence: KIETHK, (341-346) 
Charge: +2,   Monoisotopic m/z: 378.17138 Da (-52.85 mmu/-139.75 ppm),    
MH+: 755.33548 Da,    
RT: 7.11 min 
 Example MS/MS: 
 
Example XIC and MS1: 
 
y₃²⁺
192.93
b₄²⁺
237.14
b₄⁺-NH₃
455.32
b₂⁺
242.13
y₁⁺
147.03
y₄⁺
514.28
b₁⁺
129.02
b₅⁺, y₅⁺-H₂O
609.33
y₅⁺
627.34
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
369.42
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #1059   RT: 7.16
     ITMS, CID, z=+2, Mono m/z=378.17138 Da, MH+=755.33548 Da, Match Tol.=0.8 Da
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26.  Sequence: TDHGAEIVYK, (357-366) 
Charge: +2,   Monoisotopic m/z: 566.76608 Da (-19.25 mmu/-33.96 ppm),    
MH+: 1132.52489 Da,    
RT: 17.77 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₉⁺
1031.56
y₄²⁺-NH₃
253.09
y₈⁺
916.53
y₆⁺
722.46
b₉⁺
986.52
y₂⁺
310.17
b₈⁺
823.38
b₇²⁺-H₂O, b₃⁺
354.12
y₇⁺
779.39
[M+2H]²⁺-H₂O, [M+2H]²⁺-NH₃
557.93
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #2872   RT: 18.17
     ITMS, CID, z=+2, Mono m/z=566.76608 Da, MH+=1132.52489 Da, Match Tol.=0.8 Da
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27.   Sequence: SPVVSGDTSPR, (367-377) 
Charge: +1,   Monoisotopic m/z: 1101.46498 Da (-88.55 mmu/-80.39 ppm),    
MH+: 1101.46498 Da,    
RT: 16.87 min  
Example MS/MS: 
 
Example XIC and MS1: 
 
y₅⁺
575.29
y₇⁺
719.34
y₄⁺-H₂O
442.23
b₇⁺
642.28
b₉⁺-H₂O
812.38
y₉⁺
917.47
y₄⁺
460.25
[M+1H]⁺-H₂O
1083.54
400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
10
20
30
40
50
60
In
te
n
s
it
y 
[c
o
u
n
ts
] 
(1
0
^3
)
     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #1825   RT: 12.32
     ITMS, CID, z=+1, Mono m/z=1101.46498 Da, MH+=1101.46498 Da, Match Tol.=0.8 Da
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28.   Sequence: HLSNVSSTGSIDMVDSPQLATLADEVSASLAK, （388-409） 
Charge: +3,   Monoisotopic m/z: 1082.21382 Da (+340.82 mmu/+314.93 ppm),    
MH+: 3244.62692 Da,    
RT: 54.13 min  
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₉⁺
1915.09
y₁₈⁺
1815.96
y₄⁺
418.30
y₅⁺
489.33
b₁₆⁺
1630.79
b₃₁²⁺
1549.58
y₁₂⁺
1204.66
b₂₆²⁺
1334.89
b₂₇³⁺, b₁₈²⁺-H₂O, y₉⁺, b₁₈²⁺-NH₃
919.49
y₁₀⁺
990.51
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     Extracted from: C:\Xcalibur\data\Tau_01_20Jan16.raw   #10096   RT: 62.35
     ITMS, CID, z=+3, Mono m/z=1082.21382 Da, MH+=3244.62692 Da, Match Tol.=0.8 Da
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29.   Sequence: HLSNVSSTGSIDMVDSPQLATLADEVSASLAK, (388-409) 
M13-Oxidation (15.99492 Da) 
Charge: +3,   Monoisotopic m/z: 1087.54748 Da (+342.84 mmu/+315.24 ppm),    
MH+: 3260.62788 Da,    
RT: 51.68 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₀³⁺, y₃⁺
331.12
y₁₈⁺-NH₃
1799.05
y₃₀²⁺
1505.67
b₆⁺, y₁₃²⁺, y₁₉³⁺
638.44
b₁₅⁺
1559.80
b₁₆⁺
1646.66
y₇⁺
675.38
b₃₀²⁺
1521.93
b₂₂²⁺-H₂O, b₂₂²⁺-NH₃
1126.82
b₂₂²⁺, y₂₂²⁺-H₂O
1135.85
b₂₇³⁺-NH₃, y₉⁺
919.46
y₁₀⁺
990.49
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     Extracted from: C:\Xcalibur\data\Tau_02_20Jan16.raw   #6920   RT: 42.16
     ITMS, CID, z=+3, Mono m/z=1087.54748 Da, MH+=3260.62788 Da, Match Tol.=0.8 Da
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Phosphopeptides 
ERK phosphopeptide spectra 
1. Sequence: ESPLQTPTEDGSEEPGSETSDAK (45-67),  
T6-Phospho (79.96633 Da) 
Charge: +2,   Monoisotopic m/z: 1236.46860 Da (+466.04 mmu/+376.91 ppm),   
MH+: 2471.92993 Da,    
RT: 30.10 min, 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₄⁺
420.18
y₇⁺
737.34
y₅⁺
521.23
y₉⁺-H₂O
873.43
y₁₈⁺
1916.71
b₆⁺-H₂O-P
620.28
y₁₀⁺, b₂₀²⁺-P
1020.41
b₁₄⁺
1580.56
y₁₃⁺
1293.53
y₁₇⁺
1735.68
y₁₄⁺
1408.54
b₂₁²⁺, y₂₁²⁺
1128.13
y₉⁺
891.38
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     Extracted from: C:\Xcalibur\data\Tau_phosph_invitro_04Mar16.raw   #3874   RT: 26.97
     ITMS, CID, z=+2, Mono m/z=1236.46860 Da, MH+=2471.92993 Da, Match Tol.=0.8 Da
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2. Sequence: TPPAPKTPPSSGEPPK (146-161), 
T7-Phospho (79.96633 Da) 
Charge: +2,   Monoisotopic m/z: 835.02773 Da (+622.41 mmu/+745.38 ppm),    
MH+: 1669.04819 Da,    
RT: 19.12min, 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₁₀⁺-H₂O
1058.40
y₁₄⁺
1469.60
b₁₃⁺-P
1229.74
y₁₀⁺
1076.63
y₁₃⁺
1372.78y₁₂²⁺-P, y₁₁²⁺
602.52
b₇²⁺-NH₃-P
330.15
y₁₂⁺
1301.72
b₁₃⁺
1327.66
y₉⁺
895.39
y₇⁺-H₂O, y₇⁺-NH₃
684.05
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     Extracted from: C:\Xcalibur\data\Tau_phosph_invitro_04Mar16.raw   #2680   RT: 18.64
     ITMS, CID, z=+2, Mono m/z=835.02773 Da, MH+=1669.04819 Da, Match Tol.=0.8 Da
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3. Sequence: SGYSSPGSPGTPGSR (166-180),  
S8-Phospho (79.96633 Da) 
Charge: +2,   Monoisotopic m/z: 737.27942 Da (-24.55 mmu/-33.3 ppm),    
MH+: 1473.55156 Da,    
RT: 21.99 min, 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₂⁺
262.39
b₄⁺-H₂O
377.19
b₁₀⁺-P
859.33
b₁₁⁺-P
960.45
b₅⁺-H₂O
464.20
b₁₁⁺-H₂O, b₁₂⁺-NH₃-P
1040.39
y₁₀⁺
992.41
y₄⁺
416.20
b₈⁺-NH₃-P, [M+2H]²⁺-P
688.45
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     Extracted from: C:\Xcalibur\data\Tau_phosph_invitro_05Mar16.raw   #3165   RT: 22.21
     ITMS, CID, z=+2, Mono m/z=737.27942 Da, MH+=1473.55156 Da, Match Tol.=0.8 Da
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4. Sequence: TPPKSPSSAK (202-211), 
S5-Phospho  
Charge: +2,   Monoisotopic m/z: 540.2600 Da  
RT: 11.29 min, 
Example MS/MS: 
 
Example XIC and MS1: 
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5. Sequence: SPVVSGDTSPR (367-377), 
S9-Phospho (79.96633 Da) 
Charge: +2,   Monoisotopic m/z: 591.10393 Da (-159.78 mmu/-270.3 ppm),    
MH+: 1181.20058 Da,    
RT: 17.56min, 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₉⁺
997.47
y₄²⁺-P
221.04
b₉⁺-P
812.45
b₇⁺
642.35
y₈⁺
898.42
[M+2H]²⁺-H₂O-P, [M+2H]²⁺-NH₃-P
533.49
y₆⁺
712.31
y₇⁺
799.45
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     Extracted from: C:\Xcalibur\data\Tau_phosph_invitro_05Mar16.raw   #2323   RT: 16.31
     ITMS, CID, z=+2, Mono m/z=591.10393 Da, MH+=1181.20058 Da, Match Tol.=0.8 Da
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6. Sequence: SPVVSGDTSPR (367-377),  
T8-Phospho (79.96633 Da) 
Charge: +1,   Monoisotopic m/z: 1181.46529 Da (-54.58 mmu/-46.19 ppm),    
MH+: 1181.46529 Da,    
RT: 17.70 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
b₇⁺
643.04
y₈⁺-P
800.39
y₄⁺-P
442.20
y₄⁺, y₅⁺-NH₃-P
540.17
y₉⁺-P
899.41
y₉⁺
997.37
[M+1H]⁺-H₂O
1163.43
[M+1H]⁺-P
1083.47
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     Extracted from: C:\Xcalibur\data\Tau_phosph_invitro_04Mar16.raw   #2529   RT: 17.61
     ITMS, CID, z=+1, Mono m/z=1181.46529 Da, MH+=1181.46529 Da, Match Tol.=0.8 Da
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7. Sequence: HLSNVSSTGSIDMVDSPQLATLADEVSASLAK (388-409),  
M13-Oxidation (15.99492 Da), S16-Phospho (79.96633 Da)  
Charge: +3,   Monoisotopic m/z: 1114.19767 Da (+337.58 mmu/+302.98 ppm),    
MH+: 3340.57844 Da,    
RT: 56.12 min 
Example MS/MS: 
 
Example XIC and MS1: 
 
y₄⁺
418.21
b₃₀²⁺-H₂O, y₃₁²⁺-P, b₃₀²⁺-NH₃
1553.09
b₁₇³⁺-P, b₁₆³⁺, y₆⁺
576.32
b₁₈²⁺-NH₃-P, y₉⁺
919.43
b₂₅²⁺-H₂O-P, b₂₅²⁺-NH₃-P, y₁₃⁺
1275.67
[M+3H]³⁺-P
1081.39
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     Extracted from: C:\Xcalibur\data\Tau_phosph_invitro_05Mar16.raw   #7713   RT: 55.91
     ITMS, CID, z=+3, Mono m/z=1114.19767 Da, MH+=3340.57844 Da, Match Tol.=0.8 Da
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Additional ERK fragmentation spectra (Credit to Charleen) 
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GSK3β phosphopeptide fragmentation spectra (Credit to Charleen) 
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CDK5 phosphopeptide fragmentation spectra (Credit to Charleen) 
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